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GLOSSARY Genetic epidemiology Studies the role of genetic factors and their 
interaction with environmental factors in the occurrence of disease
Heritability Proportion of population variance in a trait attributable to
segregation of a gene or genes
Locus Physical location of a gene
Allele Alternative forms of a gene or marker due to changes at the DNA
level
Genotype The observed alleles at a genetic locus of an individual
Phenotype Physical, biochemical or physiological appearance of a 
disorder
Haplotype The ordered arrangement of alleles on a chromosome
Genetic heterogeneity Several genes are associated with the same 
disease
Locus heterogeneity occurs when different genes lead to the same 
phenotype
Allelic heterogeneity occurs when variations in the same gene result in
the same phenotype
Epistasis Two or more genes interacting with one another in a 
multiplicative fashion
Proband Individual in a pedigree that causes the pedigree to come to the
attention of medical or research personnel
Polymorphism A piece of DNA that has more than one form (allele), each
of which occurs with at least 1% frequency
Polygenic A trait is considered polygenic when caused by the combined
effects of three or more loci
Multifactorial A trait is considered multifactorial when two or more 
genes, together with environmental factors, cause a phenotype
Genetic drift Random fluctuation of allele frequencies when genes 
are transmitted from one generation to the next
Founder effect Loss of genetic variation when a population is formed by
a small number of individuals derived from a larger population 
(extreme example of genetic drift)
Linkage disequilibrium Two alleles at different loci that occur together
within an individual more often than would be predicted by
chance. Also called population allelic association
Recombination The process during meiosis by which two-paired 
chromosomes exchange genetic material
8
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Recombination fraction The frequency of crossing over between two 
loci
Microsatellite A DNA variant due to tandem repetition of a short DNA 
sequence
Single Nucleotide Polymorphism (SNP) DNA sequence variation due to
change in a single nucleotide
9
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Introduction
Cardiac output x peripheral resistance = mean arterial blood pressure. Behind this appa-
rently simple equation belies the very complex physiology of blood pressure regulation.
Pathophysiological changes in blood pressure homeostasis may cause a chronic rise in
arterial blood pressure. This condition is defined as hypertension and usually diagnosed
when systolic blood pressure exceeds 140 mmHg and/or when diastolic blood pressure
exceeds 90 mmHg (table 1).1,2
Epidemiology
Hypertension is the most prevalent cardiovascular risk factor in the industrialized world,
affecting about 30 % of the adult population and up to 60 % of those aged above 70
years.3 Epidemiological surveys have revealed many factors that are associated with
blood pressure levels, including age, sex, race, socio-economic status, nutrition, alcohol
intake, stress, smoking and physical activity.4 Large population-based studies have shown
a strong positive and continuous relationship between blood pressure levels and risk of
cardiovascular morbidity and mortality.5-10 Hypertension is a common and powerful
contributor to the major cardiovascular diseases: coronary heart disease, stroke, periphe-
ral artery disease, renal disease and heart failure.11-13 Elevated blood pressure tends to
cluster with other cardiovascular risk factors such as obesity, dyslipidemia, glucose into-
lerance, hyperinsulinemia and left ventricular hypertrophy.10 Less than 20 % of hyper-
tension occurs in the absence of any of the above-mentioned metabolically linked risk
factors. Although hypertension independently contributes to risk of cardiovascular
events, its impact is highly influenced by the presence of associated risk factors. 
Despite the overwhelming number of known risk factors, in over 90 % of hyperten-
sive patients no single identifiable cause can be established. Chronically elevated blood
pressure without a known pathological cause is usually referred to as “primary” or “essen-
tial” hypertension. Essential hypertension is a very heterogeneous disorder, most likely
the result of a complex interplay between inherited, behavioral and environmental fac-
tors that all influence physiological pathways involved in blood pressure regulation. 
Pathophysiology
Essential hypertension may have its origin as early as the start of intrauterine life.
Adverse environment during critical periods of development in fetal life and infancy may
predispose to an unfavorable cardiovascular risk profile in later life.14,15 Experimental
and observational studies provide strong evidence for the importance of environmental
and cultural effects on the development of hypertension.16 These factors include obesi-
ty, high sodium intake, low potassium intake, excessive alcohol consumption and a
15INTRODUCTION
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sedentary life style. Besides environmental factors, physiological and genetic factors have
also been implicated in the development of hypertension. 
The most important physiological factors that influence blood pressure homeostasis
are sodium and fluid handling by the kidneys and the regulation of vasomotor tone. Both
are under the influence of neuronal and endocrine systems. In hypertensive patients, the
kidneys are not able to adequately excrete sodium and water at a normal arterial pres-
sure.17 The causes of this impaired renal-pressure natriuresis remain to be determined.
Obesity has been suggested as one of the possible causes, as it induces an increase in
renal tubular absorption and impairs pressure natriuresis through activation of the sym-
pathetic and renin-angiotensin system as well as physical compression of the kidneys.18
The kidney-fluid system is important in establishing long-term blood pressure regulation
and impairment of renal-pressure natriuresis is likely to play a central role in the deve-
lopment of hypertension.19 
Another hallmark of essential hypertension is an increased peripheral vascular
resistance due to alterations in the structure, mechanical properties and function of
small arteries, which is reflected in a reduced lumen and increased media:lumen ratio.20
Whether this vascular remodeling process is a primary cause of hypertension or occurs in
response to elevated blood pressure is subject of ongoing debate. Recently, endothelial
dysfunction, a condition characterized by platelet aggregation, inflammation, impaired
modulation of vascular growth, dysregulation of vascular remodeling and impaired endo-
thelium-dependent vasorelaxation, has also been implicated in the etiology of hyperten-
sion.21 Indeed, nitric oxide-related vasodilatation, a characteristic of healthy endotheli-
um, is impaired in hypertensive patients.22
Two important endocrine regulatory systems are involved in the cardiovascular and
renal changes observed in hypertensive patients: the sympathetic nervous system and the
renin-angiotensin aldosteron system (RAAS). Increased sympathetic nervous system acti-
16 CHAPTER 1
Table 1. Definition and classification of blood pressure levels according to the 1999 WHO/ISH 
criteria and the 2003 ESH guidelines
Category SBP (mmHg) DBP (mmHg)
Optimal < 120 < 80
Normal 120-129 80-84
High-Normal 130-139 85-89
Grade 1 hypertension (mild) 140-159 90-99
Grade 2 hypertension (moderate) 160-179 100-109
Grade 3 hypertension (severe) ≥ 180 ≥ 110
Isolated systolic hypertension ≥ 140 < 90
SBP, Systolic blood pressure; DBP, Diastolic blood pressure.
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vity increases blood pressure and contributes to the development and maintenance of
hypertension through stimulation of the heart, peripheral vasculature and renin release
in the kidneys, causing increased cardiac output, increased vascular resistance and fluid
retention.23
RAAS influences cardiovascular and renovascular homeostasis in various ways (figu-
re 1). Renin is secreted by the kidney in response to reduced glomerular perfusion, 
reduced salt intake or stimulation of the sympathetic nervous system. Renin converts
angiotensinogen into angiotensin I, which is in turn converted into angiotensin II by the
angiotensin-converting enzyme (ACE). ACE also inactivates bradykinin, an important
mediator in the release of potent vasodilators such as nitric oxide, prostacyclin and tis-
sue plasminogen activator. Angiotensin II (ANG II) is the key peptide in the RAAS system.
The effects of ANG II on blood pressure regulation are predominantly mediated through
the angiotensin receptor I, located primarily in the adrenal glands, vascular smooth mu-
scle cells, kidneys and the heart.24 ANG II increases blood pressure via different path-
ways. First, it is a very potent systemic and renal vasoconstrictor and induces sodium and
17INTRODUCTION
 Angiotensinogen
Angiotensin I
Angiotensin II
Vasoconstriction
Aldosteron release
Vasopressin release
Sodium and fluid retention
Cell growth and proliferation
Vasodilatation
Cell differentation
Inhibition cell proliferation
Renal sodium excretion
Renin
Angiotensin-converting enzyme
Inactivation bradykinin 
Hypertension
Left Ventricular hypertrophy
Vascular media hypertrophy
Atherosclerosis
Glomerulosclerosis
AT I receptor AT II receptor
Vasoconstriction
Figure 1. Schematic overview of the renin-angiotensin system and its effects on blood pressure 
regulation.
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fluid retention in the kidneys.25 Second, ANG II mediates cell growth and proliferation of
vascular smooth muscle cells, cardiomyocytes and coronary endothelial cells by stimula-
ting various cytokines and growth factors, such as insulin-like growth factor-I and pla-
telet derived growth factor.20,26 Furthermore, ANG II may induce endothelial dysfuncti-
on by reducing nitric oxide bioavailability.27
Besides ANG II and the catecholamines, several other hormones with growth inducing
properties have been linked to hypertension, e.g. insulin, growth hormone and insulin-
like growth factor I (IGF-I). IGF-I is thought to contribute to the vascular remodeling pro-
cess observed in hypertension by stimulating vascular smooth muscle cell growth in res-
ponse to humoral stimuli and elevation in vascular wall stress.28 In addition to these
mitogenic effects, IGF-I also acts on vascular tone via endothelial nitric oxide release.29
Increased cardiac IGF-I expression has been implicated in the development of left ven-
tricular hypertrophy associated with hypertension.30
In conclusion, altered renal and vascular function seem to form the corner stones of
the pathophysiology of hypertension, cemented by various neuronal, endocrine, environ-
mental and genetic stimuli.
Genetics
Many population-based studies as well as adoptions studies have indicated that familial
aggregation of blood pressure is largely due to genetic factors.31-33 A greater concor-
dance rate of blood pressure in monozygotic twins versus dizygotic twins also indicates
that genetic factors play an important role in blood pressure regulation. Given an affec-
ted first-degree relative, the risk of hypertension is increased 2-5 fold in family members
compared to the population risk. Genetic factors may explain up to 30-40 % of the blood
pressure variation in the population.34 
So far, the elucidation of a number of mutations that contribute to Mendelian forms
of salt-sensitive hypertension have been the bright spot in the area of molecular gene-
tics of hypertension.35 Although these single-gene mutations are extremely rare and
unlikely to explain the blood pressure variation at the population level, understanding
the pathophysiological mechanisms underlying these monogenic forms of hypertension
may provide new insights into pathways involved in more common forms of hyperten-
sion. Despite the identification of several Mendelian forms of hypertension, genetic
heterogeneity, unknown genetic models of inheritance and immeasurable environmental
effects complicate the search for genetic factors that play a role in the development of
hypertension. This may explain why, up to now, no genes with substantial effects on
blood pressure variance in the general population have been identified.
Studies on the genetics of hypertension have largely focused on the analysis of can-
didate genes in biological systems known to affect blood pressure. Although some pro-
18 CHAPTER 1
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mising findings relate to genes of the renin-angiotensin system, these genetic variants
seem to influence blood pressure only modestly and most susceptibility genes have not
shown very consistent and reproducible associations with hypertension or blood pressu-
re. An important limitation of the candidate gene approach is that it is restricted to
known variants in susceptibility genes, which has led to interest in screening of the enti-
re genome in search of new candidate regions explaining blood pressure variation or
hypertension.36 Although these genome wide scans have identified new promising loci
on several chromosomes, these regions are still broad and in need of confirmation. 
All in all, modest but hopeful results have emerged from both candidate gene studies
and genome wide searches, however a major breakthrough in the search of susceptibili-
ty genes for hypertension is eagerly awaited.
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Introduction
Unraveling the genetics of complex diseases has been and continues to be one of the
major challenges in the field of biological science. Many areas of research have sought
to find the ideal study design in order to shed a light on the genetic background of com-
plex diseases. Although many disease genes have been identified, the majority of these
genes are involved in monogenic Mendelian disorders with simple patterns of inheritan-
ce. The mapping of susceptibility genes involved in common complex diseases is a consi-
derably more daunting task, asking for newer and more ingenious research approaches.
Genetic epidemiology is a field of research that aims to identify the role of genetic fac-
tors, and their interaction with environmental factors, in the development of disease in
the population. Recently, the focus of attention in genetic epidemiological research has
shifted from family-based research on monogenic disorders to population-based research
of complex, multifactorial disorders.
Human essential hypertension is a classic example of a complex, multifactorial trait.
Blood pressure regulation is most likely the product of many genes, interacting with each
other and with environmental factors. Although several Mendelian forms of hyperten-
sion have been identified in family-based studies, the contribution of these rare genes to
blood pressure variation in the general population is likely to be very small. Large-scale
population-based studies will be needed to identify susceptibility genes for hypertension
that are relevant for the general population. In these studies close integration of gene-
tic, physiological and epidemiological knowledge of hypertension will play a pivotal role
for the future identification of genes influencing blood pressure homeostasis.
In this paper we will review the basic principles underlying genetic epidemiological
research of complex traits. We will discuss the different approaches that are used in
genetic epidemiological studies, and how these studies have been, and will be applied to
disentangle the genetic basis of human hypertension.
Background
Hypertension is a very common disease and a major risk factor for cardiovascular mor-
bidity and mortality.1-3 Family, twin and adoption studies have clearly demonstrated that
blood pressure is a heritable trait.4-8 Up to 40 % of blood pressure variance in the gene-
ral population may be explained by genetic factors.9,10
During the sixties a heated debate between Pickering and Platt arose over the
question whether hypertension represents the upper tail of a continuous blood pressure
distribution and is determined by a number of genes or is a qualitative trait due to an
effect of a few major genes.11,12 Platt assumed that the bimodality of blood pressure
distribution in his study population reflected the effect of major genes causing hyper-
tension. Pickering observed that the frequency distribution curves for blood pressure in
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the relatives of patients with hypertension were similar in shape to those of a popula-
tion-based sample but shifted upwards by about the same amount at all ages. So, blood
pressure appeared to be inherited as a graded characteristic over the whole range of
blood pressure levels. 
At present, hypertension is assumed to represent the upper tail of a continuous blood
pressure distribution, and considered a complex, multifactorial and polygenic trait,
potentially influenced by the additive effects of many genes, interacting with various
environmental factors. Despite significant progress in the development of genomic and
statistical tools, the genetic dissection of hypertension remains a major challenge.
Definition of the phenotype
In studies on the genetics of (complex) diseases, identification and precise definition of
the phenotype (trait) of interest is crucial. Although this may seem very straightforward,
in hypertension research it is not always that easy. First of all, blood pressure is a highly
variable trait. Blood pressure measurements can be very much influenced by the techni-
cal accuracy of the measurement device, biological variability of blood pressure (e.g.
diurnal rhythm and posture) and the presence of a physician, so called “white-coat
hypertension”. These measurement errors may be minimized by careful standardization of
measurement technique, training of observers and ambulatory or self-monitoring of
blood pressure. Blood pressure levels should preferably be measured in exactly the same
way in each participant, and the “threshold” for diagnosis of hypertension should be
based on (internationally) generally accepted criteria in order to generate valid and
reproducible results.13
Second, blood pressure is a polygenic trait, the result of many genes each with small
additive effects. The continuous blood pressure distribution in the population suggests
that blood pressure raising alleles will act in an additive or multiplicative manner to
increase pressure at any level of blood pressure. So, genes that influence blood pressure
variation are likely to also contribute to hypertension. Conversely, genes involved in
hypertension are likely to influence blood pressure variation within the normotensive
range. As a result, blood pressure can be studied both as a quantitative and qualitative
trait (hypertension). Besides sampling families over the whole range of blood pressure
distribution, selecting families from the top and bottom end of this distribution is assu-
med to increase the power of genetic analyses, as these families are likely to be more
genetically distinct.14-16 Sampling siblings with extreme concordant or discordant blood
pressure levels may increase the power to detect low-frequency alleles which will incre-
ase or decrease blood pressure.17-19 Another approach is to identify hypertensive sub-
jects who are thought to have a more homogeneous genetic background for their high
blood pressure. Stratification based on hypertension-related (intermediate) phenotypes
26 CHAPTER 1
isocrg_def_f  16-08-2004  12:43  Pagina 26
such as low plasma renin, obesity, dyslipidemia or insulin resistance could increase the
homogeneity of the study population.20,21 A fairly recent strategy to increase homoge-
neity, is to sample hypertensive subjects that originated from a genetically isolated popu-
lation. They are assumed to share a more common genetic background because they are
all descendants from a limited number of common ancestors. Studying hypertensive
patients in this population may facilitate the identification of susceptibility genes, as
they are thought to have hypertension due to the same reduced number of mutations
inherited from a common ancestor. 
Finally, studying additional blood pressure phenotypes, besides systolic and diastolic
blood pressure, such as the age-at-onset of hypertension, pulse pressure and mean arte-
rial pressure, may be of interest because these phenotypes may lead to the identification
of a different set of genes involved in blood pressure homeostasis. Indeed, Daw et al. ana-
lyzed age-at-onset of hypertension and SBP and they observed that age-at-onset was
better at identifying “slope genes” whereas SBP might be more suitable to identify “base-
line” genes.22
Evidence for genetic effects on blood pressure regulation
Clustering of a disease in families is suggestive for a genetic component in the develop-
ment of this disease. Familial aggregation of a disease is present when the prevalence of
the disease is more frequent in family members of an affected individual than in the
general population. Familial aggregation of hypertension has been reported for the first
time over 30 years ago and has since then been confirmed in numerous studies.6,7,23,24
Given an affected first-degree relative, the risk of hypertension is found to be increased
2-5 fold in family members compared to the population risk. This risk measure is usu-
ally referred to as λS (lambda sib), which is the ratio of the risk of hypertension for sib-
lings of a proband (affected family member) compared to the population risk. 
Blood pressure levels within family members are highly correlated, with correlations
ranging from 0.14-0.18 between parent-offspring and sibling pairs, up to 0.25-0.27 for
dizygotic twins and up to 0.55-0.58 for monozygotic twins.25 As families share genes and
environment, these correlations are also the result of shared environment. However, rela-
tively low blood pressure correlations between spouse pairs (0.06-0.08) and higher con-
cordance rates of monozygotic versus dizygotic twins implicate a substantial influence
of genetic factors in family blood pressure correlations. Furthermore, adoption studies
indicate higher blood pressure correlations between parents and their biological children
than between parents and their adopted children.6
The strength of a genetic component can be expressed in a quantity called heritabi-
lity, which defines the proportion of phenotypic variance due to genetic factors over the
total phenotypic variance observed. Heritability encompasses two genetic compo-
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nents: additive and dominance genetic effects. Narrow-sense heritability (denoted as h2)
reflects the additive genetic effects and is a measure of the predictability of offspring
trait values based on parental trait values. The magnitude of genetic effects in traits that
are assumed to have a polygenic background (many genes each with a small additive
effect) is usually reflected in the narrow-sense heritability. Broad-sense heritability esti-
mates (denoted as H2) also include dominance genetic effects, which explain part of the
heritability due to the effects of major genes. However, they are not thought to contri-
bute substantially to the heritability of complex quantitative traits in the general popu-
lation. Large family-based studies have estimated narrow-sense heritabilities for DBP and
SBP between 20-40 %.26-29 In twin studies heritability estimates of blood pressure usu-
ally vary around 60 %.8,30
Segregation analysis: determination of the mode of inheritance
A segregation analysis aims to determine the transmission pattern of a trait within fami-
lies and tests this pattern against predictions from specific genetic models. Various trans-
mission models can be specified including major gene effects, Mendelian inheritance, all
transmission due to shared environmental factors and more complicated mixed models
with a single major gene and a polygenic component. In segregation analyses all para-
meters are estimated using maximum likelihood methods. These parameters consist,
among other things, of allele frequencies, transmission patterns and susceptibility para-
meters. The likelihood represents the probability of observing the data given a certain set
of parameters. The likelihood of different models can be compared using the likelihood
ratio test or examining Akaike’s information criterion. A more detailed description of the
statistical methods in segregation analysis can be obtained in Khoury et al.31
Segregation analyses in 1050 pedigrees of the Framingham Heart Study for a quan-
titative and qualitative blood pressure trait (SBP and hypertension) both identified the
same best fitting model: a mixed model allowing for two major genes and polygenic
effects. However, the model parameter estimates were very different for both traits.32
This underlines that the choice of blood pressure phenotype may have an important
influence on the estimation of the parameters in the segregation model. Most segrega-
tion analyses for SBP and DBP have not been very consistent ranging from a no trans-
mission, environmental model to a model with polygenic and/or major gene effects.33-35
Heterogeneity of the study samples and the compound nature of blood pressure may be
responsible for the inability to detect consistent segregation models.
Study Design
There are two general approaches for mapping genes in complex disorders. The first com-
prises a genome wide screen using a linkage analysis approach, which is limited to a
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family-based study design. The second approach includes candidate gene studies based
on association analyses, which can be conducted in family-based and population-based
studies. 
Genome wide screen
A genome wide screen comprises of scanning of the whole genome using markers
approximately evenly spaced across the entire genome. These DNA markers can be muta-
tions in single base pairs (Single Nucleotide Polymorphisms (SNPs)) or a variable number
of repeats of two or more base pairs (microsatellites). A statistical method called linkage
analysis is used to analyze the results of a genome screen. Linkage is tested using either
a parametric or a non-parametric model. 
The parametric linkage approach is a model-based method that requires that an
assumption of the genetic model is specified a priori, including specification of certain
parameters such as mode of inheritance, disease and marker allele frequencies and pene-
trance. This can be done in a segregation analysis. For each of the markers evidence for
linkage to a possible disease mutation is tested using statistical procedures that identify
the co-segregation of a trait or disease and a specific variant of the DNA marker within
affected family members. The basic principle of this method is that loci physically close
together on a chromosome are likely to be transmitted together. Patients who inherit a
disease gene from a common ancestor, are expected to share also parts of the chromo-
some surrounding the disease gene. So, any marker located nearby the causal disease
mutation is expected to be more often shared by affected relatives (cases) than by unaf-
fected relatives (controls) (Figure 1). Evidence for linkage is usually presented in the form
of a LOD-score function. The LOD-score stands for the logarithm of the likelihood that a
locus is linked to the trait versus no linkage to the trait. This LOD-score is dependent on
the recombination fraction (θ). This is the probability that two alleles at different loci on
the same chromosome are derived from different parental chromosomes. When there is
tight linkage between two alleles the recombination fraction is zero, when there is no
linkage between two alleles the recombination fraction is 0.5. The closer two loci are on
a chromosome the less likely that a recombination has occurred during meiosis, meaning
alleles from both loci are always inherited together. This condition is known as linkage
disequilibrium. The recombination fraction has evolved into a measure of genetic distan-
ce, defined in centiMorgan (cM). One cM corresponds approximately to a recombination
fraction of 1 %. In general, a LOD score above 3.0 is considered substantial evidence for
linkage and warrants additional fine mapping in the region of interest. This parametric
linkage approach, also referred to as LOD score analysis, is very powerful but highly
dependent on correct assumptions made about the genetic model. 
A non-parametric linkage method does not require prior knowledge of the genetic
model. This non-parametric method examines which parts of the genomes of a pair of
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affected relatives are identical by descent (IBD).36 The most familiar model prob-
ably is the sibpair method.37-39 Siblings share about 50 % of their genetic material. The
probability of siblings sharing no, one or two alleles with each other is respectively 25,
50 and 25 %. Linkage is supported if two affected or two unaffected siblings are signi-
ficantly more alike (more allele sharing) at a marker locus than sibling pairs with just one
affected member. Affected sibs are expected to share more alleles for markers located
close to the disease mutation than expected under the null hypothesis (one allele sha-
red). Non-parametric linkage was originally used in siblings, but has been extended to
pedigrees. A locus that might harbor genes that influence quantitative (complex) traits
is called a quantitative trait locus (QTL) and can be detected using non-parametric or
model free linkage.
Candidate gene studies
In contrast to linkage studies, which are usually genome wide, association studies are
usually restricted to candidate genes or candidate regions in the genome. There are two
types of candidate gene association studies. The concept of population-based genetic
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Figure1. Linkage analysis: segregation of disease mutation through a pedigree. Together with the
mutation, DNA flanking the mutation is also transmitted. Due to recombination the part of 
shared DNA, including the mutation, becomes smaller over generations.
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association studies is very similar to that of classic case-control studies in epidemiology.
In these studies, the frequency of (functional) allelic variants is compared between sub-
jects with a specific phenotype (hypertension) and subjects without this phenotype (nor-
motension). A quantitative trait value, e.g. systolic blood pressure, may also be compared
between subjects with different allelic variants. This allelic association can be explained
either by a direct biological action of the polymorphism or by linkage disequilibrium with
a nearby susceptibility gene. Attractive candidate genes are those that may, either by
influencing protein levels or protein functionality, alter the function of a protein that
may play a role in the development of the disease of interest. Failure to replicate popu-
lation-based genetic association studies is a very common problem and has often been
ascribed to population stratification. Population stratification exists when the population
under study consists of a mixture of two or more subpopulations that have different alle-
le frequencies and disease risks. An approach to overcome this problem is the careful
matching of cases and controls in a population-based study design, or the use of fami-
ly-based controls. The latter forms the basis of the transmission-disequilibrium test (TDT),
a family-based association method.40,41 This test assesses the difference between the
frequency of marker alleles transmitted from heterozygous parents to the affected off-
spring and the frequency of markers not transmitted. TDT involves establishment of a
pseudo case-control study, in which cases are the parental alleles transmitted to the
affected proband, and controls are those that were not transmitted. So, as case-control
pairs are matched within a family, allele frequency differences at the population level
become irrelevant. A drawback of the TDT design is the need of parental DNA, who may
be deceased when studying late-onset disorders. 
As the phenotype of complex diseases is polygenic in nature, association studies con-
sidering only a small fraction of the genetic variants may not suffice to find relevant
candidate genes. The creation of the Single Nucleotide Polymorphism (SNP) consortium
has led to the identification of 1.5 million SNPs, the most common form of human gene-
tic variation.42-44 Between 50.000 and 100.000 of these SNPs lie within coding and adja-
cent regions and may alter gene function and protein expression.45 With the develop-
ment of high throughput genotyping technologies, large-scale testing of these SNPs in
whole-genome association studies is likely to become feasible in the next few years. 
Finding genes for hypertension and blood pressure regulation
Studies on the genetics of hypertension and blood pressure regulation have developed
into a major field of research over the last decade. The bright spot of this research area
has been the identification of several Mendelian forms of hypertension. However, these
forms are rare and in the vast majority of patients the genetic basis of their hyperten-
sion is likely to be the result of many genes, each with small additive effects.
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So far, genetic studies on hypertension have largely sought to associate polymorphic
variations in candidate genes with the risk of hypertension or variation in blood pressu-
re levels. However, these association studies are restricted to known variants in genes of
which we a priori expect that they may possibly be involved in the physiological path-
ways of blood pressure regulation. This limitation has led to interest in conducting geno-
me scans, aimed at identifying new susceptibility genes for hypertension. 
In the following section, a brief overview will be given regarding the findings on
monogenic forms of hypertension, candidate genes and genome scans for hypertension
and blood pressure regulation.
Mendelian forms of hypertension
In favor of Platt, who argued that major genes must be involved in the development of
hypertension, several monogenic forms of hypertension have been identified. Some of
these Mendelian forms of hypertension are associated with defects in steroid metabo-
lism, e.g. the syndrome of apparent mineralcorticoid excess (AME), an autosomal form of
hypertension due to inactivating mutations in the 11-hydroxysteroid dehydrogenase.46
Liddle’s and Gordon’s syndrome are monogenic disorders associated with abnormalities in
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Figure 2. Allele sharing in a genetically isolated population.
A disease-associated mutation is introduced into the population by a founder chromosome 
(above). This mutation, together with surrounding DNA, is shared by patients with the same 
phenotype (IBD). Although they may not be aware, they all descend from the same founder.
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renal ion transport and cause a salt-sensitive form of hypertension.47,48 Pheochromo-
cytomas cause an episodic form of hypertension and are the consequence of mutations
in proto-oncogenes or tumor suppressor genes.49-51 Monogenic forms of hypertension
are summarized in table 1. Although these forms are rare and do not explain blood 
pressure variability in the general population, they might help in better understanding
the pathophysiology of hypertension and offer clues towards identifying genes involved
in more common forms of hypertension.
Candidate genes for hypertension and blood pressure regulation
Blood pressure homeostasis is the result of a complex integrated physiological network,
including renal, neuronal, endocrine and vascular systems. Within this network most like-
ly multiple genes are expressed, influencing blood pressure in various ways. Consequently,
there are many genes that may potentially serve as candidate genes for hypertension.
Several candidate genes in the renin-angiotensin aldosteron system (RAAS) have been
identified as genetic determinants of blood pressure. The most prominent one is the
insertion(I)/ deletion(D) polymorphism in the angiotensin-converting enzyme (ACE).
Subjects carrying two copies of the D-allele have 50 % higher plasma and tissue ACE
levels.52,53 Higher ACE levels may account for higher angiotensin II generation, an impor-
tant vasoconstrictor, and increased bradykinin inactivation, a potent vasodilator. Both
may increase vascular resistance causing a rise in blood pressure. Although many asso-
ciation studies on the ACE I/D polymorphism and hypertension have been performed, 
findings remain inconsistent.54-57 Differences in the effects of gene-gene and gene-
environment interactions in the various study populations may explain part of the 
controversial role of this gene in the development of cardiovascular disease. 
Single nucleotide polymorphisms in the angiotensinogen (AGT) gene have been con-
sistently associated with elevated angiotensinogen levels and hypertension in many stu-
dies.58-60 The 235T variant of the M235T polymorphism was more frequently observed in
hypertensive cases than controls in a study by Jeunemaitre et al.59 This polymorphism
appeared to be in tight linkage disequilibrium with a promoter mutation –6 bp up-
stream of the initial transcription site, resulting in a higher basal transcription rate and,
consequently higher AGT levels.61 Other genetic variations in the RAAS that have been
associated with hypertension include those observed in the angiotensin II type 1 recep-
tor gene and aldosterone synthase gene.62,63
Candidate genes that may influence the effects of the sympathetic nervous system
on blood pressure, include genetic variations in the α- and -adrenoreceptors.64-66
Genetic mutations that alter renal sodium reabsorption have also been implied in the
genetics of hypertension. A polymorphism (G460T) in the α-adducin gene has been asso-
ciated with increased salt-sensitivity in hypertensive patients.67 A common polymor-
phism in exon 10 of the 3-subunit of the G-protein gene has been associated with 
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adipositas and hypertension.68,69 A polymorphism in the endothelial nitric synthase gene
has been associated with endothelial function during pregnancy and blood pressure 
response to exercise.70
Genome wide scans for hypertension and blood pressure
In the last few years, several genome wide scans for hypertension and blood pressure
have been reported.71 These genome wide scans have identified numerous chromosomal
regions that might be close to QTLs influencing blood pressure. Most data was based
either on (affected) sibling pairs or (nuclear) families. Although these genome wide
screens are very diverse in phenotype definition, ethnicity of the study population, selec-
tion criteria and number and structure of family data used, a number of regions have
been consistently reported in multiple studies. Regions on chromosome 2p72-75,
6q72,76,77 and 15q72,76,78 have been identified in at least three different studies.
Although several studies reported chromosomal regions nominal or suggestive of linka-
ge, significant “genome-wide“ linkage was reported only for a few regions located on
chromosomes 2, 4, 6, 17 and 18.77,79-82
Most regions identified so far are broad and may represent false positive linkage due
to lack of statistical power. The shift from identifying regions of interest in linkage stu-
dies to identifying susceptibility genes for hypertension therefore remains one of the lar-
gest challenges in hypertensive research for the upcoming years.
Genetic research in isolated populations
Although many loci for common diseases have been mapped in outbred populations,
results have been very inconsistent and few loci have proven to be reproducible. Genetic
heterogeneity in outbred populations is likely to play an important role in the disap-
pointing results. Recently, population isolates have been identified as a powerful tool to
study the genetics of complex diseases.83,84 They show considerably less genetic diversi-
ty than outbred populations as by definition these isolates originate from a small num-
ber of founders. Many of these populations have experienced population bottlenecks,
characterized by a marked reduction in population sample size followed by the survival
and expansion of a small random sample of the original population. Consequently, the
occurrence of genetic drift and inbreeding will reduce genetic diversity in these popula-
tions. It is expected that fewer susceptibility genes for common diseases segregate in
these populations due to a more restricted gene pool.84-86 So, founder effects in combi-
nation with genetic drift increase the genetic homogeneity and make it more likely that
patients in genetic isolates have developed disease due to the same mutation, inherited
from a common ancestor. The availability of accurate genealogical records allows for the
analysis of extended pedigrees, increasing the power of genetic analyses.87 Patients in
isolated populations are expected to share the same disease gene and considerable parts
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of DNA surrounding the disease gene (haplotype) originating from a common ancestor
(figure 2). The extent of linkage disequilibrium (LD) determines the size of the shared
ancestral haplotypes: the more time has elapsed since a mutation was introduced into a
population, the more likely an ancestral haplotype has been disrupted by a recombina-
tion event, reducing the extent of LD and the size of the shared haplotype. Linkage dis-
equilibrium mapping also known as Identity by Descent (IBD) or haplotype mapping aims
at identifying shared haplotypes in the vicinity of disease genes in affected persons more
often than in healthy controls This can be done in specific candidate regions of the ge-
nome or by scanning of the whole genome (genome screen).88-90 
Finland and Iceland are well known North European isolated populations, which have
identified several candidate regions for complex disorders.91,92 So far, two genome wide
screens for hypertension have been preformed in isolated communities. Kristjansson et
al. found significant linkage to chromosome 18q in 490 Icelandic hypertensive patients.81
A genome wide scan in 35 related individuals with severe hypertension, all inhabitants of
an isolated Sardinian village, revealed significant linkage to chromosome 2p.79 However,
others have not yet replicated these findings.
A drawback of genetic studies in isolated populations could be that only a few sus-
ceptibility genes segregate within this population and that the effects of these genes are
limited to the specific population that was studied and thus results may not be exten-
dable to the general population. Studies in more recently isolated populations may over-
come this problem as they are expected to more closely resemble the general population. 
Conclusions
The completion of the sequence of the human genome has nourished high expectations
about the discovery of genes involved in human diseases. Although major progress has
been made in identifying genes involved in a large number of familial disorders, at the
population level, the genetic background of common complex disorders remains to be
elucidated. The genetic analysis of hypertension has revealed many complex and incon-
sistent results. Blood pressure regulation appears to be the result of many genes, which
act and interact in an additive and/or multiplicative fashion with other genes and envi-
ronmental factors. This severely complicates genetic research strategies as different com-
binations of genes may result in hypertension in different individuals. Study populations
may be admixed with different subpopulations, each with their own specific set of genes
and environmental risk factors causing hypertension. Given this high level of genetic
heterogeneity in hypertension, selection of etiologically distinct subgroups of patients,
identified based on their ethnic background, exposure to environmental risk factors or co
morbidity, may be warranted in order to increase the power of genetic studies. A promi-
sing study design in this respect is the inclusion of hypertensive patients living in gene-
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tic isolates, as they are expected to be genetically as well as environmentally more homo-
geneous than patients of outbred populations. However, whether susceptibility genes
identified in isolated populations also contribute to disease in the general population
remains to be determined. 
In conclusion, studies on the genetics of hypertension have developed into a refined
area of research. The continuing discovery of variants of the human genome that con-
tribute to the genetic diversity of the human population and the development of more
powerful genetic analytical methods will enable future research to identify susceptibili-
ty genes as well as determine the importance of gene-gene and gene-environment inter-
actions in the regulation of blood pressure.
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1.3. SCOPE OF THE THESIS
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A better understanding of the genetic basis of hypertension may provide more insight
into the pathophysiology of this condition, and consequently lead to more effective pre-
ventive and treatment strategies. Unraveling the complex genetics of hypertension has
proven difficult, nevertheless in this thesis a careful attempt was made. We conducted a
genetic epidemiological search for the identification and quantification of genetic risk
factors in the development of hypertension and its cardiovascular sequelae. First, two
candidate genes were studied in relation to hypertension, atherosclerosis and cardiac
disease in a population-based cohort study. Second, heritability of blood pressure and
familial aggregation of hypertension was studied in a Dutch genetically isolated com-
munity. 
Chapter 2 describes the results of two candidate gene studies in the Rotterdam study.
A polymorphism in the angiotensin-converting enzyme (ACE) gene is studied in relation
to blood pressure, carotid artery atherosclerosis and heart failure. In Chapter 3 the results
of two association studies regarding a genetic polymorphism in the promoter region of
the insulin-like growth factor-I (IGF-I) gene are presented. This polymorphism is studied
in relation to early signs of atherosclerosis in the carotid arteries, arterial stiffness and
left ventricular hypertrophy. Chapter 4 encompasses the results of two studies performed
in a genetically isolated population in the Southwest part of the Netherlands. In the first
study heritability estimates of blood pressure are presented. In the second study we des-
cribe the familial aggregation of hypertension in this population. Finally, in Chapter 5 the
work described in this thesis is concluded with a discussion on the role of candidate gene
studies and the value of genetically isolated populations in the search of susceptibility
genes for hypertension and its cardiovascular sequelae.
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2.CANDIDATE GENE STUDIES
ANGIOTENSIN CONVERTING ENZYME 
INSERTION/DELETION POLYMORPHISM
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2.1. SMOKING-DEPENDENT EFFECTS OF THE ANGIOTENSIN-
CONVERTING ENZYME GENE INSERTION/DELETION 
POLYMORPHISM ON BLOOD PRESSURE
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ABSTRACT54
Objective: Studies on the role of the Angiotensin-
Converting-Enzyme (ACE) gene in the development
of hypertension have yielded conflicting results.
Recent studies suggested that the ACE gene might
have smoking-dependent effects on the develop-
ment of cardiovascular disease. We studied the 
relation between the ACE insertion/deletion 
polymorphism, blood pressure and risk of hyper-
tension in current, former and non-smokers in a 
population-based cohort. 
Methods: We included 2414 non-smokers, 2794
former smokers and 1508 current smokers, all par-
ticipants of the Rotterdam Study. In each group, we
assessed the relation between the ACE I/D poly-
morphism, systolic (SBP) and diastolic blood 
pressure (DBP) and risk of hypertension. Mean blood
pressure levels and prevalence of hypertension were
compared between carriers and non-carriers of the
D-allele. All analyses were adjusted for age, sex, BMI,
diabetes mellitus, HDL- cholesterol, total cholesterol
and anti-hypertensive medication use. 
Results: In non- and former smokers, blood 
pressure and the risk of hypertension did not differ
significantly between genotypes. In smokers, we
found a significant increase in SBP in DD-carriers
(139.6 ± 22.8 mmHg) compared to II-carriers (136.0
± 22.7 mmHg)(p=0.04). No effect of ACE genotype
was observed for DBP. The risk of hypertension was
significantly increased in smokers who carried one
(OR: 1.4; 95%CI: 1.0-1.9; p=0.05) or two copies of
the D-allele (OR: 1.5; 95%CI: 1.1-2.2; p=0.02). 
Conclusion: The D-allele of the ACE polymorphism
is associated with a significantly increased SBP and
risk of hypertension in smokers. Our study under-
lines the importance of gene-environment inter-
actions in the study of candidate genes for 
hypertension. 
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Introduction
Angiotensin converting enzyme (ACE), also known as kinase II (EC 3.4.15.1), is involved in
the generation of angiotensin II (ANGII) and the degradation of bradykinin.1 Since both
vasoactive peptides mediate a great variety of cardiovascular effects, it is thought that
ACE plays a prominent role in cardiovascular physiology. The major therapeutic advances
made by ACE-inhibitors in the treatment of hypertension and heart failure emphasize the
important role of ACE in the cardiovascular system. An insertion/deletion (I/D) poly-
morphism in the gene coding for ACE has been found to account for about half of the
variance in serum ACE levels.2 The D-allele, associated with increased ACE-activity, has
been put forward as a genetic risk factor for cardiovascular disease (CVD).3 Although
hypertension is an important risk factor for CVD, findings regarding the association bet-
ween the I/D polymorphism and blood pressure remain inconclusive.4-7
Determining the relative contribution of genetic and environmental factors in the
development of complex diseases is difficult. In fact, many of the conflicting findings on
the ACE polymorphism and blood pressure might arise from differences in gene-gene and
gene-environmental interactions between the populations studied.8 Recently, the D-alle-
le has been associated with endothelial dysfunction, especially in smokers.9-11 Both smo-
king and the D-allele have been associated with increased generation of ANGII, which in
turn has been shown to increase the formation of super oxide anions and the degrada-
tion of nitric oxide (NO), causing endothelial dysfunction.12 In a large population-based
cohort, we assessed the effect of the ACE polymorphism on blood pressure and risk of
hypertension. To study whether there are smoking-dependent effects of the ACE poly-
morphism, non-smokers, former smokers and current smokers were analyzed separately.
Methods
Study Population
The study was conducted within the Rotterdam Study, a single-center prospective fol-
low-up study in which all residents aged 55 years and over of the Rotterdam suburb
Ommoord were invited to take part. The baseline examination of the Rotterdam Study
was conducted between 1990 and 1993. The Medical Ethics Committee of Erasmus
Medical Center Rotterdam approved the study. Written informed consent was obtained
from all participants. The design of the study has been described previously.13 7983 par-
ticipants were examined (response 78%). In 6869 subjects, the ACE insertion/deletion
polymorphism was genotyped successfully (86%). In the remaining 1114 subjects, no
genotypes were available. We included 2414 non-smokers, 2794 former smokers and
1508 current smokers in our study. We excluded 155 subjects because no information on
smoking status was available. 
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Measurements
At baseline, information concerning medical history, medication use and smoking beha-
vior was obtained with a computerized questionnaire.13 Height and weight were 
measured and body mass index (BMI in kg/m2) was calculated. Blood pressure was 
measured twice, after a minimum of 5 minutes rest, in the sitting position at the right
upper arm using a random zero sphygmomanometer. Participants were asked to abstain
from smoking and drinking alcoholic or caffeine-containing beverages at least two hours
before blood pressure measurements were taken. The average of two measurements,
obtained at a single visit, was used for analysis. Hypertension was defined as a diastolic
blood pressure (DBP) of 100 mmHg or higher and/or a systolic blood pressure (SBP) of
160 mmHg or higher and/or use of anti-hypertensive medication indicated for treatment
of hypertension (grade 2 and 3 of the 1999 WHO criteria)14. Diabetes mellitus was def-
ined as the use of blood glucose-lowering medication and/or random serum glucose level
≥ 11.1 mmol/l. History of myocardial infarction (MI) was defined as self-reported MI con-
firmed by a physician or MI on ECG. Total serum cholesterol and HDL-cholesterol were
determined with an automated enzymatic procedure.15
Genotyping
The II, ID and DD genotypes were detected using the polymerase chain reaction techni-
que (PCR) according to the method of Lindpaintner et al. with some modifications.16 The
insertion and deletion alleles of the ACE gene were identified using a set of oligonucle-
otide primers flanking the polymorphic site in intron 16 (sense primer, 5’GCC CTG CAG
GTG TCT GCA GCA TGT3’ and antisense primer, 5’GGA TGG CTC TCC CCG CCT TGT CTC3’).
The final volume of the PCR mix was 20 ml, containing 50 ng DNA, PCR buffer
(Invitrogen), 1.3 mM MgCl2, 200 mmol dNTPS, 20 pmol primer mix and 0.35 units Taq
polymerase. The thermo cycling procedure was identical to the method of Lindpaintner
et al. The result of amplification was a 319-bp amplicon for the D-allele and a 597-bp
amplicon for the I-allele. Because the D-allele in heterozygous subjects is preferentially
amplified, there is a tendency of misclassification of ID-genotypes into DD-genotypes (4-
5%). In order to avoid this misclassification, a second independent PCR was performed
with a primer pair that recognizes an insertion specific sequence (5’TGG GAC CAC AGC
GCC CGC CAC TAC3’ and 5’TCG CCA GCC CTC CCA TGC CCA TAA3’). To optimize the
second PCR, 10% DMSO, 0.35 units AmpliTaq Gold DNA polymerase and GeneAmp PCR
Gold buffer (Applied Biosystems) were used in the PCR mix. This reaction yielded a 335-
bp amplicon only if the I-allele was present. All reactions were performed in 96-well pla-
tes with the help of a robot (Beckman Biomek® 2000). Fragments were separated and
visualized using 3% Agarose gels, Ethidium Bromide staining and UV trans-illumination.
Two independent investigators read pictures from each gel. All ambiguous samples were
analyzed a second time.
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Data Analysis
Hardy-Weinberg equilibrium proportions of the ACE insertion/deletion polymorphism
were tested using the GENEPOP-package (Raymond M. & Rousset F., 1995. GENEPOP 
version). General characteristics, stratified by smoking status and ACE genotype, were
compared using the unpaired T-test for continuous variables and 2- statistics for dicho-
tomous variables. Mean systolic and diastolic blood pressure in non-, former and current
smokers were stratified by ACE genotype and analyzed using multivariate analysis of
variance. To examine the effect of the ACE genotype on the risk of hypertension, logistic
regression analysis was performed within the non-, former and current smokers. In these
analyses, subjects carrying the II-genotype were used as the reference group. The analy-
ses on hypertension, SBP and DBP were adjusted for possible confounders age, sex, BMI,
total cholesterol, HDL-cholesterol and diabetes mellitus. The analyses on SBP and DBP
were additionally adjusted for anti-hypertensive medication use. For all statistical analy-
ses we used SPSS for Windows, version 11.0.
Results
Genotype frequencies were in Hardy-Weinberg equilibrium in all three smoking groups. 
Table 1 presents baseline characteristics of the overall study population and stratified by
smoking status. About 50-60% of the current and former smokers were male, compared
to only 9% in non-smokers. Current smokers were younger (66.7 ± 8.2 yrs) compared to
former smokers (68.5 ± 8.2 yrs) and non-smokers (71.9 ± 10.0 yrs) (p<0.01). SBP was sig-
nificantly lower in current and former smokers (136.6 ± 22.5 mmHg and 138.6 ± 21.8
mmHg) compared to non-smokers (142.4 ± 22.8 mmHg) (p<0.05). DBP was lowest in cur-
rent smokers and highest in former smokers (73.2 ± 11.8 mmHg vs. 74.0 ± 11.6 mmHg).
The prevalence of hypertension was lowest in current smokers (27.9%) and highest in
non–smokers (39.6%) (p<0.01). The use of anti-hypertensive medication was also lowest
in current smokers (23.9% compared to 33.1% for former and 37.1% for non-smokers)
(p<0.05). BMI, total and HDL-cholesterol were significantly lower in current and former
smokers compared to non-smokers (p<0.05). The prevalence of myocardial infarction was
significantly higher in current and former smokers than in non-smokers (12.1 % and 13.6
% vs. 7.9 %) (p<0.01). The prevalence of diabetes mellitus did not differ significantly be-
tween the three groups. 
In table 2a, 2b and 2c, general characteristics of non-smokers, formers smokers and
current smokers, stratified by ACE genotype, are presented. Mean packyears (mean num-
ber of cigarettes smoked per day times the total years of smoking ± SD) for current smo-
kers was 30.4 ± 19.8 for II-carriers, 33.3 ± 22.2 for ID-carriers and 30.7 ± 20.1 for DD-
carriers. Mean packyears for former smokers was 26.0 ± 26.7 for II-carriers, 24.7 ± 24.5
for ID-carriers and 26.0 ± 26.5 for DD-carriers. Both in current and former smokers mean
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Total study population Non-smokers Former smokers Current smokers
Number - no (%) 6869 2412 2794 1508
Sex - % men 40.1 9.4 60.3** 53.2**
Age - yrs 69.5 ± 9.2 71.9 ± 10.0 68.5 ± 8.2* 66.7 ± 8.2*
SBP - mmHg 139.3 ± 22.4 142.4 ± 22.8 138.6 ± 21.8* 136.6 ± 22.5*
DBP - mmHg 73.7 ± 11.6 73.6 ± 11.6 74.0 ± 11.6 73.2 ± 11.8
Hypertension - % 34.3 39.6 33.7* 27.9**
Anti-hypertensive medication - % 32.6 37.1 33.1* 23.9**
BMI - kg/m2 26.3 ± 3.7 26.8 ± 3.9 26.4 ± 3.4* 25.4 ± 3.8**
Total cholesterol - mmol/l 6.6 ± 1.2 6.7 ± 1.2 6.5 ± 1.2* 6.6 ± 1.3*
HDL-cholesterol - mmol/l 1.3 ± 0.4 1.4 ± 0.4 1.3 ± 0.4* 1.3 ± 0.4*
Myocardial Infarction - % 10.9 7.9 13.6** 12.1**
Diabetes mellitus - % 10.3 11.4 9.3 10.5
Table 1. General characteristics of the total study population and stratified by smoking status
All values are presented as percentage or mean ± standard deviation. *Significantly different
from non-smokers, p<0.05. **Significantly different from non-smokers, p<0.01.
ACE genotype II ID DD
Number - no (%) 512 (21.2) 1199 (49.7) 701 (29.1)
Sex - % men 9.0 9.7 9.1
Age - yrs 71.7 ± 10.2 72.0 ± 9.8 72.0 ± 10.1
SBP - mmHg 141.7 ± 23.2 142.1 ± 23.0 142.6 ± 21.8
DBP - mmHg 73.0 ± 11.7 73.9 ± 11.6 74.0 ± 11.2
Hypertension - % 36.9 40.5 40.1
Anti-hypertensive medication - % 34.7 36.6 39.6
- -blocker 16.1 15.5 14.2
- diuretic 17.5 19.7 21.0
- other 12.4 13.0 15.2
BMI - kg/m2 26.9 ± 4.0 26.6 ± 3.8 26.9 ± 4.0
Total cholesterol - mmol/l 6.7 ± 1.3 6.7 ± 1.2 6.7 ± 1.2
HDL-cholesterol - mmol/l 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.4
Myocardial Infarction - % 6.6 10.1 7.6
Diabetes mellitus - % 12.3 12.1 9.4
Table 2a. General characteristics non-smokers stratified by ACE genotype
All values are presented as percentage or mean ± standard deviation.
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packyears did not significantly differ between genotypes. Within the non- and former
smokers, no significant differences in general characteristics were seen between the
genotype strata. In current smokers however, SBP was significantly higher in DD-subjects
(137.8 ± 23.8 mmHg) compared to II-subjects (134.3 ± 20.7 mmHg) (p<0.05). The preva-
lence of hypertension was significantly higher in DD-and ID-subjects (29%) than in II-
subjects (23%) (p<0.05). The use of anti-hypertensive medication was also significantly
higher in ID- and DD-subjects (26.3 and 23.4%) compared to II-subjects (19.2%) (p<0.01).
Use of diuretics and other forms of anti-hypertensive medication was highest in ID-sub-
jects. Mean age, percentage of males, BMI, total and HDL-cholesterol, and the prevalen-
ce of MI and diabetes mellitus did not differ significantly between the three genotypes. 
Figure 1 shows mean adjusted SBP, stratified by ACE genotype in non-, former and
current smokers. SBP was significantly lower in smokers compared to non- and former
smokers, independent of genotype status (p<0.05). Within the smokers group, SBP signi-
ficantly increased with the number of D-alleles present (p-trend=0.05). Smokers carrying
the DD-genotype had a mean SBP of 139.6 ± 22.8 mmHg compared to 136.0 ± 22.7
mmHg for smokers carrying the II-genotype. The difference in SBP between II and DD-
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ACE genotype II ID DD
Number - no (%) 625 (22.4) 1381 (49.4) 788 (28.2)
Packyears smoking 26.0 ± 26.7 24.7 ± 24.5 26.0 ± 26.5
Sex - % men 63.0 59.4 59.6
Age - yrs 67.9 ± 8.1 68.7 ± 8.1 68.7 ± 8.3
SBP- mmHg 137.8 ± 21.5 138.4 ± 22.0 139.2 ± 21.5
DBP- mmHg 74.4 ± 11.8 73.8 ± 11.7 74.1 ± 11.1
Hypertension - % 32.6 34.6 32.8
Anti-hypertensive medication - % 32.3 33.9 32.1
- -blocker 17.0 16.5 15.5
- diuretic 14.1 14.1 13.8
- other 13.6 14.8 14.6
BMI - kg/m2 26.3 ± 3.3 26.4 ± 3.5 26.5 ± 3.3
Total cholesterol - mmol/l 6.5 ± 1.3 6.6 ± 1.2 6.5 ± 1.2
HDL-cholesterol - mmol/l 1.3 ± 0.4 1.3 ± 0.4 1.3 ± 0.4
Myocardial Infarction - % 14.9 14.5 14.1
Diabetes mellitus - % 9.1 10.2 8.0
Table 2b. General characteristics former smokers stratified by ACE genotype
All values are presented as percentage or mean ± standard deviation. Packyears is defined as
mean number of cigarettes smoked per day times the total years of smoking. 
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carriers in smokers was significant (3.6 mmHg; 95 %CI: 0.3-6.9, p=0.04). In non-smokers,
SBP did not differ significantly between genotypes (II: 140.3 ± 23.3 mmHg, ID: 140.7 ±
23.0 mmHg, DD: 141.3 ± 21.5 mmHg). Findings in former smokers were similar to those
of non-smokers; no effect of the ACE polymorphism on SBP was observed in this group
(II: 138.3 ± 21.6 mmHg, ID: 138.2 ± 22.1 mmHg, DD 139.1 ± 23.3 mmHg).
In figure 2, mean adjusted DBP in non-, former and current smokers, stratified by ACE
genotype, is presented. Mean DBP did not differ significantly between II, ID and DD sub-
jects within the three smoking groups. 
Figure 3 shows the risk of hypertension in non-, former and current smokers for each
genotype. Subjects homozygous for the I-allele were used as the reference group and
their risk of hypertension defined as one. In non- and former smokers, subjects carrying
one or two copies of the D-allele did not have a significantly increased risk of hyperten-
sion. In smokers, the risk of hypertension was significantly increased both in ID-subjects
and DD-subjects. Smokers who carry one or two copies of the D-allele had an increased
risk of hypertension of 1.4 (95% CI: 1.0-1.9, p=0.05) and 1.5 (95%CI: 1.1-2.2, p=0.02) res-
pectively.
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ACE genotype II ID DD
Number - no (%) 336 (22.3) 778 (51.6) 394 (26.1)
Packyears smoking 30.4 ± 19.8 33.3 ± 22.2 30.7 ± 20.1
Sex - % men 49.1 54.8 53.6
Age - yrs 66.0 ± 8.0 67.0 ± 8.1 66.7 ± 8.4
SBP - mmHg 134.3 ± 20.7 136.8 ± 22.8 137.8 ± 23.8*
DBP - mmHg 73.0 ± 11.8 73.2 ± 11.7 73.7 ± 11.9
Hypertension 23.2 29.0* 29.6*
Anti-hypertensive medication - % 19.2 26.3** 23.4*
- -blocker 9.9 11.1 10.5
- diuretic 7.1 12.0* 8.7
- other 6.8 12.6* 9.7
BMI - kg/m2 25.7 ± 4.4 25.4 ± 3.7 25.2 ± 3.5
Total cholesterol - mmol/l 6.7 ± 1.3 6.6 ± 1.2 6.6 ± 1.2
HDL-cholesterol - mmol/l 1.3 ± 0.4 1.3 ± 0.3 1.3 ± 0.4
Myocardial Infarction - % 9.5 12.9 13.7
Diabetes mellitus - % 8.6 11.3 10.4
Table 2c. General characteristics current smokers stratified by ACE genotype
All values are presented as percentage or mean ± standard deviation. *Significantly different
from II-subjects, p<0.05. **Significantly different from II-subjects, p<0.01. Packyears is defined
as mean number of cigarettes smoked per day times the total years of smoking.
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Figure 1. Systolic blood pressure (mmHg) in non-smokers, former smokers and current smokers, stratified 
by ACE genotype: II (white bars), ID (black bars) and DD (gray bars). *p for trend=0.05. **Significantly dif-
ferent between II and DD-subjects, p<0.05. All values were adjusted for age, sex, BMI, total cholesterol, 
HDL-cholesterol, diabetes mellitus and anti-hypertensive medication.
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Figure 2. Diastolic blood pressure (mmHg) in non-smokers, former smokers and current smokers, stratified 
by ACE genotype: II (white bars), ID (black bars) and DD (gray bars). All values were adjusted for age, sex, 
BMI, total cholesterol, HDL-cholesterol, diabetes mellitus and anti-hypertensive medication.
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Figure 3. Risk of hypertension in non-smokers, former smokers and current smokers, stratified by ACE 
genotype: II (white bars), ID (black bars) and DD (gray bars). Subjects carrying two copies of the I-allele 
were used as a reference in each smoking group. *Significantly different from reference group (II), p<0.05. 
All values were adjusted for age, sex, BMI, total cholesterol, HDL-cholesterol and diabetes mellitus.
Discussion
In this population-based study, we found a significant association between the ACE I/D
polymorphism, systolic blood pressure and the risk of hypertension in smokers. Subjects
who smoke and carry the D-allele have significantly increased systolic blood pressure and
an increased risk of hypertension compared to subjects who smoke and carry the II-geno-
type. We also found that in smokers, who carry one or two copies of the D-allele, even
though they have higher systolic blood pressure, a higher percentage uses anti-hyper-
tensive medication than in smokers carrying the II-genotype. In non-smokers and former
smokers, no relation between the ACE genotype and blood pressure or risk of hyperten-
sion was observed. 
The ACE I/D polymorphism has been studied extensively in relation to hypertension
but findings remain controversial. Since regulation of blood pressure most likely results
from a complex of interactions between gene-gene and gene-environmental factors,
part of the conflicting findings on candidate genes for hypertension may be explained
by differences in genetic make-up and environmental exposure status of the populations
studied.8 The large diversity in geographical, racial and medical background of the study
populations may have yielded false positive as well as false negative associations. This
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context-dependency may also account for the conflicting findings on the ACE gene and
cardiovascular disease. Three large population-based studies found evidence for an effect
of the ACE polymorphism on blood pressure in males only, however many others could
not confirm any association between the ACE gene and blood pressure in neither men
nor women.7,17-22 Although this male-specificity of the ACE gene remains to be fully
investigated it could have accounted for our (false) negative findings in the non-smo-
kers group, since in this group only 9% was male. Nevertheless, male-specificity is unli-
kely to have caused the negative findings in the former smokers group, since about 60%
was male in this group. Our findings suggest that male-specific findings on the ACE gene
may in fact be confounded by differences in environmental exposure status, e.g. smo-
king-habits, between males and females. 
Recently, a number of studies have indeed raised evidence for smoking-associated
effects of the ACE I/D polymorphism on cardiovascular disease. Hibi et al.23 reported an
increased severity of coronary atherosclerosis in subjects who smoke and carry two copies
of the D-allele. In a study by Butler et al.10, significant blunting of endothelial function
was observed in DD-carriers, especially when they smoked. So far, these studies on smo-
king-associated effects of the ACE gene have been performed in small, selected groups
of patients and, although endothelial dysfunction is one of the key features of hyper-
tension, studies on the smoking-associated effect of the ACE-gene in the development
of high blood pressure have not been performed. 
In order to appreciate our results in the right context, several issues require dis-
cussion. We have found that carrying the D-allele is associated with increased systolic
blood pressure in smokers, but, overall, smokers had significantly lower systolic blood
pressure and were less often hypertensive than non- and former smokers. This observa-
tion has been reported consistently in other large epidemiological studies.24 A great
number of possible explanations for this observation have been discussed, but the under-
lying mechanism remains essentially unexplained. Our findings suggest that, besides the
effect of the ACE genotype in smokers, there must be other smoking-associated factors
that cause smokers to have lower blood pressure than non-smokers. Another issue that
needs to be addressed is that the effect of the D-allele and smoking seems to be restric-
ted to systolic blood pressure only. In accordance with our findings, smoking has fre-
quently been associated with increased arterial stiffness, as expressed by an increase in
systolic rather than diastolic blood pressure.25-27 Findings regarding the ACE I/D poly-
morphism and systolic blood pressure or isolated systolic hypertension have not, how-
ever, been very conclusive so far.28,29
Our findings suggest that there is a direct effect of smoking together with the D-alle-
le on blood pressure. This observation may be explained by the fact that both smoking
and ACE increase the degradation of NO and production of free radicals, causing endo-
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thelial damage and impaired vasodilatation.11,30 There is also evidence that suggests that
smoking causes enhanced endothelial ACE activity through increased ACE expression.31
We are the first to assess the systemic smoking-associated effects of the ACE gene in
the general elderly population. Although the smoking-dependent effects of the ACE gene
may be different or even absent in a younger population we believe our study provides
additional evidence to the observation that the ACE gene may have smoking-dependent
effects on the vasculature. Several studies have already reported that smoking status may
influence the effects of the ACE-genotype on vasomotor tone and endothelial function.
We hypothesize that synergistic effects on the modulation of vascular tone may explain
the effects of the D-allele and smoking on systolic blood pressure. Although our findings
may not have direct implications for the treatment of hypertension, we think our obser-
vation may contribute to a better understanding of the pathophysiological mechanism
of gene-environment interactions in the development of high blood pressure. 
In conclusion, we found a modest but significant effect of the ACE I/D polymorphism
on systolic blood pressure and risk of hypertension in smokers. Although the exact patho-
physiological pathway of the effects of smoking together with the presence of the D-
allele on the development of high blood pressure remains to be solved, our study underl-
ines the importance of gene-environment interactions in the study of complex diseases
such as hypertension.
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2.2. A STUDY OF GENE-ENVIRONMENT INTERACTION ON THE 
ANGIOTENSIN CONVERTING ENZYME GENE: A COMBINED 
FUNCTIONAL AND POPULATION-BASED APPROACH
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ABSTRACT70
Introduction: Studies on the role of the
insertion/deletion (I/D) polymorphism of the
angiotensin-converting-enzyme (ACE) gene
in atherosclerosis have been inconsistent. In
a meta-analysis, we recently showed that
this relationship is stronger in high-risk
populations. In this paper we used a com-
bined functional and population-based
approach to investigate a gene-environment
interaction of the ACE I/D polymorphism in
relation to carotid artery wall thickness. 
Methods: The study was embedded in the
Rotterdam Study, a prospective population-
based cohort study. In 5321 subjects, IMT
was measured in the carotid arteries by
ultrasonography and ACE genotype was
determined by size-analysis of polymerase
chain reaction products. 
Results: In multiple regression analysis, the
ACE I/D polymorphism and smoking were
the main determinants for plasma ACE 
activity (r2 = 0.28). There was a positive
asso-ciation between the D allele of the I/D
polymorphism and carotid IMT among cur-
rent smokers (p = 0.03). Subjects carrying
only one of the risk factors (smoking or the
D allele) did not show significant differences
in IMT compared to II non- and former smo-
kers group, while carriers of both risk factors
had significant higher IMT. The association
was not present in non- and former smo-
kers.
Discussion: The results provide further evi-
dence that genetic and environmental fac-
tors interact in the formation of the arterial
lesions. This study shows that large popula-
tion based studies can be helpful in 
unraveling the genetic origin of complex
diseases such as atherosclerosis. 
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Introduction
Angiotensin converting enzyme (ACE) is a key component in the renin angiotensin system
(RAS), converting angiotensin I to angiotensin II.1 It also inactivates vasodilator bradyki-
nin. Both peptides play central roles in blood pressure regulation and are believed to be
important in the pathogenesis of cardiovascular diseases. ACE levels in plasma and tissue
are under genetic control.2-4 There is a common insertion/deletion (I/D) polymorphism in
the ACE gene characterized by the presence or absence of a 287 bp alu repeat. Subjects
with the DD genotype have higher plasma ACE activity compared to those with ID and II
genotypes.2,3 This finding predicts that carriers of this genotype may have an increased
blood pressure and higher prevalence of cardiovascular diseases. 
Findings on the association between the ACE I/D polymorphism and atherosclerosis
using ultrasonographic measurements of carotid arteries have been inconsistent. Some
studies showed a relation between atherosclerosis and the presence of the D allele,5-8
while others failed to show such association.9,10 The majority of the studies conducted
until now were based on relatively small sample sizes, which may in part explain the
inconsistency, particularly when interactions were studied.11 A recent evaluation of can-
didate gene studies in a meta-analysis demonstrated that large studies are needed to
show the effects of the genes involved in complex traits.11 Recently, we performed a
meta-analysis of the association between this polymorphism and carotid artery intima
media thickness (IMT), using all studies conducted until October 2002.12 When pooling
the data of 23 articles (9833 subjects), we found that carriers of the DD genotype have
an increased thickness of common carotid IMT. The relation was most pronounced in
high-risk populations suggesting gene-environment interactions.12
From our meta-analysis it is not clear which factor is interacting with the ACE gene.
As studies of gene-environment interactions are prone to false positive and negative fin-
dings, we used a combined functional and population-based approach. To unravel the
role of interactions of the ACE I/D polymorphism with other factors, in this study we
aimed to identify the non-genetic determinants of the renin-angiotensin system, speci-
fically those associated with serum ACE activity. We studied various vascular risk factors
in relation to ACE activity and found that smoking was the only determinant of ACE 
activity in addition to the ACE gene. Second, we investigated the ACE gene and its inter-
action with smoking in relation to carotid ultrasonographic measurements and found
evidence that smoking modifies the effects of the ACE I/D polymorphism on carotid arte-
ry lesions. 
Methods
Study population
This study is embedded in the Rotterdam Study, an ongoing population-based follow-up
study. The study is designed to investigate the determinants of chronic diseases in the
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elderly and has been described in more detail elsewhere.13 In brief, baseline data were
collected between March 1990 and July 1993 on 7983 subjects, aged 55 years or older,
living in Rotterdam, the Netherlands.13 The study was approved by the Medical Ethics
Committee of Erasmus Medical Center Rotterdam, and written informed consent was
obtained from all participants. All participants were interviewed at home by a trained
research assistant using computerized questionnaires, and they subsequently visited the
study center. Smoking history was assessed during the interview at home and was cate-
gorized as never, former, or current smoker. At the study center an extensive physical
examination was performed, including ultrasonography of carotid arteries. Blood sample
was drawn and serum and plasma were stored at -80°C. 
Carotid ultrasonography
Carotid atherosclerosis was assessed by carotid duplex scan ultrasonographic investiga-
tion of the carotid arteries, by means of a 7.5 MHz linear array transducer (ATL, Ultramark
IV). Measurements of intima media thickness were performed offline from the frozen
images recorded on videotape. Details about this measurement have been published pre-
viously.14 Briefly, the interfaces of the far and near wall of the distal common carotid
artery are marked over a length of 10 mm. We used the average of the measurements of
3 frozen images of both the left and right arteries. Carotid IMT was determined as the
mean of the maximum IMT of near and far wall measurements of both the left and right
arteries. Results from a reproducibility study of IMT measurements have been published
elsewhere.15 In short, mean differences (SD) in common carotid IMT between paired 
measurements of sonographers, readers and visits were 0.005 mm (0.09), 0.060 mm (0.05)
and 0.033 mm (0.12), respectively. We defined plaques as focal widening of the vessel
wall with protrusion into the lumen, composed of calcified or non-calcified components.
The protrusion was evaluated by eye, without measuring the thickness of the lesions or
of the adjacent structure. The total plaque score reflected the total number of sites with
plaques and ranged from 0 to 6 (left- and right-sided common carotid arteries, bifurca-
tion, and internal carotid arteries).
Laboratory assessments 
Colorimetric determination of ACE activity was performed in the stored plasma samples
(-80ºC). Because of cost considerations, ACE levels were assessed in a random group of
215 individuals. The measurements were carried out with a kit by Fujirebio Inc, which
uses a p-hydroxy-Hip-His-Leu substrate.16 Fluorimetric assay of ACE activity in plasma
was performed by measuring the release of His-Leu from the substrates Hip-His-Leu and
Z-Phe-His-Leu.17,18 DNA was isolated from the blood samples using standard procedures
(salting out method).19 The II, ID and DD genotypes were detected by PCR according to
the method of Lindpaintner et al20 with some modifications. The insertion and deletion
alleles of the ACE gene were identified by using a set of oligonucleotide primers flanking
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isocrg_def_f  16-08-2004  12:43  Pagina 72
the polymorphic site in intron 16. The final volume of the PCR mix was 20 ml containing
50 ng DNA as template and 1 x PCR buffer (Gibco), 1.3 mM MgCl2, 200 mmol dNTPS, 20
pmol primer mix and 0.35 units Taq polymerase in a PE9600 PCR machine. The thermo-
cycling procedure was completely identical to the method of Lindpaintner et al20. The
result of amplification were 319-bp and 597-bp amplicons for the D and I alleles res-
pectively. Because the D allele in heterozygous samples is preferentially amplified, there
is a tendency of misclassification for about 4 – 5 % of ID genotypes to DD. In order to
avoid this misclassification, a second independent PCR has been performed with a pri-
mer pair that recognizes an insertion specific sequence. To optimize the second PCR 10%
DMSO, 0.35 units AmpliTaq Gold DNA polymerase and 1 x GeneAmp PCR Gold buffer
(Applied Biosystems) was added to the PCR mix with annealing temperature of 67°C. The
reaction yielded a 335-bp amplicon only if the I allele was present. All reactions were
performed in 96-well plates and handled by a robot (Beckman Biomek® 2000). In the
post-PCR analyses, 10 ml of PCR product was loaded on 3% agarose gel. Fragments were 
visualized using ethidium bromide staining and UV transillumination. Two independent 
investigators read pictures from each gel and all ambiguous samples were analyzed a
second time.
Statistical analyses
Hardy-Weinberg equilibrium was tested with a 2-test. We analyzed the distribution of
conventional cardiovascular risk factors among three genotype groups using 2-statistics
for dichotomous variables and ANOVA analyses for continuous variables. Multiple linear
regression analysis was used to analyze the relation between vascular risk factors and
ACE activity. The differences of ACE activity and IMT between the smoking and genoty-
pe groups were tested using a general linear model univariate procedure, adjusted for age
and gender. In addition, subjects were divided into two groups based on the number of
plaques in the carotid arteries (0-2 plaques and 3 or more plaques). Logistic regression
was used to estimate the adjusted odds ratios for the different genotype groups using
subjects with the II genotype as reference. No adjustments were initially made for vas-
cular risk factors such as hypertension, since they may act as intermediate factors.
Interaction of the ACE genotype with smoking was tested using a multiplicative model.
All statistical analyses were conducted using SPSS for windows version 11.0.
Results
We performed our analysis on 5321 subjects for whom the complete data of ACE geno-
typing, IMT measurements and smoking status were available. Data for at least one of the
variables was missing in the remaining subjects due to logistic reasons; mainly because
the subjects were too old or disabled to visit the research center for the examination. In
our sample, the frequency of the D allele was 53.3% and the distribution of the genoty-
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ACE genotype
II (n = 1156) ID (n = 2657) DD (n = 1508)
Sex - % male 41.70 40.80 39.66
Age – yrs 68.03 ± 8.53 69.08 ± 8.67† 69.25 ± 8.89†
Body mass index – kg/m2 26.39 ± 3.82 26.22 ± 3.65 26.31 ± 3.63
Current smokers - % 22.88 23.60 20.82
Total cholesterol - mmol/l 6.62 ± 1.28 6.66 ± 1.17 6.61 ± 1.21
HDL cholesterol - mmol/l 1.34 ± 0.35 1.35 ± 0.35 1.35 ± 0.37
SBP – mmHg 137.67 ± 21.61 139.09 ± 22.66 140.01 ± 22.84†
DBP – mmHg 73.48 ± 11.64 73.53 ± 11.63 73.73 ± 11.29
Hypertension* - % 31.78 36.03† 35.05
Common carotid IMT - mm10-1 7.88 ± 1.53 7.99 ± 1.59 8.03 ± 1.59†
No. of carotid plaques >= 3 - % 20.90 23.58 23.75
Table 1. Demographic characteristics of subjects stratified by ACE I/D Genotype
Values are presented as percentage or mean ± standard deviation. ACE, angiotensin-converting
enzyme; I/D, insertion/deletion; HDL, high density lipoprotein; BP, blood pressure; IMT, intima
media thickness. *Hypertension defined as SBP >= 160 mmHg or DBP >=100 mmHg or medica-
tion use. †p<0.05 compared to II genotype.
Variable ß SE p-value
ACE I/D polymorphism* 2.71 0.35 <0.01
Current smoking 1.92 0.61 <0.01
Male sex 0.63 0.54 0.24
Age -0.07 0.06 0.20
Body mass index 0.07 0.08 0.37
Total cholesterol -0.19 0.23 0.42
HDL cholesterol 0.95 0.76 0.22
SBP -0.01 0.02 0.84
DBP -0.02 0.04 0.56
Table 2. Vascular risk factors and their association with plasma ACE levels
ß: regression coefficient; SE: standard error of the coefficient.
*Number of the D alleles used in the equation (II = 0, ID = 1 and DD = 2).
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pes and allele frequencies were in Hardy-Weinberg equilibrium (II, 21.7%; ID, 49.9%; and
DD, 28.3%; p-value = 0.82). Among the remaining subjects for whom the genotype fre-
quencies were available (n = 1548), no deviation from Hardy-Weinberg equilibrium was
observed. Furthermore, there was no significant difference in the genotype frequencies
between the two samples (p-value= 0.44). 
Table 1 shows the demographic characteristics of the participants stratified by ACE
genotype. No significant differences were found among the 3 genotypes with respect to
classical cardiovascular risk factors. However, the carriers of the D allele were signifi-
cantly older than the II carriers but the difference was only 1.22 years. Furthermore, 
carriers of the DD genotype had a significantly higher mean systolic blood pressure as
well as a higher mean of carotid IMT compared to the II genotype. Although there was a
slight increase in the percentage of subjects with three or more plaques with the num-
ber of D alleles present, the frequency did not differ significantly between carriers of the
D allele and carriers of the II genotype (Table 1).
In the sample of 212 individuals for whom both plasma ACE activity and I/D genoty-
pes were measured, the allele and genotype proportions were consistent with Hardy-
Weinberg equilibrium (p-value = 0.48). In multiple linear regression analysis, ACE I/D
polymorphism and smoking were the only determinants of plasma ACE activity (Table 2).
These two factors together explained 28% of the variation of the enzyme levels in serum
(r = 0.53, p<0.01). The activity of ACE was not significantly different between former
smokers and non-smokers (14.83 ± 3.57 and 15.58 ± 3.87 U/l, respectively); therefore we
combined these two groups. Overall, the ACE activity was 1.8 U/l higher in current smo-
kers compared to non- and former smokers (p<0.01). Although the difference in ACE
activity between smokers and non- and former smokers was largest in the ID and DD
group, it was not significantly different from the difference in the II group (Figure 1).
When studying the joint effects of smoking and the ACE I/D polymorphsim on IMT,
there was a significant increase in mean carotid IMT in the number of D alleles present
in current smokers (p for trend = 0.04). The difference in IMT (mean ± SE) between DD
and II genotypes in smokers was 0.26 ± 0.12 10-1 mm, (p-value=0.03). In contrast, IMT
was not significantly associated with the D allele among non- and former smokers
(Figure 2). The p-value for interaction between ACE genotypes and smoking status was
0.08. The differences in IMT between the ACE genotype groups in smokers reduced but
did not disappear when adjusted for systolic blood pressure. Subjects carrying only one
of the risk factors (smoking or the D allele) did not show significant differences in IMT
compared to the non- and former smokers group carrying the II genotype, while carriers
of both risk factors had significant higher IMT (p<0.01).
The odds ratios of having three or more plaques in carotid arteries in current smokers
were 1.14 (95% CI: 0.81-1.59) and 1.40 (95% CI: 0.96-2.04) for ID and DD genotypes res-
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Figure 2. Carotid intima media thickness (IMT) in different genotype groups stratified by 
smoking status. Data are adjusted for age and gender. *Significantly different from non- and 
former smokers in II genotype group. †Significantly different from smokers in II genotype 
group.
17.9*
14.7*
12.9
19.5*
16.8*
13.7
10
12
14
16
18
20
22
II ID DD
Genotypes
Non/former smokers Smokers
A
C
E
 le
ve
l (
U
/L
)
n = 35 n = 11 n = 88 n = 23 n = 45 n = 10
Figure 1. Plasma ACE activity in different genotypes groups, stratified by smoking status.
Data are adjusted for age and gender, *Significantly different from non- and former smokers in
II genotype group.
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pectively. This increase of odds ratios with the number of the D alleles was borderline sig-
nificant (p=0.07) while in non- and former smokers the odds ratios remained the same
between genotype groups.
Stratified analyses concerning the combined effect of ACE polymorphism and other
cardiovascular risk factors (hypertension, hyperlipidemia, diabetes mellitus, obesity, age
and gender) on carotid IMT did not show any significant difference among and between
the stratified groups. In all the analysis the mean IMT difference between DD and II geno-
types was less than 0.20 10-1mm and did not reach significance level (p>0.10).
Discussion
In this population-based study, we found a modest but significant association between
the ACE I/D polymorphism and carotid IMT in the presence of smoking. In non- and for-
mer smokers, no significant association between the ACE genotype and IMT was 
observed.
This study is the largest population-based study performed on the ACE I/D polymor-
phism and carotid artery lesions. The next largest study, which included 3657 individuals
in Japan did not observe a relation between ACE and IMT.21 Difference in ethnicity could
be a possible explanation; however, the problem in comparing findings is that the inter-
action between the ACE I/D polymorphism and smoking was not studied by Mannami et
al.21 Findings of other studies on the interaction between the ACE gene and smoking
have not been very consistent. An interaction between smoking and the ACE I/D geno-
type on atherosclerosis was reported by Hibi et al.22 They showed a smoking-associated
effect of the ACE genotype on the severity of coronary atherosclerosis.22 In contrast,
another study found an association between the ACE I/D polymorphism and carotid IMT
only among non- and former smokers, particularly those on chronic cardiovascular medi-
cation.23 Yet others failed to find evidence for interactive effects of the ACE gene on
carotid IMT.24
Genetic studies aiming to uncover gene-environment interactions are prone to false
positive and negative findings. To obtain internal consistency in our study, we did not
only study the relation of the ACE gene to atherosclerosis but also to ACE activity, which
has been studied extensively in relation to polymorphisms in the ACE gene.25-28 Since
Rigat et al reported in 1990 that the ACE I/D polymorphism determines the plasma acti-
vity of the enzyme, many studies have replicated this finding.2,3,8,10 Our data also con-
firm that presence of the deletion allele is significantly associated with the plasma ACE
activity. The ACE activity values in our study were in the same range as those reported in
other population studies that used the same method of measurement.8,29 Although ACE
levels were determined in stored sera and laboratory drift may have occurred, such drift
is unlikely to be associated with the ACE genotype. 
To unravel the role of interactions of the ACE I/D polymorphism with other vascular
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risk factors, we focused on identifying determinants in the renin angiotensin system,
more specifically those associated with serum ACE activity. In our population-based
study, we found that besides the ACE I/D polymorphism, smoking is the only other fac-
tor related to plasma ACE activity, suggesting they use the same pathways. The vascular
risk factors that might be related to serum ACE activity are not well known. In one report
smoking and blood pressure30, and in another male sex and history of hypertension31
were correlated with serum ACE activity. In our sample, the I/D polymorphism and smo-
king together explained 28% of the variance in ACE activity. On average, current smo-
kers had 1.8 U/L higher ACE activity in plasma. The effect of smoking on ACE activity was
larger in the ID and DD genotype groups than in the II genotype group, although the dif-
ferences were not significant. A possible effect of smoking on cleavage secretion of ACE
from the endothelial cells may explain this finding.32 Additionally, there are indications
that nicotine increases expression of a number of genes in endothelium, including ACE.33
The values for IMT in our study strongly concurred with those reported by Tabara et
al, using a sample with the same age.34 In order to test if the observed association be-
tween ACE I/D polymorphism and carotid IMT in presence of smoking was through blood
pressure, we adjusted our analysis for systolic blood pressure. Our result suggests that
blood pressure does not fully explain the association. Recently, it has been shown that
the DD genotype is associated with a significant blunting in nitric oxide (NO) mediated
vasodilatation, possibly due to increased angiotensin II–induced NO breakdown and/or
reduced bradykinin-mediated NO release.35 In addition, other studies have shown that
smoking decreases plasma NO levels that may also lead to impaired endothelium-depen-
dent vasodilation.36,37,38 Furthermore, smoking induces oxidative stress by reducing con-
centrations of NO and other antioxidants in plasma.39 Concurrently, carriers of the DD
genotype showed a lower antioxidant response compared to II and ID genotypes.40 The
above-mentioned observations provide a possible pathophysiological mechanism for our
findings and underline that carriers of the DD genotype who smoke are likely to be at a
higher risk of atherosclerosis. 
Using a combined functional and population-based approach provides us with a 
priori hypothesis for the environmental factor(s) that may interact with the gene.
However, the question remains if other environmental factors can show the same 
pattern of interaction. The results of the stratified analyses showed no significant evi-
dence for joint effect of the ACE I/D polymorphism and other factors, prompting smo-
king as the best candidate for this interaction.
In summary, we found a positive association between the D allele of the ACE I/D poly-
morphism and carotid IMT in the presence of smoking. This association provides further
evidence that genetic and environmental factors interact in the formation of arterial
lesions. There may be various pathways underlying the observation of an effect of the
isocrg_def_f  16-08-2004  12:43  Pagina 78
ACE gene on IMT in smokers only, but on the basis of the present results it is not 
possible to fully explain the underlying mechanism. Our findings remain to be confirmed
in future studies. 
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2.3. ANGIOTENSIN CONVERTING ENZYME 
INSERTION/DELETION POLYMORPHISM AND RISK OF 
HEART FAILURE IN HYPERTENSIVE SUBJECTS
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ABSTRACT86
Aims: Cardiac angiotensin-I conver-
ting enzyme (ACE) activity is influen-
ced by the ACE I/D polymorphism.
Evidence suggests that the DD-geno-
type may be a risk factor for cardiac
hypertrophy and heart failure, espe-
cially in hypertensive subjects. We
assessed the relation between the ACE
I/D polymorphism and the risk of 
incident heart failure in normotensive
and hypertensive subjects.
Methods and Results: We investiga-
ted 4264 normotensive and 2174
hypertensive participants of the
Rotterdam Study; a population based
prospective cohort study. All subjects
were available for follow-up from
1990 until 2000. Incidence rates (IR)
of heart failure in normotensive sub-
jects were the same over all genotype
strata (10 per 1000 personyears). In
hypertensive subjects, the IR increased
with the number of D-alleles present
(II: IR=13, ID: IR=18 and DD: IR=20
per 1000 personyears). Hypertensive
subjects carrying the II-genotype did
not have an increased risk of heart 
failure compared to normotensive II
subjects. However, hypertensive sub-
jects carrying one or two copies of the
D-allele did have a significantly in-
creased risk of heart failure (ID: RR:
1.4 (1.1-1.9) and DD: RR: 1.5 (1.2-2.1)).
Conclusion: Our findings suggest that
the ACE I/D polymorphism may play a
modifying role in the development of
heart failure in hypertensive subjects.
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Introduction
Heart failure is a complex clinical syndrome that can result from any structural or func-
tional cardiac disorder that impairs adequate ventricular filling or ejecting of blood.
Coronary artery disease and hypertension are among the most common risk factors.
Regardless of the initial cause of cardiac stress, the heart will respond with a set of adap-
tive mechanisms in order to maintain its pumping function. Both clinical and experi-
mental data suggest that activation of local renin angiotensin system (RAS) in the heart
plays an important role in this compensatory mechanism to maintain adequate haemo-
dynamic function.1 Recent studies have shown that cardiac expression of angiotensin-I
converting enzyme (ACE) and angiotensinogen is increased in experimental heart 
failure.2,3 In patients with chronic heart failure, cardiac expression of ACE was found to
be increased up to threefold compared to the hearts of subjects without heart failure.4
An Insertion/Deletion (I/D) polymorphism, characterized by the presence or absence
of a 287-base pair alu repeat sequence in intron 16 of the ACE gene, has been reported
to be responsible for about 50% of the interindividual variability in serum ACE levels.5,6
Both serum ACE levels and cardiac ACE activity were highest in subjects carrying two
copies of the D-allele.5-7 The DD-genotype has been put forward as a risk factor for left
ventricular remodeling in hypertensive subjects.8,9 Raynolds et al. observed an increased
frequency of the DD-genotype in patients with both ischaemic and idiopathic dilated
cardiomyopathy.10
We examined the role of the ACE I/D polymorphism in the development of heart fai-
lure in a population-based cohort study. Since several studies reported an effect of the
D-allele on cardiac disease in hypertensive subjects only, we analyzed normotensive and
hypertensive subjects separately.
Methods
Study Population
The study was conducted within the Rotterdam Study, a single-center prospective fol-
low-up study in which all residents aged 55 years and over of the Rotterdam suburb of
Ommoord were invited to take part. The baseline examination of the Rotterdam Study
was conducted between 1990 and 1993. The Medical Ethics Committee of Erasmus
Medical Center Rotterdam approved the study. Written informed consent was obtained
from all participants. The design of the study has been described previously.11 7983 par-
ticipants were examined (response 78%). In 6869 subjects, the ACE I/D polymorphism was
genotyped successfully (86%). In the remaining 1114 subjects, no genotypes were avail-
able. We excluded 211 subjects because no information on blood pressure levels was 
available. 
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At baseline, information concerning medical history, medication use and smoking
behavior was obtained with a computerized questionnaire.11 Blood pressure was measu-
red twice, after a minimum of 5 minutes rest, in the sitting position at the right upper
arm using a random zero sphygmomanometer. Participants were asked to abstain from
smoking and drinking alcoholic or caffeine-containing beverages at least two hours
before blood pressure measurements were taken. The average of two measurements was
used for analysis. Hypertension was defined as a diastolic blood pressure (DBP) of 100
mmHg or higher and/or a systolic blood pressure (SBP) of 160 mmHg or higher and/or
use of anti-hypertensive medication indicated for treatment of hypertension (grade 2
and 3 of the 1999 WHO/ISH criteria and 2003 ESH/ESC criteria).12,13 
Heart failure assessment
Assessment of prevalent heart failure at the baseline examination in the Rotterdam
Study has been described in detail earlier.14 We excluded subjects with prevalent heart
failure from our study (n=220). All participants of the Rotterdam Study were continu-
ously monitored for the occurrence of heart failure during follow-up from 1990 until
2000, using automated linkage with files from general practitioners. All available medi-
cal data, such as hospital discharge letters and notes from general practitioners, were
obtained from the medical records in case of possible heart failure. Apart from this sys-
tematic follow-up procedure, we used verified hospital discharge diagnoses for case fin-
ding, gathered from all hospitals in the Rotterdam area as described above. 
The diagnosis of heart failure was classified as definite, probable, possible or unlike-
ly. Definite heart failure was defined as a combination of heart failure diagnosed by a
medical specialist and the presence of typical symptoms of heart failure, such as breath-
lessness at rest or during exertion, ankle edema and pulmonary crepitations, confirmed
by objective evidence of cardiac dysfunction (chest X-ray, echocardiography). This defi-
nition is in accordance with the criteria of the European Society of Cardiology.15
Probable heart failure was defined as heart failure diagnosed by a general practitioner,
with at least two typical symptoms suggestive of heart failure, and at least 1 of the fol-
lowing: history of cardiovascular disease (e.g. myocardial infarction, hypertension), res-
ponse to treatment for heart failure, or objective evidence of cardiac dysfunction, while
symptoms could not be attributed to another underlying disease. 
Two research physicians independently classified all information on potential heart
failure events. If there was disagreement, a consensus was reached in a separate session.
Finally, a cardiologist verified all probable and possible cases, and all cases in which the
two physicians could not reach consensus. If the cardiologist disagreed with the research
physicians, the cardiologist’s judgment was considered decisive. The research physicians
and the cardiologist based their decisions on the same data. Only definite and probable
cases were included in the analyses.
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After heart failure cases were diagnosed as definite or probable, the date of incident
heart failure was defined as the day of the first occurrence of symptoms suggestive of
heart failure or the date of the first prescription of a loop diuretic or an ACE-inhibitor. 
Genotyping
The II, ID and DD genotypes were detected using the polymerase chain reaction techni-
que (PCR) according to the method of Lindpaintner et al with some modifications.16 In
order to avoid misclassification of ID genotypes into DD genotypes, a second PCR was
performed using an I-specific primer.
Statistical Analysis
Overall general characteristics of normotensive and hypertensive subjects and those 
stratified by ACE genotype, were compared using univariate analysis of variance for con-
tinuous variables and chi-square statistics for dichotomous variables. Differences in
median follow-up between the normotensive and hypertensive group, and between
genotypes within the normotensive and hypertensive group were tested using a Mann-
Whitney non-parametric test for independent samples. Incidence rates (IR) were 
expressed as number of cases per 1000 personyears and presented with 95% confidence
intervals (CI), based on the assumed Poisson distribution for the observed number of
cases. We constructed a numerical variable for the ACE-genotype groups (1-2-3; II-ID-
DD) and performed a linear regression in order to test for trend of IR in the normoten-
sive and hypertensive groups. Relative risks of incident heart failure were assessed using
Cox proportional hazard regression analysis. Proportionality of hazards was assessed and
satisfied by means of a log-minus-log plot. All risk estimates are presented with 95%
confidence intervals (CI). We adjusted for age and sex in all analyses. To assess the effect
of the ACE I/D polymorphism independent of possible confounding or mediating factors,
analyses were repeated adding body mass index (BMI), diabetes mellitus, smoking, myo-
cardial infarction, total and HDL-cholesterol to the model. We tested for statistical inter-
action between the ACE I/D polymorphism and hypertension by adding an interaction
term to the regression model: hypertension (dichotomous) x ACE-genotype (categorical).
All presented p-values are two-sided. We performed all analyses with SPSS version 11.0. 
Results
A total of 6438 subjects were available for follow-up until January 1, 2000. Baseline des-
criptives of the total study population are presented in table 1. We included 4264 nor-
motensive subjects and 2174 hypertensive subjects in our study. Both groups followed
Hardy-Weinberg Equilibrium proportions for the ACE I/D polymorphism. Median follow-
up was 7.2 (6.7;8.1) years for normotensive subjects and 7.0 (5.3;8.0) years for hyperten-
sive subjects. In hypertensive subjects, median follow-up was significantly shorter for
subjects carrying two copies of the D-allele than for subjects carrying two copies of the
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Table 1.Baseline descriptives norm
otensive and hypertensive subjects: overall and stratified by ACE genotype
N
orm
otensive subjects 
H
ypertensive subjects
ACE genotype
O
verall
II
ID
D
D
O
verall
II
ID
D
D
N
um
ber - n (%
)
4264 (66.0)
962 (22.6)
2106 (49.4)
1196 (28.0)
2174 (34.0)
441(20.3)
1116 (51.3)
617 (28.4)
M
edian follow
-up (yrs)
7.2 (6.7;8.1)
7.2 (6.7;8.1)
7.2 (6.7;8.2)
7.2 (6.7;8.1)
7.0 (5.3;8.0)*
7.1 (5.7;8.2)†
7.1 (5.6;8.0) 
7.0 (4.8;7.9)
Age - yrs 
68.0 ±
8.9
67.6 ±
8.8
68.1 ±
8.8
68.4 ±
9.2
71.0 ±
8.8*
70.6 ±
9.0
71.1 ±
8.6
71.2 ±
9.1
Sex - %
 m
ale
42.9
43.2
43.0
42.4
35.3*
34.9
36.1
34.0
SBP - m
m
H
g
130.7 ±
16.1
130.6 ±
16.3
130.2 ±
16.4
131.4 ±
15.8
156.8 ±
22.4*
156.3 ±
22.7
156.5 ±
22.2
157.6 ±
22.5
D
BP - m
m
H
g
70.9 ±
10.0
70.8 ±
10.1
70.6 ±
9.9
71.4 ±
9.9**
80.0 ±
12.0*
80.4 ±
12.5
80.0 ±
12.0
79.4 ±
11.7
D
iabetes m
ellitus - %
7.1
6.5
8.0
6.0
15.0*
15.9
15.8
13.0
M
yocardial Infarction-%
11.3
10.2
11.8
11.3
15.6*
14.6
16.0
15.5
BM
I - kg/m
2
25.8 ±
3.5
25.8 ±
3.7
25.7 ±
3.5
25.9 ±
3.5
27.2 ±
3.9*
27.5 ±
3.8†
27.2 ±
4.0 
27.1 ±
3.7 
Total cholesterol - m
m
ol
6.6 ±
1.2
6.5 ±
1.3
6.6 ±
1.2
6.6 ±
1.2
6.7 ±
1.2*
6.8 ±
1.3 
6.7 ±
1.3 
6.7 ±
1.2 
H
D
L-cholesterol - m
m
ol
1.4 ±
0.4
1.4 ±
0.4
1.4 ±
0.4
1.4 ±
0.4
1.3 ±
0.4*
1.3 ±
0.3
1.3 ±
0.4
1.3 ±
0.4
Sm
oking (current) - %
24.7
25.9
25.5
22.4
18.4*
16.6
19.3
17.9
Values are presented as percentage or m
ean ±
standard deviation, except for follow
 up, w
hich is presented as m
edian (interquartile range). *Significantly different
from
 norm
otensive subjects, p<0.005. **Significantly different from
 norm
otensive ID
-subjects, p<0.05. †Significantly different from
 hypertensive D
D
-subjects, p<0.05.
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I-allele. Hypertensive subjects were significantly older and less often male than normo-
tensive subjects. This difference was the same over all genotype strata. Within the nor-
motensive group, DBP was significantly higher in subjects carrying the DD-genotype
compared to subjects carrying the ID-genotype. Prevalence of diabetes mellitus and
myocardial infarction, mean BMI and total cholesterol levels were significantly higher in
hypertensive subjects compared to normotensive subjects. In the hypertensive group,
BMI was significantly higher in subjects carrying the II-genotype compared to subjects
carrying the DD-genotype. HDL-cholesterol and percentage current smokers were signi-
ficantly lower in hypertensive subjects than in normotensive subjects. This difference was
the same over all genotype strata.
Table 2 shows number of cases, personyears and incidence rates (IR) of heart failure
observed in normotensive and hypertensive subjects stratified by ACE genotype. During
44,883.1 personyears of follow-up 543 participants developed heart failure. In normo-
tensive subjects, the IR of heart failure was about 10 per 1000 personyears, independent
of genotype status. In hypertensive subjects, the IR of heart failure significantly 
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Normotension Hypertension
ACE Number of Person IR Number of Person IR 
genotype cases years (95%CI) cases years (95% CI)
II 67 6823.4 10 (8-12) 39 3020.2 13 (9-17)
ID 131 14970.7 9  (7-10) 138 7616.4 18 (15-21)
DD 88 8377.2 11 (8-13) 80 4075.2 20 (16-24)
Table 2. Number of cases and incidence rates of heart failure stratified by ACE genotype in 
normotensive and hypertensive subjects.
Incidence rate (IR) presented as number of cases per 1000 personyears with 95% confidence
interval.
Model 1 Model 2
Normotension Hypertension Normotension Hypertension
Risk overall: 1.0 (ref) 1.6 (1.4-1.9)† 1.0 (ref) 1.4 (1.2-1.7)†
Risk stratified by ACE genotype:
II 1.0 (ref) 1.1 (0.8-1.7) 1.0 (ref) 1.2 (0.8-1.8)
ID 0.9 (0.6-1.2) 1.5 (1.1-2.0)** 1.0 (0.7-1.3) 1.4 (1.1-1.9)*
DD 1.0 (0.7-1.4) 1.6 (1.2-2.2)** 1.1 (0.8-1.6) 1.5 (1.2-2.1)*
Table 3. Risk of heart failure in normotensive and hypertensive subjects: overall and stratified 
by ACE genotype
Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, BMI, smoking, diabetes melli-
tus, myocardial infarction, total and HDL-cholesterol. Significantly different from overall normo-
tensive group, †p<0.001. Significantly different from II normotensive group, *p<0.05, **p<0.01.
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increased with the number of D-alleles present (p for trend<0.05). In subjects carrying
the II-genotype the IR of heart failure was 13 per 1000 personyears (95%CI: 9;17). In
subjects carrying one or two copies of the D-allele the IR of heart failure increased up to
18 (15;21) and 20 (16;24) per 1000 personyears, respectively.
In table 3, the relative risks (RR) of heart failure for hypertensive and normotensive
subjects, overall and stratified by ACE genotype, are presented. Overall, hypertensive sub-
jects had a significantly increased risk of 1.4 (1.2;1.7) of heart failure compared to nor-
motensive subjects. In the normotensive group, the risk of heart failure did not differ
between the different ACE genotype groups.  Hypertensive subjects carrying two copies
of the I-allele did not have an increased risk of heart failure compared to normotensive
subjects carrying two copies of the I-allele (RR: 1.2 (0.8;1.8) (model 2). However, hyper-
tensive subjects carrying one or two copies of the D-allele had a significantly increased
risk of heart failure compared to normotensive II subjects (ID: RR: 1.4 (1.1;1.9) and DD:
RR: 1.5 (1.2;2.1)) (model 2). Additional analyses including also mild hypertensive subjects
in the hypertensive group (cut-of value for diagnosis hypertension: SBP ≥ 140 mmHg or
DBP ≥ 90 mmHg) did not show a significant effect of the ACE-genotype on the risk of
heart failure. Although the direction of the risk estimates was the same (RR: ID: 1.2
(0.8;1.8) and DD: 1.4 (0.8;2.5) (results not shown in table).
The statistical interaction term between the D-allele of the ACE-genotype and hyper-
tension was borderline significant, (p=0.059). 
Discussion
We observed an increased risk of heart failure in hypertensive subjects compared to nor-
motensive subjects that was dependent on the presence of the D-allele of the ACE I/D
polymorphism. Hypertensive subjects did not have a significantly increased risk of heart
failure compared to normotensive subjects, unless they carried one or two copies of the
D-allele. The incidence rate of heart failure in hypertensive subjects increased with the
number of D-alleles present. As the incidence of heart failure marks the end of the fol-
low-up period, this may also explain the shorter follow-up period observed in hyperten-
sive DD subjects compared to II subjects.
Hypertension is the most common condition antedating heart failure in the general
population.17,18 Especially in the elderly, heart failure is often preceded by long standing
high blood pressure and LVH.19,20 However, the extent of cardiac remodeling does not
always seem to correlate with the extent of cardiac damage. In fact, hypertension may
lead to severe heart failure in one patient whereas hypertension may be without any per-
ceivable effects on cardiac function in another patient. As a consequence, it has been
hypothesized that genetic factors may modulate the manifestation or progression of car-
diac remodelling.21
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The ACE I/D polymorphism is by far the most frequently studied candidate gene in the
development of left ventricular hypertrophy and heart failure. Homozygosity for the D-
allele has been associated with higher prevalence of LVH and increased heart weight in
(untreated) hypertensive subjects.8, 9,22-24 Raynolds et al. were the first to report an asso-
ciation between the ACE I/D polymorphism and heart failure. They observed an increased
frequency of the DD-genotype in subjects with ischaemic and dilated cardiomyopathy.10
Since local formation of angiotensin II (ANG II) within the myocardium is thought to be
involved in the cardiac remodeling process, elevated cardiac ANG II levels in subjects 
carrying the D-allele, may partly explain the association between the DD-genotype and
various cardiac disorders.7 
Although cardiac chymase is also an important ANG II generating enzyme in the
heart, two studies observed that in failing hearts ACE enzyme gene expression was in-
creased, whereas cardiac chymase enzyme gene expression was not.4,33 This may suggest
that in failing hearts ANGII formation is more dependent on ACE than on cardiac chy-
mase and therefore can potentially be modified by the ACE I/D polymorphism. 
Nevertheless, findings remain controversial and so far positive and negative results
seem to outweigh eachother.25-27 Many of the conflicting findings on the ACE I/D poly-
morphism and cardiac disease are most likely due to small sample sizes and large hetero-
geneity of the populations that were studied. Another reason for the inconsistent 
findings may be that the ACE I/D polymorphism by itself does not have enough biologi-
cal significance to exert an effect on cardiac tissue, especially since the RAS is normally
under strict negative feedback inhibition. This has led to the hypothesis that an effect of
the ACE I/D polymorphism on cardiac function may only become clinically relevant under
specific conditions in which the cardiac growth machinery is already activated.28 In line
with this hypothesis, Montgomery et al. observed increased left ventricular mass after
rigorous exercise only in those participants who carried a copy of the D-allele.29 Another
study observed increased adverse cardiac remodeling in subjects with the ACE ID- and
DD-genotype after they had experienced a myocardial infarction.30
We believe our findings provide additional evidence for a modifying effect of the ACE
I/D polymorphism in the development of cardiac disease. In our study, the D-allele was
associated with an increased risk of heart failure in hypertensive subjects only, which
may suggest that the D-allele has an effect on the heart merely when local RAS is alre-
ady activated because of increased haemodynamic load. Since asymptomatic cardiac
remodeling usually precedes the development of clinically overt heart failure in hyper-
tensive subjects, we believe our findings are in accordance with the observation that,
especially in subjects with hypertension, the D-allele of the ACE I/D polymorphism is
associated with increased levels of various echocardiography measures of cardiac hyper-
trophy.8,9,31,32
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Until now, our study is the largest population based study that assessed the role of
the ACE I/D polymorphism in heart failure in a relatively homogenous population, as 98
% of the participants in our study are Caucasians and they all live in the same area of
Rotterdam. In contrast to case-control studies on heart failure that have been conduc-
ted so far, the prospective nature of our study makes our results less prone to survival
bias. Still several issues need to be addressed. We observed a significantly increased risk
of heart failure in moderate and severe hypertensive subjects only. Additional analyses
including also mild hypertensive subjects did not show a significantly increased risk of
heart failure for ID and DD-carriers, although the risk estimates were in the same direc-
tion as those for moderate to severe hypertensive subjects. We believe this implies a
“threshold” effect of the ACE I/D polymorphism, as its detrimental effects on cardiac
function only become present when the heart already is under severe cardiac stress due
to substantially elevated blood pressure levels. Second, we did not account for lifestyle
or dietary factors that may have influenced our genotype-phenotype relationship.
Kuznetsova et al. recently observed that the relationship between left ventricular mass
index and the ACE I/D polymorphism might be modulated by sodium intake.34 Finally, we
were not able to discern the different etiologies of heart failure (idiopathic, ischemic or
other) in our study. However, we think that the ACE I/D polymorphism may be more
important as a modulator in the way the myocardium responds to cardiac damage
(“remodeling”) than in the events leading to cardiac damage. 
The ACE I/D polymorphism may increase the risk of heart failure through an effect on
blood pressure or an increased risk of myocardial infarction; however, our results do not
support this. On the contrary, our findings suggest that hypertension by itself is not a
real strong predictor of heart failure, unless one or two copies of the D-allele are present.
Furthermore, correction for baseline and incident MI in our analyses did not change the
association between heart failure and the ACE I/D polymorphism. In addition, the preva-
lence of MI did not differ significantly between the genotype groups in hypertensive sub-
jects.
In conclusion, our findings suggest that the ACE I/D polymorphism may play a modi-
fying role in the development of heart failure in hypertensive subjects, regardless of the
initial cause of cardiac damage. We believe these findings may provide an additional
genetic clue as to whether some hypertensive subjects do develop cardiac hypertrophy
resulting in heart failure, whereas others do not.
References 1. Dostal DE, Baker KM. The cardiac renin-angiotensin system: cocep-
tual, or a regulator of cardiac function? Circ Res. 1999;85:643-50.
2. Finckh M, Hellmann W, Ganten D, Furtwangler A, Allgeier J, Boltz M,
isocrg_def_f  16-08-2004  12:43  Pagina 94
Holtz J. Enhanced cardiac angiotensinogen gene expression and 
angiotensin converting enzyme activity in tachypacing-induced 
heart failure in rats. Basic Res Cardiol. 1991;86:303-16.
3. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific
activation of cardiac angiotensin converting enzyme in experimental
heart failure. Circ Res. 1991;69:475-82.
4. Studer R, Reinecke H, Muller B, Holtz J, Just H, Drexler H. Increased 
angiotensin-I converting enzyme gene expression in the failing 
human heart. Quantification by competitive RNA polymerase chain 
reaction. J Clin Invest. 1994;94:301-10.
5. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An
insertion/deletion polymorphism in the angiotensin I-converting 
enzyme gene accounting for half the variance of serum enzyme 
levels. J Clin Invest. 1990;86:1343-6.
6. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. 
Evidence, from combined segregation and linkage analysis, that a 
variant of the angotensin I-converting enzyme (ACE) gene controls 
plasma ACE levels. Am J Hum Genet. 1992;51:197-205.
7. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR,
Riegger GA, Schunkert H. Angiotensin-converting enzyme in the 
human heart. Effect of the deletion/insertion polymorphism. 
Circulation. 1995;92:1387-8.
8. Gharavi AG, Lipkowitz MS, Diamond JA, Jhang JS, Phillips RA. 
Deletion polymorphism of the angiotensin-converting enzyme gene
is independently associated with left ventricular mass and geometric
remodeling in systemic hypertension. Am J Cardiol. 1996;77:1315-9.
9. Perticone F, Maio R, Cosco C, Ceravolo R, Iacopino S, Chello M, 
Mastroroberto P, Tramontano D, Mattioli PL. Hypertensive left ven-
tricular remodeling and ACE-gene polymorphism. 
Cardiovasc Res. 1999;43:192-9.
10. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman
LS, Taft CS, Perryman MB. Angiotensin-converting enzyme DD geno-
type in patients with ischaemic or idiopathic dilated cardiomyopathy.
Lancet. 1993;342:1073-5.
11. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. 
Determinants of disease and disability in the elderly: the Rotterdam
Elderly Study. Eur J Epidemiol. 1991;7:403-22.
12. 2003 European Society of Hypertension-European Society of 
95CANDIDATE GENE STUDIES
isocrg_def_f  16-08-2004  12:43  Pagina 95
Cardiology guidelines for the management of arterial hypertension.
J Hypertens. 2003;21:1011-53.
13. 1999 World Health Organization-International Society of 
Hypertension Guidelines for the Management of Hypertension. 
Guidelines Subcommittee. J Hypertens. 1999;17:151-83.
14. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman
A, Grobbee DE. Prevalence of heart failure and left ventricular dys-
function in the general population; The Rotterdam Study. 
Eur Heart J. 1999;20:447-55.
15. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment
of chronic heart failure. Eur Heart J. 2001;22:1527-60.
16. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, 
LaMotte F, Buring J, Hennekens CH. A prospective evaluation of an 
angiotensin-converting-enzyme gene polymorphism and the risk of
ischemic heart disease. N Engl J Med. 1995;332:706-11.
17. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression 
from hypertension to congestive heart failure. 
JAMA. 1996;275:1557-62.
18. Vasan RS, Levy D. The role of hypertension in the pathogenesis of 
heart failure. A clinical mechanistic overview. 
Arch Intern Med. 1996;156:1789-96.
19. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart fai-
lure: the Framingham Study. J Am Coll Cardiol. 1993;22:6A-13A.
20. Francis GS, Tang WH. Pathophysiology of congestive heart failure. 
Rev Cardiovasc Med. 2003;4 Suppl 2:S14-20.
21. Schunkert H. Molecular genetics of congestive heart failure. Scand 
Cardiovasc J Suppl. 1998;47:37-43.
22. Kuznetsova T, Staessen JA, Wang JG, Gasowski J, Nikitin Y, Ryabikov
A, Fagard R. Antihypertensive treatment modulates the association 
between the D/I ACE gene polymorphism and left ventricular hyper-
trophy: a meta-analysis. J Hum Hypertens. 2000;14:447-54.
23. Celentano A, Mancini FP, Crivaro M, Palmieri V, Ferrara LA, De 
Stefano V, Di Minno G, de Simone G. Cardiovascular risk factors, 
angiotensin-converting enzyme gene I/D polymorphism, and left 
ventricular mass in systemic hypertension. 
Am J Cardiol. 1999;83:1196-200.
24. Nakahara K, Matsushita S, Matsuoka H, Inamatsu T, Nishinaga M, 
Yonawa M, Aono T, Arai T, Ezaki Y, Orimo H. Insertion/deletion poly-
96 CHAPTER 2
isocrg_def_f  16-08-2004  12:43  Pagina 96
morphism in the angiotensin-converting enzyme gene affects heart
weight. Circulation. 2000;101:148-51.
25. Montgomery HE, Keeling PJ, Goldman JH, Humphries SE, Talmud PJ,
McKenna WJ. Lack of association between the insertion/deletion 
polymorphism of the angiotensin-converting enzyme gene and idio-
pathic dilated cardiomyopathy. J Am Coll Cardiol. 1995;25:1627-31.
26. Sanderson JE, Yu CM, Young RP, Shum IO, Wei S, Arumanayagam M,
Woo KS. Influence of gene polymorphisms of the renin-angiotensin
system on clinical outcome in heart failure among the Chinese. 
Am Heart J. 1999;137:653-7.
27. Sanderson JE, Young RP, Yu CM, Chan S, Critchley JA, Woo KS. Lack 
of association between insertion/deletion polymorphism of the angi-
otensin-converting enzyme gene and end-stage heart failure due to
ischemic or idiopathic dilate cardiomyopathy in the Chinese. 
Am J Cardiol. 1996;77:1008-10.
28. Schunkert H. Controversial association of left ventricular hypertro-
phy and the ACE I/D polymorphism--is the mist clearing up? 
Nephrol Dial Transplant. 1998;13:1109-12.
29. Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi MA, 
Hemingway H, Statters D, Jubb M, Girvain M, Varnava A, World M, 
Deanfield J, Talmud P, McEwan JR, McKenna WJ, Humphries S. 
Association of angiotensin-converting enzyme gene I/D polymor-
phism with change in left ventricular mass in response to physical 
training. Circulation. 1997;96:741-7.
30. Ohmichi N, Iwai N, Maeda K, Shimoike H, Nakamura Y, Izumi M, 
Sugimoto Y, Kinoshita M. Genetic basis of left ventricular remodeling
after myocardial infarction. Int J Cardiol. 1996;53:265-72.
31. West MJ, Summers KM, Burstow DJ, Wong KK, Huggard PR. Renin 
and angiotensin-converting enzyme genotypes in patients with 
essential hypertension and left ventricular hypertrophy. Clin Exp 
Pharmacol Physiol. 1994;21:207-10.
32. Pontremoli R, Sofia A, Tirotta A, Ravera M, Nicolella C, Viazzi F, 
Bezante GP, Borgia L, Bobola N, Ravazzolo R, Sacchi G, Deferrari G. 
The deletion polymorphism of the angiotensin I-converting enzyme
gene is associated with target organ damage in essential hyperten-
sion. J Am Soc Nephrol. 1996;7:2550-8.
33. Serneri GGN, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, 
Bandinelli B, Bertolozzi I, Polidori I, Toscano T, Maccherini M, Modesti
97CANDIDATE GENE STUDIES
isocrg_def_f  16-08-2004  12:43  Pagina 97
PA. Cardiac angiotensin II formation in the Clinical Course of heart 
failure and its relationship with left ventricular function. 
Circ Res. 2001;88:961-8.
34. Kuznetsova T, Staessen JA, Stolarz K, Ryabikov A, Tikhonoff V, 
Olszanecka A, Bianchi G, Brand E, Casiglia E, Dominiczak A, Fagard R,
Malyutina S, Nikitin Y, Kawecka-Jaszcz K. Relationship between left 
ventricular mass and the ACE D/I polymorphism varies according to 
sodium intake. J Hypertens 2004;22:287-295.
98 CHAPTER 2
isocrg_def_f  16-08-2004  12:43  Pagina 98
isocrg_def_f  16-08-2004  12:43  Pagina 99
isocrg_def_f  16-08-2004  12:43  Pagina 100
3.CANDIDATE GENE STUDIES
INSULIN-LIKE GROWTH FACTOR-I PROMOTER 
POLYMORPHISM
isocrg_def_f  16-08-2004  12:43  Pagina 101
isocrg_def_f  16-08-2004  12:43  Pagina 102
3.1. POLYMORPHISM IN THE PROMOTER REGION OF THE 
INSULIN-LIKE GROWTH FACTOR I GENE IS RELATED TO 
CAROTID INTIMA MEDIA THICKNESS AND AORTIC  PULSE 
WAVE VELOCITY IN SUBJECTS WITH HYPERTENSION
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ABSTRACT104
Background and Purpose: Low circulating levels
of Insulin-like Growth factor I (IGF-I) have been
associated with an increased risk for atherosclero-
sis. Absence of the 192-bp (wildtype) allele in the
promoter region of the IGF-I gene has been asso-
ciated with low circulating IGF-I levels. We exam-
ined the role of this polymorphism in relation to
blood pressure and two early markers of athero-
sclerosis: carotid intima media thickness (IMT) and
aortic pulse wave velocity (PWV). 
Methods: 5132 subjects of the Rotterdam study,
aged 55-75 years, were included in this study. In
3769 subjects, who did not use blood pressure
lowering medication, the association between the
IGF-I polymorphism and blood pressure was exam-
ined. In the total population, 3484 normotensive
subjects, 1648 hypertensive and 462 non-treated
hypertensive subjects, the association between
this polymorphism and IMT and PWV was 
examined. 
Results: Mean systolic and diastolic blood pressu-
re did not differ between genotypes. In hyperten-
sive subjects IMT was significantly increased in non
carriers of the 192-bp allele (0.83 mm) compared
to heterozygous or homozygous carriers (0.80 mm)
(p=0.04). PWV was also significantly higher in
hypertensive subjects who were non carriers of the
192-bp allele (14.3 m/s) compared to heterozygous
(14.1 m/s) or homozygous carriers (13.7 m/s)
(p=0.02). Findings were more pronounced in
hypertensive subjects without medication use. In
normotensive subjects no association between this
polymorphism, IMT and PWV was observed.
Conclusion: Our study suggests that hypertensive
subjects who have low IGF-I levels because of a
genetic polymorphism in the IGF-I gene are at
increased risk of developing atherosclerosis.
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Introduction
Insulin-like Growth Factor I (IGF-I) may play an important role in the development of
cardiovascular disease.1,2 Its contribution to the development of atherosclerosis is a topic
of increasing interest in both human and animal studies.3-5 Low circulating IGF-I levels
have been associated with the early development of cardiovascular disease.6-8 Because
of its growth mediating and vasodilator properties, IGF-I is assumed to be an important
mediator in the pathophysiological response to increased blood pressure in the vessel
wall. Animal studies have shown that an increase in haemodynamic load is accompanied
by increased IGF-I expression in both cardiac and vascular tissues.9-11
We have recently demonstrated that a polymorphism in the promoter region of the
IGF-I gene is associated with serum IGF-I levels. In our studies, absence of the 192-bp
(wildtype) allele was associated with 20% lower circulating IGF-I serum levels at middle
age, lower body height and a reduction in birth weight.12,13 This polymorphism can be
used to study subjects with a genetic predisposition towards chronic low exposure of IGF-
I in all tissues of the body, including those of cardiovascular origin. 
In this population-based study we examined the effect of this polymorphism on
blood pressure and the development of atherosclerosis. We used two early markers of 
atherosclerosis in this study: intima media thickness of the carotid arteries (IMT) and 
aortic pulse wave velocity (PWV).
Materials and Methods
Study Population
The study was performed within the Rotterdam Study, a single-center prospective fol-
low-up study, in which all residents aged 55 years and over of the Rotterdam suburb
Ommoord were invited to take part. The baseline examination of the Rotterdam Study
was conducted between 1990 and 1993. The study was approved by the Medical Ethics
Committee of Erasmus Medical Center Rotterdam. Written informed consent was ob-
tained from all participants. The design of the study has been described previously.14 
We examined 7983 participants (response 78%). Because no DNA was available for
948 subjects and in 23 subjects genotyping failed, 7012 subjects were successfully geno-
typed for the IGF-I gene. The relation between the IGF-I polymorphism and serum IGF-I
levels was assessed in a subgroup of 150 subjects, consisting of 50 subjects randomly
drawn from each genotype group. Since serum IGF-I levels show an age-dependent de-
cline and are related to the development of cardiovascular disease, we excluded all 
subjects aged over 75 years in order to avoid any bias in our results because of selective
mortality. Therefore only subjects who were between 55-75 years of age at baseline exa-
mination and successfully genotyped were included in this study (n=5132). 
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In a subgroup of 3769 subjects, who did not use blood pressure lowering medication,
the association between the IGF-I polymorphism and systolic and diastolic blood pressu-
re was examined. In the total study population (n=5132), the IGF-I polymorphism was
examined in relation to intima media thickness and pulse wave velocity. This relation was
also examined separately in a subgroup of 1648 hypertensive subjects and in a subgroup
of 3484 normotensive subjects. Since lowering of blood pressure is known to influence
the development of atherosclerosis, the relation between the IGF-I polymorphism, IMT
and PWV was also assessed in 462 hypertensive subjects who did not use any blood pres-
sure lowering medication. 
Measurements
At the baseline examination, information concerning medical history, medication use and
smoking behavior was obtained with a computerized questionnaire.14 Height and weight
were measured and body mass index (BMI in kg/m2) was calculated. Blood pressure was
measured in sitting position at the right upper arm using a random zero sphygmomano-
meter. The average of two measurements was used for analysis. Hypertension was defin-
ed as a diastolic blood pressure of 100 mmHg or higher and/or a systolic blood pressure
of 160 mmHg or higher and/or use of anti-hypertensive medication indicated to treat
high blood pressure (grade 2 and 3 of the 1999 WHO criteria).15 Diabetes mellitus was
defined as the use of blood glucose-lowering medication and/or random serum glucose
level ≥ 11.1 mmol/l. Total serum cholesterol and HDL-cholesterol were determined with
an automated enzymatic procedure.16 Total IGF-I levels were determined in non-fasting
serum by a commercially available radioimmunoassay (Medgenix Diagnostics, with an
intra- and interassay variation of 6.1% and 9.9%). 
Intima media thickness of the left and right carotid artery was assessed by ultra-
sound.17,18 The beginning of the dilatation of the distal common carotid artery served as
a reference point for the start of the measurement and IMT was measured over an ave-
rage distance of 10 mm.  The lumen-intima interface and the media-adventitia interfa-
ce of the near and far walls of the distal common carotid artery were measured offline.
In each subject mean IMT of far and near wall ((left + right)/2) was taken as measure for
wall thickness of the distal common carotid artery. The intraclass correlation coefficient
for assessment of common carotid IMT was 0.74.19 Carotid -femoral Pulse Wave Velocity
was assessed using an automatic device (Complior, Colson, Garges-les-Gonesse Cx,
France) that recorded the time delay between the rapid upstroke of the feet of simulta-
neously recorded pulse waves in the carotid artery and femoral artery.20 The distance 
traveled by the pulse, between the carotid and the femoral artery, was measured over the
surface of the body using a tape measure. PWV was calculated as the ratio between the
distance traveled by the pulse wave and the foot-to-foot delay and expressed in meters
per second. We used the average of at least 10 successive measurements, to cover a com-
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plete respiratory cycle, in the analysis. The intraclass correlation coefficient for carotid-
femoral PWV was 0.80.19 
The IGF-I gene promoter polymorphism was genotyped as described earlier.12 Based
on our previous studies, three genotype groups were distinguished: homozygous carriers
of the 192-bp allele, heterozygous carriers and non carriers of this allele. 
Data Analysis
Hardy-Weinberg equilibrium of the IGF-I promoter polymorphism genotypes was tested
using the GENEPOP-package (Raymond M. & Rousset F, 1995. GENEPOP version). General
characteristics of the total study population, stratified by genotype, were compared
using the univariate analysis of variance for continuous variables and 2- statistics for
dichotomous variables. To examine the effect of the IGF-I genotype on intima media
thickness and pulse wave velocity in hypertensive and normotensive subjects separately,
we stratified all subjects based on their genotype and the presence or absence of hyper-
tension. Subjects homozygous for the 192-bp allele and normotensive were used as the
reference category in these analyses. All analyses on systolic and diastolic blood pressu-
re, intima media thickness and pulse wave velocity were adjusted for possible confoun-
ders: age, sex, BMI, total cholesterol, HDL-cholesterol, smoking and diabetes mellitus.
Additional analyses, adjusting for myocardial infarction and stroke, were performed to
correct for possible confounding by the presence of prevalent cardiovascular disease.
SPSS for Windows software package, version 10.0, was used to perform all analyses.
Results
Genotype frequencies in the total study population and in the normotensive and hyper-
tensive subjects were in Hardy Weinberg Equilibrium (p=0.4).
In table 1, the general characteristics of the total study population for each geno-
type group are presented. Serum total IGF-I levels were significantly lower in non carriers
of the 192-bp allele (16.7 nmol/l) compared to homozygous carriers (20.5 nmol/l)
(p=0.003). Levels of cardiovascular risk factors are in the high normal range, as can be
expected in a population of elderly subjects. No significant differences between homo-
zygous, heterozygous and non carriers of the 192-bp allele were observed. 
In table 2, systolic and diastolic blood pressures, prevalence of hypertension, mean
IMT of the carotid arteries and aortic PWV are presented for each genotype group. Crude
results (not shown) did not differ significantly from those after adjustment for possible
confounders. Systolic and diastolic blood pressure and the prevalence of hypertension did
not differ between the genotype groups. IMT was significantly increased in non carriers
of the 192-bp allele compared to heterozygous and homozygous carriers (p for
trend=0.02). PWV did not differ between genotype groups in the overall analysis.
In figure 1, mean IMT by genotype for all normotensive, all hypertensive subjects and
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non-treated hypertensive subjects is presented. IMT was significantly higher in hyper-
tensive subjects compared to normotensive subjects in all genotype groups (p<0.005). In
all hypertensive subjects IMT was significantly higher in non carriers of the 192-bp 
allele (0.83 mm) compared to heterozygous and homozygous carriers (0.80 mm) (p=0.04).
In non-treated hypertensive subjects IMT was also higher in non carriers (0.85 mm) com-
pared to heterozygous (0.80 mm) and homozygous carriers (0.80 mm) (p=0.01). In nor-
motensive subjects, IMT did not differ significantly between the genotype groups. 
In figure 2, mean PWV by genotype for all normotensive, all hypertensive subjects and
non-treated hypertensive subjects is presented. PWV was significantly higher in hyper-
tensive subjects than in normotensive subjects in all genotype groups (p<0.005). In
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Homozygous carriers Heterozygous carriers Non carriers
192-bp allele 192-bp allele 192-bp allele
Number of subjects 2209 2244 602
Serum total IGF-I levels* - nmol/l 20.5 ± 6.2 (n=50) 19.6 ± 6.4 (n=50) 16.7 ± 5.0 (n=50)†
Men -% 43.3 44.2 40.2
Age – yrs 65.0 ± 5.5 64.9 ± 5.5 64.9 ± 5.5
Body mass index - kg/m2 26.3 ± 3.7 26.2 ± 3.5 26.4 ± 3.6
Current smoking - % 25.7 26.8 21.4
Total cholesterol - mmol/l 6.7 ± 1.2 6.7 ± 1.2 6.7 ± 1.1
HDL-cholesterol - mmol/l 1.4 ± 0.4 1.3 ± 0.4 1.4 ± 0.4
Diabetes mellitus - % 8.2 8.4 11.9
Table 1. General characteristics of total study population stratified by IGF-I genotype
All values are presented as mean ± standard deviation or percentage. *Measured in a subset of
the total study population (n=150). †Significantly different from homozygous carriers (p=0.003).
Homozygous carriers Heterozygous carriers Non carriers
192-bp allele 192-bp allele 192-bp allele
Systolic blood pressure* - mmHg 135.2 ± 21.2 135.1 ± 21.0 134.0 ± 21.2
Diastolic blood pressure* - mmHg 73.5 ± 11.0 74.0 ± 11.2 72.8 ± 10.7
Hypertension - % 31.1 31.5 30.3
Intima media thickness - mm 0.76 ± 0.14 0.77 ± 0.15 0.78 ± 0.14†
Pulse wave velocity - m/s 13.3 ± 2.9 13.3 ± 3.0 13.3 ± 2.9
Table 2. Systolic and diastolic blood pressure, prevalence of hypertension, intima media thick-
ness and pulse wave velocity in total study population stratified by IGF-I genotype 
All values are presented as mean ± standard deviation or percentage and adjusted for age, sex,
BMI, total cholesterol, HDL-cholesterol, diabetes and smoking. *Only subjects without use of any
blood pressure lowering medication (n=3769). †Significantly different from homozygous car-
riers; p<0.05.
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Figure 1. Intima media thickness (mm) by IGF-I genotype in normotensive subjects (white bars), 
all hypertensive subjects (grey bars) and non-treated hypertensive subjects (black bars). 
*Significantly different from homozygous carriers in all hypertensive subjects, p<0.05. 
**Significantly different from homozygous carriers in non-treated hypertensive subjects, p<0.01.
Adjusted for age, sex, BMI, total cholesterol, HDL-cholesterol, diabetes mellitus and smoking.
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Figure 2. Pulse wave velocity (m/s) by IGF-I genotype in normotensive subjects (white bars), all 
hypertensive subjects (grey bars) and non-treated hypertensive subjects (black bars). 
*Significantly different from homozygous carriers in all hypertensive subjects, p<0.05. 
**Significantly different from homozygous carriers in non-treated hypertensive subjects, p<0.05.
Adjusted for age, sex, BMI, total cholesterol, HDL-cholesterol, diabetes mellitus and smoking.
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hypertensive subjects, PWV was significantly higher in non carriers of the 192-bp allele
(14.3 m/s) compared to heterozygous carriers (14.1 m/s) and homozygous carriers (13.7
m/s) (p=0.02). In non-treated hypertensive subjects, the difference in PWV between non
carriers and carriers of the 192-bp allele increased. Non carriers had significantly higher
PWV (15.0 m/s) than heterozygous (14.2 m/s) and homozygous carriers (13.8 m/s)
(p=0.03). In normotensive subjects PWV did not differ significantly between the genoty-
pe groups.  Additional analyses adjusting for myocardial infarction and stroke did not
significantly change the results presented in table 2 and the figures.
Discussion
In this population based study we found an association between a genetic polymorphism
in the promoter region of the IGF-I gene and IMT of the carotid arteries in the general
population. Further analysis revealed that the association between this polymorphism
and atherosclerosis was most pronounced in hypertensive subjects. Hypertensive subjects
who did not carry a copy of the 192-bp allele had an increased carotid IMT and higher
aortic PWV compared to heterozygous and homozygous carriers of the 192-bp allele. The
effect of this polymorphism was even stronger in subjects with untreated hypertension.
In normotensive subjects no association was found between this polymorphism and IMT
or PWV.
Since IMT and PWV are considered reliable indicators of the structural and functio-
nal changes in the vasculature, we used both as early markers of atherosclerosis.21
Recent findings in our study population have shown a strong positive association be-
tween aortic stiffness (as measured by PWV) and common carotid IMT.19 PWV and IMT
have been reported to be strongly associated with vascular risk factors and the preva-
lence of cerebrovascular and cardiovascular disease.18,22-24
We have previously observed that non carriers of the 192-bp allele have signi-
ficantly lower circulating IGF-I levels than heterozygous or homozygous carriers of this
allele.12 Findings by Janssen et al., who observed an inverse relation between circulating
IGF-I levels and atherosclerosis in another population-based study, suggested that low
IGF-I levels may play a role in the development of atherosclerosis in the general popula-
tion.7 Studies in GH-deficient patients have already indicated that low circulating IGF-I
levels may play an important role in the development of cardiovascular disease.25
GH-deficient patients have significantly increased intima media thickness, decreased
systemic nitric oxide (NO) generation and a tendency towards impaired flow-mediated
vasodilatation.26-28 They also have increased levels of circulating inflammatory cardio-
vascular risk markers, such as CRP, IL-6 and TNF-α.29,30 In addition, an increase in 
circulating IGF-I levels, observed during GH-replacement therapy, is accompanied by a
reduction in intima media thickness and a decrease in circulating inflammatory 
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markers.29,31-33 Although the exact mechanism by which IGF-I influences the develop-
ment of atherosclerosis is still unknown, the effects of IGF-I on the vascular endo-
thelium are thought to be partly mediated by NO, which is not only known to induce
vasorelaxation but also inhibits platelet aggregation, leukocyte adhesion and smooth
muscle cell growth.28,34,35
Our findings support the observation that low levels of serum IGF-I may affect the
development of atherosclerosis. Of interest is that the effect of this polymorphism on IMT
and PWV was observed in hypertensive subjects only. One explanation for this finding
may be that a relatively lower expression of the IGF-I gene, in non carriers of the 192-
bp allele, only becomes clinically relevant in subjects who have an increased demand for
IGF-I. We hypothesize that in hypertensive subjects, because of increased haemodynamic
load, more IGF-I is needed to protect the vessel wall than in normotensive subjects. So,
hypertensive subjects who do not carry a copy of the 192-bp allele may not have enough
(reserve) capacity to adequately fulfill the increased demand for IGF-I. As a consequen-
ce, the anti-atherogenic effects of IGF-I in these subjects may no longer be sufficient to
prevent the development of atherosclerosis.
In our study we found an even stronger effect of this polymorphism in subjects with
untreated hypertension. This observation supports our hypothesis that especially in sub-
jects at high risk for atherosclerosis, e.g. due to increased haemodynamic load, the need
for IGF-I is increased. In line with this is the observation in animal studies that IGF-I
expression increases during periods of high haemodynamic load.9-11
Since IGF-I is also known to induce vasorelaxation, it seems surprising that we did not
observe an effect of this polymorphism in the IGF-I gene on blood pressure or the pre-
valence of hypertension. This suggests that IGF-I is not so much a determinant in the
chronic blood pressure lowering response, but rather is a mediator in limiting the dama-
ging effects of high blood pressure on the vasculature. Another important issue that
needs to be addressed is possible confounding by other cardiovascular risk factors such
as diabetes mellitus, impaired glucose tolerance, increased BMI, hyperlipidemia and
preexisting cardiovascular disease. These risk factors have also been associated with low
IGF-I levels.30,29 However, our results did not change significantly after adjustment for
these risk factors, suggesting that the effects of the IGF-I polymorphism on the vascular
endothelium are independent of other cardiovascular risk factors. 
In conclusion, our findings support the opinion that IGF-I plays a role in the patho-
genesis of atherosclerosis. The polymorphism we studied in the IGF-I gene most likely is
a modifier of the risk for atherosclerosis in subjects with hypertension. Ongoing studies
on the role of IGF-I and the interaction with its receptor and binding proteins will help
to further elucidate the exact mechanism by which IGF-I exerts its effects on the deve-
lopment of atherosclerosis in subjects with high blood pressure.
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3.2. ABSENCE OF THE 192-BASE PAIR ALLELE IN A PROMOTER
POLYMORPHISM OF THE INSULIN-LIKE GROWTH 
FACTOR-I GENE IS ASSOCIATED WITH AN INCREASED 
RISK OF LEFT VENTRICULAR HYPERTROPHY
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ABSTRACT118
Objective: Altered serum levels of insu-
lin-like growth factor I (IGF-I) have been
associated with adverse cardiac remode-
ling. A promoter polymorphism in the
IGF-I gene may alter serum IGF-I levels.
We investigated the association between
this polymorphism and left ventricular
hypertrophy.
Methods and results: This study was
performed in the Rotterdam Study, a
population-based prospective cohort
study among elderly. Analyses were per-
formed with baseline measurements in
subjects aged between 55 and 75 years,
without a history of myocardial infarc-
tion (n=1,678). Left ventricular hypertro-
phy was defined as a left ventricular mass
index ≥ 104 g/m2 in women and ≥ 116
g/m2 in men. Frequencies of left ventri-
cular geometry patterns by genotype
were also studied. Non-carriers of the
192-base pair allele of a cytosine-adeno-
sine repeat in the IGF-I gene had a 1.5
fold increased risk of left ventricular
hypertrophy as compared to subjects
homozygous for this wild type allele.
Although we found no clearly increased
association in heterozygotes, there was a
significant allele-effect relationship 
(p-trend<0.05). The small difference in
distribution of left ventricular geometry
patterns between genotypes was not sig-
nificant.
Conclusion: Non-carriers of a 192-base
pair polymorphism in the IGF-I gene are
more susceptible to the development of
left ventricular hypertrophy than 
individuals homozygous for this allele.
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Introduction
Left ventricular hypertrophy is a strong predictor for cardiovascular morbidity and mor-
tality.1 The structure of the left ventricle is influenced by several factors such as blood
pressure, age, gender, body mass index, diabetes mellitus, and pre-existing cardiovascu-
lar disease.2,3 These factors, however, do not completely explain the variability in left
ventricular mass. Of the other factors involved, insulin-like growth factor I (IGF-I) may
explain part of this variability.4 IGF-I is a polypeptide growth factor that is expressed in
many organs. It is the product of the IGF-I gene, which has been mapped to chromoso-
me 12.5 Evidence has accumulated that, in addition to its growth-promoting and meta-
bolic effects, IGF-I has cardioprotective effects by reducing myocardial apoptosis and
injury in response to ischemia.6 Moreover, findings suggest that lowered free IGF-I levels
are associated with a higher prevalence of cardiovascular disease.7
There are several limitations of studies conducted on serum IGF-I levels in relation to
cardiovascular disease. Most of these studies have been performed cross-
sectional, making it difficult to distinguish whether altered serum IGF-I levels are a cause
or a consequence of the underlying disease. In addition, serum levels of IGF-I are pro-
foundly influenced by various factors such as growth hormone, insulin, age, diet, physi-
cal activity and genetic factors.8,9 A genetic polymorphism in the IGF-I promoter region
has been identified which influences IGF-I production.10,11 Recently, we observed lower
circulating total IGF-I levels in non-carriers of the wild type allele of this polymorphism
than in homozygous carriers.12,13 Studying the effect of this polymorphism in relation to
pathology may better reflect the effects of long-term IGF-I exposure than studies on cir-
culating serum IGF-I levels, which may fluctuate considerably. Furthermore, studies of
genetic determinants of IGF-I levels may suffer less from the confounding influence of
other factors.
This study aims to investigate the association between a promoter polymorphism of
the IGF-I gene and the occurrence of left ventricular hypertrophy on the 
echocardiogram.
Methods
Setting and study population
The Rotterdam Study is a population-based prospective cohort study of cardiovascular-,
locomotor-, neurologic- and ophthalmologic diseases in the elderly.14 All inhabitants of
Ommoord, a suburb of Rotterdam in the Netherlands, who were 55 years of age or older
were invited to participate. Of the 10,275 eligible subjects, 7,983 agreed to participate
(78%). The baseline examination was conducted between 1990 and 1993. Participants
were visited at home for a standardized questionnaire and were subsequently examined
at the research center, where echocardiography was performed. Due to costs and logistic
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problems, cardiac ultrasound was carried out in a random subpopulation of the
Rotterdam Study consisting of 2,823 subjects, who were not living in nursing homes. In
19.7% (n=556), echocardiographic registrations were considered inadequate for reliable
measurement of left ventricular dimensions. This percentage is comparable to other
population-based studies.15
The present study was performed using baseline measurements in subjects between
55 and 75 years of age. Participants with a history of myocardial infarction were ex-
cluded. The analyses were restricted to persons for whom blood specimens were avail-
able for IGF-I typing, and for whom all measurements were available to determine left
ventricular mass index (n=1,678). 
Left ventricular hypertrophy
For assessment of the presence of left ventricular hypertrophy, echocardiography was
carried out with the participant in the partial left decubitus position using a 2.75-MHz
transducer (Toshiba SSH-60A Nasuworks, Otawara, Japan). Measurements were made by
experienced staff, trained at the echo lab of the Thorax Center in the Erasmus MC in
Rotterdam, according to a protocol based on the recommendations of the American
Society of Echocardiography (ASE).16 Two-dimensional imaging using parasternal long-
axis views were performed to aid M-mode studies. Measurements of the left ventricle
were performed at end-diastole, as defined by the onset of the QRS complex, according
to ASE recommendations. Left ventricular mass was determined using the Devereux-
modified ASE cube formula.17 left ventricular mass (grams) =
0.8x(1.04x[(LVED+IVS+LVPW)3-(LVED)3])+0.6, where LVED = left ventricular end diastolic
diameter, IVS = interventricular septum thickness, and LVPW = left ventricular posterior
wall thickness. Left ventricular mass was indexed to body surface area. 
Cases with left ventricular hypertrophy were defined as having a left ventricular mass
index equal to or greater than 104 g/m2 in women and 116 g/m2 in men.18,19 Since there
is no consensus concerning left ventricular hypertrophy thresholds in the medical litera-
ture, left ventricular mass index was also divided into gender specific quintiles, which has
been demonstrated to provide a good prediction of cardiovascular risk estimates.20 For
this second analysis, cases were defined as being in the highest gender specific quintile,
and controls as being in the remaining quintiles.
To study differences in left ventricular remodeling patterns according to IGF-I geno-
type, relative wall thickness (RWT) was also determined and calculated as RWT = 2 x
LVPW / LVED.21 Increased relative wall thickness was considered present when this ratio
exceeded 0.43, according to previously published criteria.22 Three mutually exclusive pat-
terns were identified: normal left ventricular geometry (normal relative wall thickness
and normal left ventricular mass index), concentric remodeling (increased relative wall
thickness but normal left ventricular mass index), and left ventricular hypertrophy (as
defined above).
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IGF-I genotype
The polymorphism under study was a cytosine-adenosine repeat in the promoter region,
1 kilo base upstream from the transcription site of the IGF-I gene. Genotyping for the
IGF-I polymorphism was performed as described elsewhere.12 Earlier, we identified ten
different alleles in the promoter region of the IGF-I gene in a sample of 900 subjects of
the Rotterdam Study.12 Of these participants, 88.4% carried at least one 192-base pair
(bp) allele, which suggests that this is the wild type allele from which all other alleles ori-
ginated. The frequency of the other 9 alleles was low. Based on this observation, using
the wild type allele, our study population was divided into three genotypes: individuals
homozygous for the 192-bp allele (43.6%), individuals heterozygous for the 192-bp alle-
le (45.6%), and non-carriers of the 192-bp allele polymorphism (10.7%). 
Other variables 
Information on several risk factors, such as age, gender, history of myocardial infarction
(confirmed by a general practitioner, cardiologist, or the electrocardiogram), smoking
(classified as never/former/current), hypertension, diabetes mellitus, and body mass index
(kg/m2) was obtained at baseline. Information on the use of medication and type of
medication were assessed during the home interview. Participants subsequently showed
all currently used medication at the research center, where a physician determined the
indication for each drug. Systolic and diastolic blood pressures from the right upper arm
were measured with a random-zero sphygmomanometer twice with the patient in a sit-
ting position. The mean of the two readings was used to determine blood pressure levels.
Hypertension was defined as use of antihypertensive medication for the indication high
blood pressure, or as a systolic blood pressure of 140 mmHg or over, or a diastolic blood
pressure of 90 mmHg or over.23 Diabetes mellitus was defined as use of anti-diabetic
medication, or a random or post-load serum glucose level higher than 11.0 mmol/l.
Analysis
Univariate comparisons were evaluated with a logistic regression model. Agreement of
the genotype frequencies with the Hardy-Weinberg equilibrium expectations was tested
using a 2-test. To investigate the association between left ventricular hypertrophy and
IGF-I genotypes, we used multivariate logistic regression to calculate odds ratios plus
95% confidence intervals (CI). An allele-effect model was assumed to explain differen-
ces between genotype groups. Participants homozygous for the 192-bp allele served as
the reference category for all analyses. Age (years), gender, hypertension, diabetes melli-
tus, and body mass index (kg/m2) were added to the model to adjust for potential con-
founding. The decision to keep potential confounders in the final model was based on
biological plausibility. None of these factors changed the point estimate of the associa-
tion between IGF-I genotype and left ventricular hypertrophy by more than 5% when
added to the univariate model. On each potential confounder more than 97% of data
was available. For categorical covariates with missing values we incorporated missing
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indicator variables in the model. We performed age- and gender adjusted logistic regres-
sion analysis to test for an allele-effect relationship (trend test). To evaluate the distri-
bution of left ventricular geometry patterns according to IGF-I genotype, percentages
per genotype were calculated. To test differences between genotypes, we used an 
ordinal regression model adjusted for age, with the different patterns of left ventricular
geometry as outcome variables.
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192-bp allele Cases* Controls OR model 1† OR model 2‡
(n=358) (n=1320)
Homozygous carriers 145 (41%) 587 (44%) 1.00 (ref.) 1.00 (ref.)
Heterozygous carriers 166 (46%) 600 (46%) 1.13 (0.88-1.46) 1.11 (0.86-1.43)
Non carriers 47 (13%) 133 (10%) 1.50 (1.02-2.21)* 1.49 (1.01-2.20)*
Table 2. Association between echocardiographically determined left ventricular hypertrophy and
IGF-I genotypes
Number (% among cases or controls); odds ratio (OR) with 95% confidence interval. *Case defi-
nition: left ventricular hypertrophy was considered present when left ventricular mass index
was equal or greater than 104 g/m2 in women and 116 g/m2 in men. †Adjusted for age (years)
and gender. ‡Adjusted for age (years), gender, body mass index (kg/m2), hypertension, and dia-
betes mellitus. *Allele-effect relationship: p-trend <0.05.
Cases* (n=358) Controls (n=1320) OR (95% CI)
[LVH +] [LVH -]
Sex – n (% female) 192 (54) 754 (57) 0.87 (0.69-1.10)
Age - yrs 65 ± 5.3 63 ± 5.3 1.07 (1.05-1.09)
Diabetes mellitus – n (%) 30 (8) 62 (5) 1.85 (1.18-2.92)
Smoking – n (%)
- Never 101 (28) 435 (33) 1.00 (ref)
- Former 171 (48) 584 (44) 1.26 (0.96-1.66)
- Current 84 (24) 296 (23) 1.22 (0.88-1.69)
Hypertension† - n (%) 223 (64) 578 (45) 2.16 (1.69-2.75)
BMI - kg/m2 27 ± 3.1 26 ± 3.3 1.09 (1.05-1.13)
SBP - mmHg 144 ± 21.7 134 ± 21.1 1.02 (1.02-1.03)
DBP - mmHg 76 ± 12.0 74 ± 11.0 1.02 (1.01-1.03)
Table 1. General characteristics of the study population.
Values for characteristics of cases and controls are presented as numbers (percentage) or mean
± SD. *Case definition: left ventricular hypertrophy (LVH) was considered present when left ven-
tricular mass index was equal or greater than 104 g/m2 in women or 116 g/m2 in men. 
†Defined as systolic blood pressure of 140 mmHg or higher or diastolic blood pressure of 90
mmHg or higher or use of antihypertensive drugs with the indication hypertension. SBP, systolic
blood pressure; DBP, diastolic blood pressure.
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Results
In total, 358 cases were identified with left ventricular hypertrophy. Genotype and 
allele distributions were in Hardy-Weinberg equilibrium (total population: p-value =
0.33). 
Table 1 presents the baseline characteristics of the study population. Participants with
left ventricular hypertrophy were on average two years older than patients with normal
left ventricular mass index (mean age 65 and 63 years respectively, t-test p<0.001). In
addition, cases had a higher mean body mass index, systolic- and diastolic blood 
pressure, and had more co-morbidity such as diabetes mellitus and hypertension. The
number of smokers did not differ significantly between participants with or without left
ventricular hypertrophy. The difference in gender distribution was not statistically 
significant. 
In table 2, point estimates are presented for the association between IGF-I genotypes
and left ventricular hypertrophy on the echocardiogram. Non-carriers of the 192-bp 
allele had a 1.50 fold increased odds of echocardiographically determined left ventricu-
lar hypertrophy as compared to individuals homozygous for the 192-bp allele. This asso-
ciation remained significant after adjustment for potential confounding factors (OR
1.49; 95%CI 1.01-2.20). The frequency of left ventricular hypertrophy was slightly but
non-significantly increased in participants heterozygous for the 192-bp allele. However,
there was a significant allele-effect relationship (p-trend <0.05). According to the model,
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Figure 1. Left ventricular remodeling and IGF-I genotypes. LVH, left ventricular hypertrophy. 
Bars add up to 100 % per genotype. Numbers in the bars are the absolute number per genoty-
pe. Ordinal regression, p=0.17. OR LVH versus concentric remodeling: 1.6 (1.0-2.6), OR LVH 
versus normal geometry 1.5 (1.0-2.2) (age and sex adjusted).
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the age- and gender adjusted odds of left ventricular hypertrophy is multiplied by 120%
per risk allele present (non-wild type). Findings were similar for the association between
IGF-I genotypes and the highest versus other gender specific quintiles of left ventricular
mass index (age-adjusted OR non-carriers 192-bp allele 1.48, 95%CI 1.001-2.18).
However, after additional adjustment for body mass index, hypertension, and diabetes
mellitus this association was not statistically significant (OR 1.46, 95%CI 0.99-2.17).
Figure 1 shows the percentages per IGF-I genotype of geometric patterns of the left
ventricle for non-carriers and participants homozygous for the 192-bp allele. Although
ordinal regression analysis estimates were not statistically significant (p=0.17), this graph
shows a tendency of percentages for non-carriers to be higher in the most unfavorable
pattern of left ventricular geometry, while concentric remodeling was more frequent in
individuals homozygous for the wild type allele. 
Discussion
In this study, non-carriers of the 192-bp allele of a cytosine-adenosine repeat in the 
promoter region of the IGF-I gene were more susceptible to the development of left 
ventricular hypertrophy than participants homozygous for the wild type allele. To our
knowledge, this is the first population-based study on the association between this IGF-
I polymorphism and left ventricular hypertrophy. The risk of elevated left ventricular
mass index detected by echocardiography in these subjects was significantly increased by
50%. Although there was no clearly increased difference in risk for participants hetero-
zygous for the wild type allele, there was a significant allele-effect relationship in this
population. In addition, there was a tendency for non-carriers to have a higher frequen-
cy of adverse cardiac remodeling with cardiac enlargement than participants homo-
zygous for the 192-bp allele. In contrast, concentric remodeling, which is a more 
appropriate response, was more frequent in individuals homozygous for the wild type
allele. Cardiovascular morbidity and mortality are known to increase as the geometric
pattern of the left ventricle changes from normal to concentric remodeling and finally
to left ventricular hypertrophy.24 In vitro and in vivo studies suggest that IGF-I may help
maintain appropriate myocardial remodeling in reaction to an injury to the heart.25 This
may provide an explanation for our findings. 
Most studies on the association between IGF-I serum levels and left ventricular mass
have been performed cross-sectional, making it difficult to distinguish whether altered
serum IGF-I levels are a cause or a consequence of left ventricular hypertrophy. In 
addition, serum levels of IGF-I are influenced by several factors, which vary over time,
including growth hormone, insulin, nutrition and physical activity. Therefore, residual
confounding can be an issue in these studies. Studying the association with the IGF-I
polymorphism may circumvent these difficulties, since this approach will probably 
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better proxy long-term exposure to circulating IGF-I. Moreover, disturbances by factors
that regulate IGF-I serum levels will not influence the genetic background. Accordingly,
potential confounding factors did not have an effect on the point estimates in this study. 
It cannot be not excluded that the IGF-I polymorphism itself is not functional but just
serves as a marker for a nearby genetic variant functionally involved in IGF-I expression.
However, the polymorphism investigated in the present study has been associated with
serum IGF-I concentrations in several studies, albeit with opposite directions.11,12
Recently, we found in a sample of 900 participants of the Rotterdam Study that non-
carriers of the 192-bp allele had lower circulating total IGF-I levels and lower body
height than carriers of this polymorphism. The main finding of this study was that the
absence of this allele was also significantly associated with an increased risk of type-2
diabetes mellitus and myocardial infarction.12 Moreover, we observed that the normal
gradual decline in circulating serum IGF-I levels during aging was highly influenced by
the presence of two 192-bp alleles in the IGF-I gene.13
In recent years, several studies provided support to the hypothesis that low serum
IGF-I is a risk factor for ischaemic heart disease and atherosclerosis.7,26-28 In addition to
its favorable effects on glycaemic control and the lipid profile29, IGF-I has beneficial
effects on cardiac remodeling by reducing myocyte apoptosis in response to 
ischemia25,30, and by improving myocardial contractility and stroke volume31.
Furthermore, IGF-I promotes cardiac hypertrophy of a physiologic phenotype32,33 and
causes systemic vascular vasodilatation34. Moreover, basal IGF-I levels are reduced in
patients with dilated cardiomyopathy35, and a recent study demonstrated an inverse
association between the severity of heart failure, by both clinical assessment and left
ventricular performance, and IGF-I levels.36 This may implicate that progression of 
disease from compensated to decompensated heart failure may be partly influenced by
the ability to generate IGF-I for cardiac remodeling. Hence, evidence suggests that IGF-I
deficiency may lead to diminished cardiac performance and adverse remodeling in reac-
tion to an injury to the heart. On the other hand, IGF-I directly stimulates growth of 
cardiac myocytes through induction of cardiac protein synthesis. In patients with acro-
megaly, IGF-I hypersecretion leads to ventricular hypertrophy with interstitial fibrosis.37
Also, in a cross-sectional study of patients with untreated essential hypertension and
normal glucose tolerance, IGF-I was a powerful independent determinant of left ventri-
cular mass.4 Therefore, both low and high levels of IGF-I seem to have adverse effects on
cardiac function and structure. 
This observational study is potentially limited by selection- and information bias and
confounding. Old and diseased individuals were less likely to participate, resulting in a
healthier study population. Random misclassification of the outcome may have occurred
due to measurement error, but this will only lead to conservative risk estimates. Potential
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confounding factors were dealt with in the analyses. None of these factors had a major
influence on the association studied.
In conclusion, non-carriers of a 192-bp allele polymorphism in the promoter region
of the IGF-I gene are more susceptible to the development of left ventricular hypertro-
phy than participants homozygous for the wild type allele. This may be the consequen-
ce of a relative IGF-I deficiency, leading to a faulty remodeling in response to 
myocardial injury. 
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ABSTRACT134
Background: Genetic factors play an important
role in the development of hypertension. Up to
now, most heritability estimates for blood 
pressure have been based on nuclear family data
and did not account for shared environment and
genetic dominance effects. In addition, the pro-
portion of shared genetic factors between 
different blood pressure traits has not been 
reported.
Aim: The present study assessed the heritability
and genetic correlations of four blood pressure
traits in the first 1000 participants of the Erasmus
Rucphen Family (ERF) Study, a family-based
cohort study.
Material and methods: All participants are 
members of an extended pedigree from a Dutch
genetically isolated population. An extensive phe-
notypic assessment consisted of blood pressure
and anthropometric measurements, laboratory
tests and a personal interview. Heritability and
genetic correlations of systolic (SBP), diastolic
(DBP), mean arterial (MAP) and pulse pressure (PP)
were assessed using a variance components
approach (SOLAR). 
Results: We were able to explain 50-70 % of the
blood pressure variance in our population.
Heritability estimates were significant for all four
blood pressure traits, ranging between 0.25-0.37.
We observed high genetic correlations between
SBP, DBP and MAP (0.93-0.98). PP showed modest
to low genetic correlations with the other blood
pressure traits (0.05-0.70).
Conclusion: Genetic factors contribute to a sub-
stantial proportion of blood pressure variance,
encouraging a search for genes involved in blood
pressure variance in this population. Including PP
in this search may lead to the identification of
genes involved in different aspects of blood 
pressure regulation, such as arterial stiffness.
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Introduction
The significance of genetic effects on blood pressure regulation has been acknowledged
for a long time. Twin, adoption and nuclear family studies indicate that a substantial pro-
portion of systolic and diastolic blood pressure variance is due to the effect of genes.1-8
However, heritability estimates range widely between different study populations,
depending heavily on the type of relative pairs used. Heritability estimates for blood
pressure normally vary around 60 % in twin studies and around 25 % in nuclear family
studies.1,3,5,6,9 As these estimates are based on blood pressure correlations between first-
degree relatives only, they are likely to be confounded by the effects of shared familial
environment, which causes an overestimation of blood pressure heritability. Large 
family-based samples, including second and third degree relatives, who do not usually
share the same household, may therefore generate more accurate heritability estimates
of blood pressure. 
In the present study we aim to assess to what extent genes and environment in-
fluence blood pressure variance in 1000 inhabitants of a genetically isolated community
in the Southwest part of the Netherlands. They were all related to each other in one
extended pedigree. The additive effect of genes (narrow-sense heritability) was estima-
ted for four quantitative blood pressure traits: systolic (SBP), diastolic (DBP), mean arte-
rial (MAP) and pulse pressure (PP). Together with our heritability estimates, we modeled
the effects of shared environment and possible genetic dominance effects, by construc-
ting a parameter based on sibships. We also estimated the proportion of blood pressure
variance explained by environmental factors. Next, we assessed the phenotypic, genetic
and environmental correlations between the four blood pressure traits. 
Material and Methods 
Setting
Analyses were performed on phenotypic data collected from Dutch inhabitants of an iso-
lated community in the Southwest part of the Netherlands, who participated in the
Erasmus Rucphen Family (ERF) study. The ERF study is a family-based cohort study and
part of an ongoing research program called Genetic Research in Isolated Populations
(GRIP). This research program aims to identify genetic risk factors in the development of
complex disorders.10 The study was approved by the Medical Ethics Committee of
Erasmus Medical Center Rotterdam. Written informed consent was obtained from all par-
ticipants. 
Participants
Genealogical records trace back almost all inhabitants of this isolated population to
about 150 individuals who founded this community around 1750. Minimal inward migra-
tion and considerable population growth have for years characterized this population.
About 20.000 inhabitants are now scattered over eight adjacent villages. Genealogical
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information of this population is currently available in the form of a large pedigree-data-
base including over 63.000 individuals. 
Eligibility for enrolment in this study was dependent on genealogical background of
the participant. Twenty couples that had at least 6 children baptized in the community
church between 1880-1900 were identified with the help of genealogical records of the
church and the municipality. All third, fourth and fifth generational descendants of these
couples and their spouses were invited to participate in the study. Data collection star-
ted in June 2002 and is still ongoing. In this study, we focus on the first 928 participants
for whom complete phenotypic and genealogical information is available at present. 
Data collection
Participants were invited for a series of clinical examinations at our research center loca-
ted within the community. At the start of the clinical examinations, fasting blood 
samples were drawn for the storage of DNA and measurement of lipids, glucose, plasma
creatinine, and plasma albumin levels according to a standardized procedure.11,12 Serum
samples were obtained from whole blood after clotting. Plasma samples were obtained
from whole blood collected in disodium EDTA.
Hyperlipidemia was defined as the use of lipid lowering medication or total cho-
lesterol levels between 6.5-9.0 mmol/l and a total cholesterol-HDL cholesterol ratio
above 5.0, or total cholesterol below 6.5 mmol/l and a ratio above 8.0, or total choles-
terol above 9.0 mmol/l, independent of the ratio, or triglycerides above 4.0 mmol/l. These
criteria are in accordance with those of the Dutch college of general practitioners.
Diabetes mellitus was defined as the use of blood glucose-lowering medication or fasting
serum glucose level above 7.0 mmol/l.13
Blood pressure was measured twice in the sitting position at the right upper arm
using an automated device (OMRON 711, automatic IS). The average of these two 
measurements was used for our analyses. Mean arterial pressure (1/3 SBP + 2/3 DBP) and
pulse pressure (SBP-DBP) were calculated. Hypertension was defined as a diastolic blood
pressure (DBP) of 90 mmHg or higher and/or a systolic blood pressure (SBP) of 140 mmHg
or higher and/or use of anti-hypertensive medication indicated for treatment of hyper-
tension.14,15 Height and weight were measured with the participant dressed in light
under clothing and body mass index was calculated (kg/m2). Waist and hip circumferen-
ce were measured on uncovered skin using a tape measure with the participant in upright
position. Waist circumference was measured halfway between the rib cage and the pel-
vic bone. Hip circumference was measured at the maximal circumference of the hips.
Waist to Hip ratio (WHR) was calculated from these data. Total body and trunk fat mass
(grams) were obtained from DEXA scans performed in a Prodigy™ total body fan-beam
densitometer and analyzed with the enCORE™ 2002 software V. 6.70.021 (GE Lunar
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Corporation Madison, WI). Total body scans were auto analyzed by the software that
employs an algorithm that divides body measurements into areas corresponding to head,
trunk, arms and legs. The trunk region was limited by an upper horizontal border below
the chin, vertical borders lateral to the ribs, and a lower border formed by oblique lines
passing through the femoral necks without touching the pelvis. All analyzes were verifi-
ed by a trained technician who performed adjustments when necessary. Daily quality
assurance tests were performed with a calibration block supplied by the manufacturer.
Repeated measurements on the calibration block had coefficients of variation less than
1%. Finally, a research physician obtained information on medical history, medication
use, smoking and alcohol use in a personal interview.
Statistical analysis
Inbreeding coefficients were calculated using PEDIG software (Bouchard D:
http://dga.jouy.inra.fr/sgqa/diffusions/pedig/pedigE.htm). The inbreeding coefficient is
the probability that the two alleles at some locus in an individual are identical by des-
cent (are copies of the same ancestral allele).
A variance component maximum likelihood approach, implemented in SOLAR soft-
ware package, was used to estimate heritability and genetic correlations, respectively, for
SBP, DBP, MAP and PP.16 Heritability (h2) was defined as the ratio of the variance of the
trait explained by additive polygenic effects to the total phenotypic variance of the trait.
In the heritability analyses, the relative contribution of these additive genetic factors to
total blood pressure variance is estimated. In order to reduce the confounding effects of
shared environment on our heritability estimates, we constructed a parameter identify-
ing sibships (denoted as c2). This parameter estimates the compound effects of shared
environment and possible genetic dominance effects (which are predominantly present
in bilineal relatives, e.g. sibships). Furthermore, we identified significant (environmental)
covariates for each blood pressure trait in order to estimate the contribution of environ-
mental factors to blood pressure variance. 
We selected a broad range of (biologically plausible) covariates that might influence
blood pressure, which were tested in a model in which the genetic parameter and the
sibship parameter were constrained to zero and phenotypic variation was influenced by
measured covariates and residual variance only. Covariates were allowed to enter the
model in a stepwise procedure. Significant effects of each covariate were tested using a
likelihood ratio test with 1 df. To make sure all covariates with possible important effects
were included in the final model, all covariates that were significant at the 0.10 level
were retained for the heritability model. Covariates that were tested included age, sex,
age2, age x sex interaction-term, various lipid measures (total cholesterol, HDL-choleste-
rol, LDL-cholesterol, triglycerides and the diagnosis hyperlipidemia), diabetes status (fas-
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ting serum glucose levels and diagnosis diabetes mellitus), lifestyle measures (smoking
status and alcohol use), blood pressure lowering medication (-blocker, diuretics, Ca-
channel antagonists, ACE inhibitors and angiotensin receptor blockers), various anthro-
pometrical measures (body mass index, waist to hip ratio, total fat mass and trunk fat
mass) and inbreeding coefficients.
Finally, the value of each blood pressure trait was modeled as a linear combination of
additive genetic effects (heritability=h2), sibship effects (c2), environmental effects (sig-
nificant covariates) and residual effects. In order to obtain a multivariate normal distri-
bution of the residuals of the blood pressure traits, SBP, DBP, MAP and PP were natural
logarithmically transformed for the analyses. Heritability and sibship effects were first
estimated including only age and sex as covariates (Model 1), then the analyses were
repeated including all significant covariates (Model 2). The significance of the genetic
and sibship effects was tested using the likelihood ratio test, where the likelihood of a
model in which heritability and the sibship parameter are estimated is compared with the
likelihood of a model in which either the heritability or the sibship parameter is con-
strained to zero. Twice the difference in the natural ln-likelihoods values of these models
yields a test statistic that is asymptotically distributed as a 2-statistic with df equal to
the difference in number of estimated parameters in the two models being compared.17 
Subsequently, a bivariate analysis was performed to estimate the genetic and en-
vironmental correlations between the four blood pressure traits.18,19 The phenotypic 
correlations between the blood pressure traits were then calculated by the following 
formula:20,21
ρP=√ h12 √ h22 ρG + √ (1-h12) √ (1-h22) ρE,
where h1
2 and h2
2 are the heritability estimates of the two blood pressure traits, for
which the phenotypic correlation is calculated, and ρG and ρE are the genetic and envi-
ronmental correlations between these two traits (as estimated in the bivariate analyses).
Significance of the phenotypic, additive genetic and environmental correlations was
determined using a likelihood ratio test. Whether a given correlation between two blood
pressure traits was significantly different form zero, was tested by comparing the likeli-
hood of a model in which this correlation was constrained to zero with a model in which
the same correlation was estimated. Twice the difference in ln-likelihoods of these
models yields a test statistic that is asymptotically distributed as a 2-statistic with df
equal to the difference in number of parameters estimated in the two models. All 
bivariate analyses were adjusted for age and sex.
The analysis of each phenotype was restricted to those individuals for whom all co-
variate data were complete (n=928). 
138 CHAPTER 4
isocrg_def_f  16-08-2004  12:43  Pagina 138
139STUDIES IN A GENETICALLY ISOLATED POPULATION
Ph
en
ot
yp
e
n
Tr
an
sf
or
m
at
io
n
M
od
el
 1
M
od
el
 2
SB
P
92
8
ln
 
ag
e 
an
d 
se
x 
ag
e,
 s
ex
, a
ge
2 ,
 a
ge
 x
 s
ex
 in
te
ra
ct
io
n 
te
rm
,
D
BP
an
ti
-h
yp
er
te
ns
iv
e 
m
ed
ic
at
io
n,
 t
ru
nk
 f
at
 m
as
s, 
to
ta
l f
at
 m
as
s,
M
AP
H
D
L-
ch
ol
es
te
ro
l, 
to
ta
l c
ho
le
st
er
ol
, a
lc
oh
ol
 in
ta
ke
 a
nd
 g
lu
co
se
 
PP
le
ve
ls
Ta
bl
e 
3.
To
ta
l n
um
be
r 
of
 in
di
vi
du
al
s, 
tr
an
sf
or
m
at
io
ns
 a
nd
 c
ov
ar
ia
te
s 
in
cl
ud
ed
 in
 h
er
it
ab
ili
ty
 a
na
ly
se
s
Number 928
Age – yrs 54.4 ± 15.2 (range: 18-92)
Sex – % male 40.0
SBP – mmHg 141.4 ± 22.0
DBP – mmHg 80.2 ± 10.1
Pulse pressure – mmHg 61.2 ± 17.6
Mean arterial pressure – mmHg 100.6 ± 12.7
Hypertension – % 46.3
Anti-hypertensive treatment –  % 21.3 (42.9 % of HT-subjects)
Total-cholesterol – mmol/l 5.6 ± 1.1
HDL-cholesterol – mmol/l 1.3 ± 0.4
LDL-cholesterol – mmol/l 3.7 ± 1.0
Triglycerides – mmol/l 1.4 ± 0.8
Glucose – mmol/l 4.8 ± 1.1
Diabetes Mellitus – % 5.9
Hyperlipidemia – % 27.6
BMI – kg/m2 27.1 ± 4.6
WHR 0.88 ± 0.1
Trunk fat mass – kg 14.0 ± 5.5
Total fat mass – kg 24.3 ± 9.3
Current smokers – % 37.0
Former smokers – % 29.9
Alcohol use – units/week 4.3 ± 9.2
Table 2. General characteristics of the study population
Values are presented as percentage or mean ± SD. SBP, systolic
blood pressure; DBP, diastolic blood pressure; BMI, body mass
index; WHR, waist to hip ratio.
Degree Relationship No of pairs
First Parent-offspring 371
Sibling 536
Second Half-sibling 43
Avuncular 875
Grandparent-grandchild 35
Third Half-avuncular 55
First cousins 2262
Half first cousins 53
Table 1. Number and types of relative pairs in 
pedigree
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Results
In total 928 participants were available for analysis. As they were recruited from one
extended pedigree, a large number of relative pairs were included. Information on 907
first-degree relative pairs, 659 second-degree relative pairs and 2370 third-degree 
relative pairs was available for this study (table 1). In 349 subjects no evidence for in-
breeding was detected based on genealogy. In the remaining 579 subjects the mean
inbreeding coefficient was 0.0086 (0.4.10-6 – 0.0436), slightly higher than that of a 
marriage of second cousins once removed. 
Table 2 presents the general descriptives of the total study population. The mean age
was 54 years, but as participants were ascertained within three generations, the age
range was very broad (18-92 years). Mean systolic blood pressure was 141.4 ± 15.2 mmHg
and mean diastolic blood pressure was 80.2 ± 10.1 mmHg. The prevalence of hyperten-
sion was 46.3 %, and 42.9 % of the hypertensive participants were currently on anti-
hypertensive treatment (21.3 % of total study population). The prevalence of diabetes
mellitus was 5.9 % and the prevalence of hyperlipidemia was 27.6 %. Furthermore, over
one third of the population was a current smoker and about one third was a former 
smoker. 
In table 3 total numbers of individuals, transformations and the significant co-
variates included in the heritability analyses are presented. Besides age and sex, 
anti-hypertensive medication use, trunk and total fat mass, total cholesterol and HDL-
cholesterol, fasting glucose levels and alcohol intake had significant effects on SBP, DBP,
MAP and PP.
Model-fit statistics for all four blood pressure traits (in model 1 and 2) are presented
in table 4. A general model, including both polygenic and sibship effects, was the best
model for SBP and PP. For both traits, the hypotheses of no sibship or no polygenic
effects were rejected. For DBP and MAP the likelihood of the models including both 
sibship and polygenic effects and a model including polygenic effects only, were almost
identical. Thus, the effect of the sibship parameter for these traits was negligible. Results
of hypothesis testing were the same for the age and sex adjusted and multivariate
adjusted analyses.
In table 5 the components of variance for SBP, DBP, MAP and PP are presented. The
proportion of phenotypic variance explained by (environmental) covariates, additive
genetic effects (heritability), sibship effects and residual environmental effects are pre-
sented for model 1 and model 2. Under both models, heritability estimates for SBP, DBP,
MAP and PP were significant, and ranged from 0.25 for SBP to 0.37 for DBP (model 2).
Sibship effects were significant for SBP and PP (0.09 and 0.10, respectively) (model 2).
For DBP and MAP no significant sibship effects were observed. Covariates explained
about 16 % of the variance of DBP and up to 35 % of the variance of SBP.
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Table 6 shows the results of the bivariate analyses. All correlations were positive and
significant, except for the genetic correlation between DBP and PP. The phenotypic 
correlations ranged between 0.15 for DBP-PP (not significant) and 0.90 for SBP-MAP and
DBP-MAP. Genetic correlations between SBP, DBP and MAP were very high (0.93-0.98),
whereas genetic correlations between PP and the other blood pressure traits were consi-
derably lower (0.05-0.70). Environmental correlations ranged widely between 0.19 for
DBP-PP and 0.89 for SBP-MAP.
Discussion
In this study we investigated to what extent genetic and environmental factors contri-
bute to blood pressure variance in 928 members of an extended pedigree living in a
genetically isolated Dutch community. Furthermore, we estimated the phenotypic, gene-
tic and environmental correlations between SBP, DBP, MAP and PP. General descriptives
of our study population indicate that this community is characterized by a relative
adverse cardiovascular risk profile, including obesity, hyperlipidemia, and a high preva-
lence of hypertension. Inbreeding effects may partly explain the increased prevalence of
hypertension, due to an increased frequency of recessive deleterious alleles as a result 
of increased homozygosity in our population. In support of this finding, several studies
of small inbred communities world wide also reported an increased prevalence of 
hypertension.22-26
We have simultaneously estimated the proportion of blood pressure variance ex-
plained by the additive effects of genes (heritability), sibship effects (including shared
environment and genetic dominance effects) and various environmental covariates.
Additive genetic, sibship and covariate effects together accounted for 50 to 70 % of the
total blood pressure variance observed in our population. All our heritability estimates
were significant and ranged between 0.25 for SBP and 0.37 for DBP. Although differen-
ces in study design, exposure to environmental risk factors, and adjustments for 
ρP ρG ρE
SBP-DBP 0.68 ± 0.03 0.93 ± 0.13 0.60 ± 0.05
SBP-MAP 0.90 ± 0.01 0.98 ± 0.04 0.89 ± 0.02
SBP-PP 0.80 ± 0.02 0.70 ± 0.11 0.84 ± 0.03
DBP-MAP 0.90 ±0.01 0.93 ± 0.03 0.88 ± 0.02
DBP-PP 0.15 ± 0.05 0.05 ± 0.22* 0.19 ± 0.09
MAP-PP 0.52 ± 0.03 0.64 ± 0.21 0.50 ± 0.06
Table 6. Phenotypic, genetic and environmental correlations between SBP, DBP, MAP and PP
ρP is the phenotypic correlation, ρG is the genetic correlation, ρE is the environmental correla-
tion. *All correlations are significant with p<0.001, except for ρP and ρG between DBP and PP.
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covariates make a direct comparison of our results with that of other studies difficult,
our heritability estimates are within the high range of those reported in other family-
based studies, which range from 0.15 to 0.40.5,7,8,27-29. 
Covariates accounted for about 16 % of DBP variance and up to one third of SBP and
PP variance. Besides age and sex, total body fat and trunk body fat mass, fasting gluco-
se levels and alcohol intake were the most important covariates influencing blood pres-
sure in this population.
As our heritability estimates were based on first, second and third degree relatives we
diminished the effects of shared familial environment on these estimates. In order to fur-
ther reduce confounding by shared environmental factors, we modeled a parameter
based on sibships. However, siblings do not only share a large part of their (childhood)
environment but also share a large part of their genes. In this respect, sibships may con-
tribute to the dominance genetic variance of a trait, because they can potentially share
two alleles identical by descent (IBD) if they inherited the same two alleles from the same
two parents at a specific locus. Therefore, our sibship parameter does not only reflect the
effects of shared environment but also includes possible genetic dominance effects on
blood pressure variance in our population. This sibship parameter explained a small pro-
portion of SBP and PP variance (±10 %), and no sibship effects were observed for DBP
and MAP. Significant genetic dominance effects for SBP in an isolated population have
been observed by Abney et al.28,30 Tambs et al. have also reported evidence for sibship
effects on SBP variance in a large Norwegian population-based survey.31 In addition,
several studies have reported evidence for major (recessive) genes influencing SBP.30,32,33
However, by modeling this sibship parameter, we were not able to determine the rela-
tive contribution of genetic dominance effects, if any, to that of shared environmental
effects in siblings. Future complex segregation or linkage analysis will be needed in order
to generate a more precise estimate of the magnitude of genetic dominance effects
influencing blood pressure variance in our study population.
Although were able to explain up to 70 % of the blood pressure variance in our study
population, a large proportion (30-50 %) of all blood pressure variance was ascribed to
residual environmental variance. This may not only reflect random environmental varia-
tion but also the effects of unexplained gene-environment and gene-gene interactions.
Furthermore, we were not able to assess the effects of all possible environmental risk fac-
tors influencing blood pressure. For example, we did not have information on dietary
habits or level of physical activity, which are both associated with blood pressure levels.
Although we believe that a large part of the effects of the above-mentioned parameters
are reflected in our body mass indices (trunk fat mass and total body fat mass), dietary
habits and physical activity may have influenced blood pressure variance in our popula-
tion independent of their effects on body composition.
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We observed high genetic correlations between SBP, DBP and MAP, indicating that
these traits may share a common genetic background. In other words, the genes that
influence SBP variance also influence DBP and MAP variance or are in strong linkage
disequilibrium with each other. In contrast, the genetic correlations between PP and the
other blood pressure traits were lower or even absent (PP and DBP). This suggests the
existence of an independent set of genes influencing PP variance. Pulse pressure is an
important measure of arterial stiffness and a strong predictor of cardiovascular morbidi-
ty and mortality, independent of blood pressure.34 Hence, significant heritability estima-
tes for PP and the results of our bivariate analyses, make this trait a suitable candidate
for future genetic analyses aimed at identifying genes involved in arterial stiffness. 
We feel the strength of our study lies within its population-based nature, embedded
in a family-based study design. The extended pedigree structure of our population en-
abled us to include a broad range of different types of relatives in our heritability 
analyses. We believe this will have reduced the confounding effects of shared envi-
ronmental factors on our heritability estimates. In addition, we introduced a parameter
based on shipships, which prevented wrongful inflation of our heritability estimates due
to shared environmental effects. Furthermore, the availability of information on various
environmental covariates of all members in the extended pedigree enabled us to esti-
mate the relative contribution of environmental factors on blood pressure variance in
this population. Finally, the members of our extended pedigree represent a random sam-
ple of our study population and were not ascertained through persons with extreme
blood pressure values. This has permitted us to make inferences about the relative impor-
tance of genetic and environmental factors on blood pressure at the population level. 
In conclusion, the presence of considerable genetic effects on various blood pressure
phenotypes in 928 participants of the ERF study provides a rationale and impetus to 
further explore the genetic background of blood pressure regulation, and hopefully iden-
tify new susceptibility genes influencing blood pressure variance in this population.
Moreover, significant heritability and evidence of a distinct genetic background for pulse
pressure, may offer the opportunity to uncover susceptibility genes related to arterial
stiffness in future linkage and segregation analyses.
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ABSTRACT150
Background: Identifying genes involved in blood
pressure regulation has proven difficult. Recently,
genetically isolated populations have come to the
attention of genetic researchers, as they may have
valuable properties increasing the chance of identi-
fying susceptibility genes for complex diseases such
as hypertension. 
Methods: We studied the familial aggregation and
general descriptives of 366 hypertensive partici-
pants in a Dutch genetically isolated population.
Blood pressure, anthropometric and laboratory
parameters were measured, and medical and family
history was assessed in a personal interview with a
research physician. The genealogical background of
all participants was traced back to 1600 with the
help of church and municipal records. Inbreeding
and kinship coefficients were calculated and com-
pared to that of a normotensive control group from
the same population (PEDIG software).
Results: About half of the study population was on
anti-hypertensive treatment, and median age-
at-diagnosis of hypertension was 50 years.
Metabolically linked risk factors were present in
about 80 % of the study population, the most pre-
valent ones being obesity and overweight. The
hypertensive study population was more closely
related and significantly more inbred than a normo-
tensive control group. Sixty percent of the 
hypertensive participants could be linked to a 
common ancestor within 10 generations.
Conclusion: This genetically isolated population
may offer opportunities to identify new susceptibi-
lity genes for hypertension as its population struc-
ture permits to use promising statistical tools to
map genes in complex diseases. In addition, inbree-
ding effects may have increased the chance to 
discover recessive mutations involved in blood 
pressure regulation in this population.
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Introduction
Studying the genetics of hypertension has proven difficult. Although 30 to 40 % of blood
pressure variation in the population is thought to have a genetic basis, studies aimed to
identify new genes involved in blood pressure regulation have not been very successful.1
Several Mendelian forms of hypertension have been identified, but these forms are rare
and not likely to explain blood pressure variation at the population level. In the majori-
ty of participants, high blood pressure is probably the outcome of the additive effects of
multiple genes with complex gene-gene and gene environment interactions. 
Various approaches to identify new genes for hypertension have been explored, inclu-
ding studies of candidate genes and whole genome searches (genome scans). Although
candidate gene studies have yielded some promising results, they are restricted to va-
riants in genes influencing physiological pathways known to be involved in blood 
pressure regulation. Appreciation of these limitations has led to the interest in conduc-
ting genome scans in the hope to identify new genes involved in blood pressure 
regulation.2 Especially population isolates are thought to offer a promising setting for
identifying new genes involved in complex diseases.3-5 The simple population history of
these isolates, characterized by a small number of founders and considerable population
growth with limited inward and outward migration, is assumed to have reduced the
genetic variability underlying complex traits. Availability of well-documented genealogi-
cal records allows for the construction of extended and multigenerational pedigrees,
including many affected individuals. This allows for the application of specific statistical
tools when analyzing the genetic data, such as identity by descent (IBD) mapping and
haplotype-sharing methods.6-8 Furthermore, inbreeding effects may increase the oppor-
tunity to map recessive genes.
In this paper we describe the population structure and give the general descriptives
of 366 hypertensive patients identified in a recently genetically isolated population in
the Southwest part of the Netherlands.
Methods
Setting
This study was conducted in a genetically isolated community in the Southwest part of
the Netherlands. Around 1750 this population consisted of a mere 150 individuals.
Demographically, this population is characterized by minimal inward migration and rapid
population growth over the last two centuries. Descendants of this population, about
20.000 individuals, are now scattered over eight adjacent villages. 
Enrollment of participants
Participants were ascertained as part of a research program called Genetic Research in
Isolated Populations (GRIP), which aims to identify genetic risk factors in the 
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development of complex disorders.9 The medical ethical committee of the Erasmus
Medical Center Rotterdam approved the scientific protocol of GRIP. Participants were
selected either through general practitioners or ascertained when visiting our research
center as a participant of the Erasmus Rucphen Family study (ERF), a family-based study
cohort study that is embedded in the GRIP research program.10 The first 97 participants
that were ascertained through their GP were collected between December 2001 and June
2002, before the start of the ERF study. The remaining 269 participants were all partici-
pants of the ERF study and included in this study between June 2002 and December
2003. 
In all participants the diagnosis hypertension was based on their medical history
and/or anti-hypertensive medication use, which was verified by a research physician.
Hypertension was defined as a systolic blood pressure above 140 mmHg or a diastolic
blood pressure above 90 mmHg, and or use of anti-hypertensive medication. These 
inclusion criteria are in accordance with the 1999 WHO criteria and 2003 ESH/ESC crite-
ria.11,12 Age-at-diagnosis was based on the medical history of the patient, either 
defined as date of first prescription of blood pressure lowering medication or the first
recorded diagnosis of hypertension made by the GP. Participants with identifiable causes
of hypertension (e.g. kidney disease) were excluded from this study. In order to increase
the homogeneity of our study population and to reduce the chance of including secon-
dary forms of hypertension, only participants born after 1940 were included. 
Data collection.
A research physician assessed all participants in a personal interview, either at home or
at the research center. During this visit, information concerning smoking behavior, alco-
hol use, medication use and medical history was recorded. In addition, all participants
were asked to fill out an extensive questionnaire on their medical and family history
(including genealogical information). Blood pressure was measured twice, separated by a
five-minute interval, in the sitting position at the right upper arm, using an automatic
device (OMRON 711, automatic IS). The mean of these two measurements was used for
analyses. Body height and weight were measured and body mass-index was calculated
(kg/m2). Fasting blood samples were drawn for the storage of DNA and the measurement
of lipids, glucose levels, creatinine, sodium, potassium and plasma albumin levels accor-
ding to a standardized procedure.13,14 Serum samples were obtained from whole blood
after clotting, and plasma samples were obtained from whole blood collected in diso-
dium EDTA. Hyperlipidemia was defined as the use of lipid lowering medication or total
cholesterol levels between 6.5-9.0 mmol/l and a total cholesterol-HDL cholesterol ratio
above 5.0, or total cholesterol below 6.5 mmol/l and a ratio above 8.0, or total choleste-
rol above 9.0 mmol/l, independent of the ratio, or triglycerides above 4.0 mmol/l. These
criteria are in accordance with those of the Dutch college of general practitioners.
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Diabetes mellitus was defined as the use of blood glucose-lowering medication or fasting
serum glucose level above 7.0 mmol/l, and glucose-intolerance was defined as a fasting
serum glucose level above 6.1 mmol/l and below 7.0 mmol/l.15 We classified participants
as overweight when their BMI was above 25.0 kg/m2 and below 30.0 kg/m2, and as obese
when their BMI was above 30.0 kg/m2. These definitions are in accordance with 
internationally accepted criteria.16,17
Genealogical data collection
Genealogical information, including name, date and place of birth of parents and grand-
parents, was collected for all participants. Church and municipal registers for this popu-
lation are readily available and date back to 1800. Furthermore, a large computerized
genealogical database including about 63.000 individuals living in our research area was
available. This database consists of genealogical information dating back to 16th centu-
ry. By means of these local municipal, church and computerized registers, information on
the genealogical background of the participants could be extended up to 16 generations.
Statistical analysis
General descriptives of the study population, stratified by gender, were compared using
2- statistics for categorical and dichotomous variables and unpaired T-test and Mann-
Whitney test for continuous variables.
Inbreeding coefficients and kinship coefficients were calculated using PEDIG software
(Bouchard D: http://dga.jouy.inra.fr/sgqa/diffusions/pedig/pedigE.htm). The inbreeding
coefficient is the probability that the two alleles at some locus in an individual are iden-
tical by descent, meaning that the identical alleles are inherited from a common
ancestor. We constructed three inbreeding categories: no inbreeding, moderate inbree-
ding and high inbreeding. Moderate inbreeding was defined as an inbreeding coefficient
higher than zero and lower than 0.57 (equal to a marriage of second cousins once remo-
ved) and high inbreeding was defined as an inbreeding coefficient above 0.57.
Percentages of hypertensive participants in each inbreeding category were compared to
that of a normotensive control group from the same population (spouses of participants
of the ERF study, n=193). A 2-statistic was used to compare the number of hyperten-
sive participants and control subjects in each inbreeding category. Kinship coefficients
are a measure of the degree of relationship between two persons. We calculated kinship
coefficients based on a pedigree of the total population for both the hypertensive 
participants and the normotensive control group. Distributions of kinship coefficients
between these two groups were compared using a 2-statistic.
Results
In total, 366 hypertensive patients participated in the study. General descriptives of the
participants, stratified by gender, are presented in table 1. Men and women were about
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equally represented in our study population (48.5 % and 51.5 % respectively). The medi-
an age was 54 years for women and 55 years for men. Mean SBP was the same for both
sexes (± 155.0 mmHg). Diastolic blood pressure was significantly lower in women com-
pared to men (p<0.001). Mean BMI was similar for men and women (± 28.5 kg/m2).
Fasting glucose levels were significantly higher in men than women (p<0.01). HDL-cho-
lesterol levels were significantly higher in women than men (1.3 mmol/l and 1.2 mmol/l,
respectively) and triglyceride-levels were significantly lower in women than men (1.5
mmol/l vs. 1.8 mmol/l). Creatinine levels were higher in men (86.3 µmol/l) than women
(69.4 µmol/l). Total cholesterol, sodium and potassium levels did not differ significantly
between sexes. The prevalence of myocardial infarction and stroke was significantly 
higher in men than women. Noteworthy, about 70 % of the total study population was
either a current smoker or a former smoker. Men used more alcohol than women, as
about 15 % of the men drank more than three alcoholic beverages a day, while in women
this was 4 % (p<0.01). 
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Men Women
Number – (%) 177 (48.5) 188 (51.5)
Age – yrs 55 (47-58) 54 (49-59)
SBP – mmHg 155.6 ± 19.2 154.8 ± 19.1
DBP – mmHg 89.4 ± 11.0 84.1 ± 12.0*
BMI – kg/m2 28.6 ± 4.4 28.4 ± 5.3
Glucose – mmol/l 5.7 ± 1.6 5.2 ± 1.3**
Total cholesterol – mmol/l 5.6 ± 1.2 5.6 ± 1.0 
HDL-cholesterol – mmol/l 1.2 ± 0.6 1.3 ± 0.4**
Triglycerides – mmol/l 1.8 ± 1.1 1.5 ± 0.6**
Sodium – mmol/l 140.2 ± 2.1 139.7 ± 3.0
Potassium – mmol/l 4.3 ± 0.4 4.1 ± 0.4
Creatinine – µmol/l 86.3 ± 15.0 69.4 ± 14.6**
Myocardial infarction – (%) 7.2 0.6**
CVA – (%) 5.2 1.6 
Current smokers – (%) 35.6 45.7
Former smokers – (%) 35.0 25.5
Alcohol use – > 3 U/d 14.7 3.7**
Table 1. General descriptives study population
All values are presented as mean ± standard deviation or percentage, except for age, which is
presented as median (interquartile range). *p<0.001 and **p<0.01, significantly different from
men.
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In table 2, clinical characteristics regarding age-at-diagnosis, medication use and
family history of hypertension are presented. The median age-at-diagnosis of hypert-
ension was about 50 years for men and women. About 53 % of the male participants and
57 % of the female participants received anti-hypertensive treatment. Within this group,
75-80 % was treated with one or two forms of blood pressure lowering medication and
20-25 % received three or more forms of anti-hypertensive medication. -blockers and
ACE-inhibitors were prescribed most in men, while in women, -blockers and diuretics
were most frequently used. ACE-inhibitor use was significantly higher among men than
women (38.8 % and 23.0 % respectively). Angiotensin receptor blocker use was higher in
women and men used Ca-blockers more frequently. 67 % of the hypertensive patients in
our study had at least one first-degree family member with hypertension.
Table 3 presents the prevalence and number of metabolically linked risk factors in our
study population. In hypertensive men, 42.1 % was overweight and 36.5 % was obese, in
hypertensive women these percentages were 33.5 and 35.1 respectively. Glucose intole-
rance was higher among men (8.9 %) than women (5.9 %). The prevalence of diabetes
mellitus was about 10 % for both sexes. Hyperlipidemia was present in about one third
of the men and about one fourth of the women. In about 20 % of the participants, no
metabolically linked risk factors were present. Half of the participants had one additio-
nal risk factor. The presence of two other risk factors was significantly more frequent in
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Men Women
Age-at-diagnosis hypertension - yrs 49 (40-55) 50 (42-56)
Anti-hypertensive treatment – (%) 53.1 57.0
Number of anti-hypertensive medication – (%)
1-2 75.3 80.1
3 or more 24.7 19.9
Type of medication – (%)
-ß-blocker 48.8 48.3
-Diuretic 36.6 43.7
-ACE-inhibitor 38.8 23.0*
-Angiotensin receptor blocker 22.5 29.9
-Ca-blocker 37.5 26.4
First-degree relatives with hypertension – (%) 67.0 67.6
Table 2. Age at diagnosis, medication use and family history of hypertension
All values presented as mean ± standard deviation or percentage, except age-at-diagnosis
hypertension, which is presented as median (interquartile range). *Significantly different from
men, p<0.05.
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men than women (27. 1 % and 18.6 %, respectively). Three other risk factors were 
present in 8.5 % of the men and 6.4 % of the women.
As median inbreeding levels did not differ significantly between men and women,
they were pooled in the analyses presented in figure 1. In this figure, percentages of the
total study population in each inbreeding category are presented and compared with
that of a normotensive control group of the same population. In 23.3 % of the hyper-
tensive population no inbreeding was observed compared to 43.5 % of the control group
(p<0.001). The number of subjects with moderate inbreeding was also higher in the
hypertensive group, although not statistically significant (hypertensive group: 41.0 %
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Hypertensive patients Normotensive controls
0 9775 (17.6) 8407 (45.4)
0-0.515 3125 (5.6) 749 (4.0)
0.515-0.512 9773 (17.6) 1300 (7.0)
0.512-0.59 10248 (18.4) 1704 (9.2)
0.59-0.56 19577 (35.2) 5686 (30.7)
0.56-0.53 2874 (5.2) 661 (3.6)
0.53-1.0 239 (0.4) 21 (0.1)
Table 4. Number of pairs in each kinship coefficient category in hypertensive patients and 
normotensive controls
Values are absolute number of pairs (percentage).
Men Women
Overweight – (%) 42.1 33.5*
Obesitas  – (%) 36.5 35.1
Glucose intolerance – (%) 8.9 5.9
Diabetes Mellitus – (%) 12.1 11.8
Hyperlipidemia – (%) 29.9 25.5
Number of risk factors present – (%)
0 16.9 21.3
1 47.5 53.7
2 27.1 18.6*
3 8.5 6.4
Table 3. Frequency of metabolically linked risk factors
All values are presented as percentage. *Significantly different from men, p<0.01.
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and control group: 36.8 %, p=0.07). The hypertensive group consisted of significantly
more participants with high inbreeding coefficients than the control group (26.8 % vs.
19.7 %, p=0.01).
Genealogical work-up of all participants revealed that 229 hypertensive participants
(62.5 %) were related to a common ancestor within 10 generations. Eighty-one hyper-
tensive participants out of these 229 participants (22.1 % of total group) were even clo-
ser related and could be traced back to a common ancestor within 7 generations. Figure
2 shows the extended pedigree for these 81 participants. Although in this pedigree mul-
tiple links be-tween participants exist, only the shortest connection with a common
ancestor is presented here for ease of interpretation.
We calculated pairwise kinship coefficients for pairs of patients and for pairs of sub-
jects in the normotensive control group. The results are presented in table 4. In the con-
trol group 45.4 % of the pairs did not have any relation with each other, whereas only
17.6 % of the hypertensive pairs were not related to each other (p<0.0001). The percen-
tage of pairs with a kinship coefficient between 0.512-1.0 was significantly higher for
hypertensive patients (59.2 %) than for normotensive controls (43.6 %) (p<0.001).
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Figure1. Inbreeding levels in hypertensive patients and control group.
*Significantly lower compared to control group, p<0.001. **Significantly higher than control 
group, p=0.01.
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Figure 2.Pedigree of 81 hypertensive patients connected to a com
m
on ancestor w
ithin 7 generations. Filled sym
bols represent the hypertensive
patients (phenotype of ancestors is not know
n).
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Discussion
We identified 366 hypertensive patients in a recent genetically isolated population. Over
60 % of these patients could be linked to a common ancestor within 10 generations.
Hypertensive patients were more closely related than a normotensive control group from
the same population. A positive family history of hypertension (first-degree relatives) was
present in almost 70 % of the participants. About half of the study population was cur-
rently receiving anti-hypertensive treatment. This is higher than recently reported by
Schelleman et al., who found in a large Dutch population based survey that, in the same
age group as our study population, only 18-30 % of hypertensive patients were trea-
ted.18 This difference is probably due to a relative over sampling of treated participants
in our study, as the first 97 participants were selected based on the diagnosis hyperten-
sion made by their general practitioner, whereas the other participants were ascertained
in a population-based study (ERF study).10
The prevalence of metabolically linked risk factors in our study population was con-
siderable, but in line with previous reports from the Framingham Heart Study.19,20 In fact,
only 20 % of the female hypertensives and even less of the male hypertensives did not
have any other risk factors. Overweight and obesity were the most frequently observed
metabolically linked risk factors in this study population, as 70 % of the hypertensive
women were overweight or obese and almost 80 % of the hypertensive men. The second
most frequent metabolically linked risk factor was hyperlipidemia, present in 25 % of the
men and 30 % of the women, followed by diabetes mellitus and glucose intolerance 
(21 % and 18 % of men and women, respectively).
In our study, the proportion of hypertensive patients with moderate to high in-
breeding was significantly larger than that of a normotensive control group of the same
population. In line with this, Rudan et al. observed significant inbreeding effects on SBP
and DBP in several villages of Croatian island isolates.21 They found that persons with
higher inbreeding levels also had higher blood pressure levels, and estimated that in-
breeding effects may account for about 38 % of all hypertension in their study popula-
tion. In addition, they observed the highest proportion of hypertensives in villages with
the highest inbreeding levels.22 We recently observed an increased prevalence of hyper-
tension in our population.10 Higher inbreeding levels in our hypertensive patients com-
pared to a group of normotensive controls could point towards recessive and partially
recessive deleterious alleles contributing to blood pressure variance in our hypertensive
population. However, the strong familial clustering and the high number of families with
patients in multiple generations indicate that most likely besides recessive mutations also
dominant mutations play a role in the etiology of hypertension in this population.
As our study was performed within an isolated community, this may offer substan-
tial advantages for a future genome screen aimed to identify new susceptibility genes for
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hypertension. First, our participants are likely to share a more common environment and
cultural background, which may avoid some of the environmental “noise” influencing
complex diseases that are determined by a combination of nurture and nature. Second,
this population originated from a limited number of founders and has known considera-
ble population expansion with minimal inward and outward migration. This is likely to
have reduced the genetic variability within this population.4 Finally, the availability of an
extended pedigree with multiple affected members, which could all be linked to a com-
mon ancestor within 10 generations, offers new statistical tools to map susceptibility
genes. Participants within this pedigree are more liable to have hypertension due to the
same mutations than unrelated participants in an outbred population. These mutations
are likely to be introduced into the pedigree by a common ancestor and may have segre-
gated over successive generations. In addition, participants in this pedigree may not only
share a mutation but also considerable parts of DNA surrounding the mutation (genomic
haplotype). This assumption forms the basis of the haplotype sharing method or linkage
disequilibrium mapping.6,8,23 The basic principle of this method is that markers located
in a shared haplotype will flag the mutation in a genome screen. A big advantage of this
method is the need for affecteds only. However, although this method has proven suc-
cessful for some rare diseases, it remains to be demonstrated for complex diseases such
as hypertension.24,25
Even though several genome-wide scans for hypertension or blood pressure have
been performed, only few studies report significant genome wide linkage.2 Of interest is
that two of these reports come from studies performed in isolated populations.26,27
Although these results seem promising, the use of population isolates may have its limi-
tations. Causal mutations or susceptibility genes identified in such a specific population
may be less important predictors of common disorders in larger more outbred popula-
tion.
In conclusion, although our hypertensive study population phenotypically does not
differ from hypertensive subjects in more outbred populations, we believe this popula-
tion may offer nice prospects to identify new susceptibility genes for hypertension
because of its isolated structure. Furthermore, increased inbreeding levels in this popu-
lation may offer the opportunity to identify recessive mutations involved in the 
etiology of hypertension.
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Introduction
The most optimistic view on the genetics of hypertension is that a relatively small num-
ber of common polymorphisms in a number of genes are capable of increasing suscepti-
bility to hypertension. This view is represented in the common disease/common variant
hypothesis, which suggests that genes underlying common diseases existed within the
founding population of contemporary humans.1-3 As Homo sapiens expanded outwards
from Africa and around the globe, ancient gene variations were also distributed global-
ly. This would mean the existence of a shared, pre-existing set of susceptibility genes for
hypertension in the global population. Consequently, the heterogeneity underlying
hypertension may be smaller than generally assumed. If the common disease/common
variant hypothesis holds, the same evolutionary ancient susceptibility alleles should be
detectable in different populations around the world.
An opposing view is that disease susceptibility arose independently in various distinct
populations. This implies that blood pressure alleles come from a larger number of youn-
ger, less frequent and more population-specific alleles: the common disease/rare variant
hypothesis.4,5 If blood pressure indeed is influenced by a large number of young rare alle-
les, they will be hard to find, especially when their effects on blood pressure are small
and influenced by other alleles or environmental factors. Consequently, hypertension-
susceptibility genes may be so numerous and their interactions so varied and context-
dependent that there is a unique profile of alleles influencing blood pressure for each
population. 
Despite these daunting perspectives we accepted the major challenge of finding
these alleles and initiated a search for the genetic basis of human hypertension and its
cardiovascular sequelae. The results of this search are presented in this thesis. The first
part of the thesis describes the findings of the genetic association studies that we con-
ducted in the Rotterdam Study. We assessed the role of two candidate genes in relation
to hypertension and three cardiovascular complications of hypertension: atherosclerosis,
left ventricular hypertrophy and heart failure. The second part of this thesis 
encompasses two studies on the heritability of blood pressure and familial aggregation
of hypertension in a Dutch genetically isolated population. 
In this chapter I will discuss the main findings and place them in a broader per-
spective. I will address the role of candidate gene studies and the advantages of geneti-
cally isolated populations in the search of cardiovascular risk genes. Finally, I will discuss
the future prospects of the studies conducted within the framework of this thesis and
give a general perspective on the future of genetic research on human hypertension.
Candidate gene studies
Historically, association studies have been the workhorse of studies investigating the
genetic basis of complex disease. The main advantage of these studies is the ability to
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detect genes with small effects (relative risks), which we expect to be the main contri-
butors to the genetics of complex diseases such as hypertension.2,6 
The Angiotensin Converting Enzyme Insertion/Deletion Polymorphism
The ACE I/D polymorphism is by far the most studied candidate gene in relation to car-
diovascular disease.7,8 This polymorphism is located in an intronic region of the ACE gene
and is most likely a neutral marker in strong linkage disequilibrium (LD) with one or more
unknown functional variants located close to or in the ACE gene.9,10 The ACE I/D poly-
morphism has consistently been associated with increased serum ACE activity.11 Findings
regarding the ACE gene and blood pressure levels or risk of hypertension, however, have
been very inconsistent.12-17 The fact that the effects of genes are likely to be influenced
by environmental factors may explain part of these conflicting findings.18,19 Genotype-
phenotype relations may depend on the environmental background of the population
under study. Context-dependent effects of the ACE gene have been reported by Turner
et al., who observed that the relation between this gene and blood pressure was 
dependent on gender, age, and measures of body size.20
Previous reports of smoking-dependent effects of the ACE gene in relation to endo-
thelial function and coronary atherosclerosis, motivated us to study the relation between
the ACE I/D polymorphism, hypertension and carotid atherosclerosis stratified by smoking
status.21,22 We hypothesized that smoking and the ACE I/D polymorphism might in-
fluence blood pressure and the development of carotid atherosclerosis by modulating
vasomotor tone and endothelial function. Indeed, persons who smoke and carry at least
one copy of the D-allele had significantly higher systolic blood pressure, an increased risk
of hypertension and increased carotid intima media thickness. In non- and former smo-
kers, no effect of the ACE genotype was observed. Our findings were strengthened by the
observation that both smoking and the ACE genotype significantly influenced serum ACE
activity.23 Thus, ACE activity may be an intermediate phenotype, responsible for the 
additive effects of the ACE I/D polymorphism and smoking on the vasculature. In a third
study we observed that the presence of the D-allele increases the risk of heart failure in
hypertensive persons, but not in normotensive persons. This suggests that an effect of
the ACE I/D polymorphism on cardiac function may only become clinically relevant under
specific haemodynamic conditions in which the cardiac growth machinery is already
activated. The results of our studies indicate that the magnitude of the effects of the ACE
I/D polymorphism on the risk of cardiovascular disease depends on the presence or
absence of other (environmental) risk factors, such as smoking or hypertension.
Insulin-like Growth Factor-I Promoter Polymorphism
Insulin-like growth factor-I (IGF-I) is an important mediator in pathophysiological res-
ponse to increased blood pressure in the vasculature.24 In addition, IGF-I is involved in
the hypertrophic response of the heart to increased arterial load and mediates tissue
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repair and cell proliferation in the ischaemic heart.25,26 Recently, we found that non-
carriers of a 19 CA repeat microsatellite polymorphism (192-bp allele), 1 kb upstream to
the IGF-I gene, have 20 % lower levels of circulating IGF-I, an increased risk of diabetes
mellitus and lower birthweight.27,28 As low IGF-I levels have been associated with an
increased risk of cardiovascular disease29-31, this prompted us to study the relation be-
tween the IGF-I polymorphism, hypertension, atherosclerosis and left ventricular hyper-
trophy. We observed an increased carotid intima media thickness and increased aortic
pulse wave velocity in hypertensive persons who did not carry a copy of the 192-bp alle-
le. In the second study, we observed that non-carriers of this 192-bp allele showed an
increased risk of left ventricular hypertrophy. 
With respect to the functionality of this polymorphism, it should be noted that
Frayling et al. observed an opposite relation between the IGF-I polymorphism and serum
IGF-I levels, and could not confirm our previous associations with height, diabetes 
mellitus and birthweight. He therefore debated the functional relevance of this poly-
morphism.32 Nevertheless, the IGF-I gene is a good candidate gene for blood pressure
and cardiac function because of the important role of IGF-I in normal and pathologic
cardiovascular physiology.24,33 In favor of involvement of the IGF-I gene in cardiac 
function and blood pressure regulation, Nagy et al. reported significant linkage of poly-
morphic microsatellite markers at IGF-I gene loci to systolic blood pressure and 
echocardiographically determined cardiac dimensions in a sibpair analysis.34 Further
identification of allelic variants within the IGF-I gene that can be tested in association
analyses, eventually coupled with protein expression studies, may confer more insight
into the role of this gene in the development of hypertension and its complications.
Validity of genetic association studies
Inconsistent results and absence of reproducibility have compromised the validity of
genetic association studies for the detection of genetic variants contributing to complex
diseases.35 Lack of reproducibility is generally attributed to inadequate statistical power,
phenotypic and genotypic complexity, and population stratification.35-38
The underlying effect-size to be detected in genetic association studies will typically
be small as for complex diseases such as hypertension many polymorphisms each with
small additive effects are likely to exist. Therefore large case-control samples are needed
in order to detect a modest genetic effect. For example, to replicate the initial findings
by Jeunemaitre et al. who observed an increased frequency of the 235T allele of the
angiotensinogen gene in hypertensive cases compared to normotensive controls, at least
400 cases and 400 controls will be needed in order to have 80 % power to detect a dif-
ference of 8 % in the frequency of this allele between hypertensive cases and controls.39
As underlined in the discussion on our findings regarding the ACE I/D polymorphism,
knowledge about specific environmental risk factors, which may interact with genetic
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risk factors, in different study populations is of great importance when initiating or repli-
cating a genetic association study. Gene-environment interactions may give rise to dif-
ferent relationships between genotypic and phenotypic variation in different study
populations, and lead to inconsistent outcomes between different genetic association
studies.
Population stratification is a problem that may arise in genetic association studies
when the study population consists of a mixture of two or more subpopulations with dif-
ferent allele frequencies and disease risks. Large differences in the prevalence of hyper-
tension and the frequency of the angiotensinogen 235T allele between the African popu-
lation and the Caucasian population, have generated inconsistent results regarding the
association between this allele and hypertension.39-41 To overcome the problem of popu-
lation stratification a few strategies can be followed. First, cases and controls should be
carefully matched by demographic background. Another approach may be the use of
anonymous genetic markers to detect population substructures.42 In family-based asso-
ciation studies the usage of a pseudo case-controls group, based on transmitted and
non-transmitted parental alleles, is a frequently used strategy, better known as the trans-
mission disequilibrium test (TDT).43,44 However, confounding by population substructure
is unlikely to be a serious problem in most association studies, as heterogeneity of study
populations is usually not very extensive.36,45 
In order to increase the validity of candidate gene studies several stringent criteria
have been proposed.46 The ideal features of a genetic association study include: “Large
sample sizes, small p-values, reported associations that make biological sense and alleles
that affect the gene product in a physiological meaningful way. In addition they should
include an initial study as well as an independent replication, the association should be
observed both in family-based and population-based studies”. In my opinion the
Rotterdam Study meets the above-mentioned prerequisites and has provided us with a
suitable study population and study design for genetic association studies. The
Rotterdam Study is a very large population-based study, including over 8000 partici-
pants, increasing the chance to detect modest genetic effects with sufficient power. The
prospective nature of this study reduces the presence of selection bias, which may con-
found genetic associations. The careful collection of extensive phenotypic information
on all participants offers the opportunity to study the pleiotropic effects of candidate
genes and take into account environmental factors influencing genotype-phenotype
relations. Finally, the Rotterdam Study provided us with an ethnically homogenous study
population as 98 % of the participants are Caucasian and they all live in the same
Rotterdam suburb. In addition, the family-based ERF study offers a select opportunity to
replicate initial findings of the Rotterdam Study in a linkage analysis. 
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Genetic research in an isolated population
An alternative approach to testing candidate genes for hypertension is to find “new”
genes responsible for blood pressure regulation in a genome-wide search. Although scan-
ning of the entire genome in search for linkage has been very successful for monogenic
disorders, linkage approaches have been far from successful for complex genetic disea-
ses. Two of the largest genome scans for blood pressure completed to date, unfortuna-
tely, were not able to provide us with more optimistic results. The US National Institute
of Health funded Family Blood Pressure Programs (NIH-FBPP), which genotyped a total
of 6245 individuals in four multi-center networks, did not find significant linkage of
blood pressure to a single locus.47-52 This program comprises the data of four large stu-
dies (GenNet, GENOA, HyperGEN and SAPHIRe), each initially set up independently.
Pooling of the individual results of these studies did not enhance any of the initial fin-
dings, most likely due to the different populations and study designs that were used in
the four studies.51 The Medical Research Council funded British Genetics of Hypertension
study (BRIGHT study), including 3599 hypertensive patients was able to identify only one
single locus on chromosome 6 that attained significant genome-wide linkage.53 Many
other, smaller studies that performed genome-wide searches for hypertension or blood
pressure in various study populations have provided us with many loci possibly involved
in blood pressure regulation, arguing in favor of the common disease/rare variant hypo-
thesis.54,55 Nevertheless, some regions on both chromosome 256-59 and 656,60,61 have
shown (suggestive) linkage to blood pressure in different study populations, which sup-
ports the common disease/common variant hypothesis. However, the presence of many
alleles possibly influencing blood pressure in outbred study populations severely 
complicates the search for susceptibility genes.
In order to reduce this problem of genetic heterogeneity, population isolates are
increasingly used in attempts to map genes underlying complex diseases.62,63
Chromosomal and mitochondrial DNA of people derived form a population isolates shows
significant less genetic diversity than that of humanity as whole.64,65 Reduced genetic
diversity in these populations is the result of a small number of founders, the occurren-
ce of population bottlenecks and a stochastic process called genetic drift. By definition,
genetically isolated populations are founded by a small number of individuals. Many iso-
lated populations have experienced a sudden decrease in size (a population bottleneck),
in the form of famine, infectious disease epidemics and war. Rapid population expansion
when a population rebounds from a bottleneck increases the occurrence of genetic drift,
which further reduces genetic diversity. Furthermore, inhabitants of most isolated com-
munities share a common environmental and cultural background, which reduces the
amount of environmental “noise” confounding genetic analyses of complex diseases.
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Finally, in genetically isolated populations genealogical records in the form of birth,
death and marriage registries are often available, which are indispensable for the recon-
struction of large pedigrees. For the GRIP study population, we now have a large 
pedigree database available including over 63.000 individuals, who all live or have lived
in this community.
As a consequence of genetic drift and founder effects, patients in a genetically iso-
lated population are likely to have inherited disease susceptibility from a common
ancestor. In our study this might imply that all 229 hypertensive patients, who were con-
nected in one extended pedigree, have hypertension because they share the same sus-
ceptibility genes, introduced into the pedigree by a common ancestor 10 generations
ago. Since adjacent markers on a chromosome are often transmitted together, our hyper-
tensive patients who have inherited the same disease susceptibility genes are also likely
to share considerable parts of DNA surrounding the disease gene. This property has been
exploited statistically in order to increase the power to detect susceptibility loci.66-68 Two
genome screens for hypertension performed in genetically isolated populations 
identified significant “genome-wide” linkage on chromosome 2p and 18q.69,70
We observed significant heritability estimates for blood pressure, ranging between 25
and 40 %, and substantial familial aggregation among hypertensive patients in this 
community, which provide a good rationale to further explore the genetic background of
blood pressure in this population. 
Future perspectives
In this thesis the search for cardiovascular risk genes has focused on two important areas
in genetic epidemiological research: the study of candidate genes and the study of gene-
tically isolated populations in order to map new susceptibility genes for hypertension. 
I believe candidate gene studies in the form of “high quality” association studies,
which have adapted stringent criteria with respect to sample size, phenotypic and geno-
typic assessment and biological plausibility, will continue to play an important role in
future research on the genetics of hypertension. Moreover, the creation of the Single
Nucleotide Polymorphism (SNP) database will in the near future lead to large-scale,
genome-wide association studies.2,71,72 This approach entails the study of variations in
(candidate) genes on a large scale, i.e. conducting high density genome scans that are
dependent on linkage disequilibrium.71 A large scale SNP-discovery project has already
led to the identification of 1.5 million SNPs, the most common form of human genetic
variation.71,73,74 Between 50.000 and 100.000 of these SNPs lie within coding and adja-
cent regions and some will alter gene function and protein expression.72 Genome-wide
association studies using evenly spaced SNP markers are now being contemplated in
population-based case-control studies, in which they compare the genotypes of a large
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number of polymorphic markers between subjects with the trait (e.g. hypertension) and
controls.75,76 Although high throughput SNP genotyping methods have been developed,
genotyping many individuals for about 100.000 SNPs remains a daunting task and is not
yet feasible. 
An approach that is perhaps more feasible will come from the identification of haplo-
type blocks, based on linkage disequilibrium (LD) between considerable parts of the
human genome, in which a small number of common haplotypes represent 90 % of all
chromosomal variation.77 This suggests that 6 to 8, or even less, carefully selected “tag”
SNPs may explain the vast majority of genetic variation within each of these haploty-
pes.78 Thus a careful selection of SNP markers, which represent not only genes but also
the common haplotypes of genes may offer the possibility to detect disease association
in a genome-wide scan.79,80 Especially in young genetically isolated populations, such as
the GRIP population, where haplotype blocks might be considerably longer due to exten-
ded LD between marker and disease alleles, this may proof a powerful tool for the iden-
tification of susceptibility genes.68,81 The resources needed for the identification of gene
variants that cause susceptibility for hypertension, including the availability of a large
number of SNP markers, advanced technology for high throughput, rapid and low cost
genotyping and definition of the extent and nature of LD in the human population, are
therefore eagerly awaited.
The use of genetically isolated populations in the search of susceptibility genes for
complex diseases has emerged over the last few years. The general assumption is that in
these populations affected individuals have a tendency to share ancestral haplotypes and
a hopefully common disease mutation.82 The value of the GRIP population in our search
of susceptibility genes for hypertension will be two-fold. First, the extended pedigree
structure of the hypertensive patients in our study offers the opportunity to identify
candidate regions in linkage analysis and use haplotype mapping to identify risk haplo-
types and hopefully pinpoint a disease locus. We will then test the relevance of these risk
haplotypes and/or susceptibility loci in the general population, in a case-control setting
within the Rotterdam study. Second, the family-based structure of the ERF-study offers
the opportunity to identify quantitative trait loci (QTLs) for blood pressure in future
genome wide scans.
To close, whether we will be able to find all genetic pieces for the complex puzzle of
blood pressure regulation, to be honest, I do not know. What I do know is that con-
siderable progress is being made and promising results are emerging continuously. The
advance of genome-wide association testing with the identification of haplotype blocks
in the human genome and the gene-mapping opportunities of genetically isolated popu-
lations are bound to confer more insight into the genetics of hypertension and its car-
diovascular sequelae. Identification of genetic variants involved in the development of
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hypertension will offer many opportunities to investigate the physiological, biochemical
and therapeutic aspects of blood pressure control. Moreover, the high prevalence of
hypertension in the general population alone warrants a decisive search for genetic 
factors in blood pressure regulation, in the hope that one-day advances made in genetic
research will translate into improvement of human health.
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185SUMMARY
Hypertension, or elevated arterial blood pressure is a substantial public health problem,
affecting about 25 % of the adult population. This disorder is a major risk factor for com-
mon causes of morbidity and mortality including stroke, myocardial infarction, heart 
failure, and end-stage renal disease. Despite the morbid consequences of hypertension,
its pathogenesis remains to be fully elucidated. Difficulties in defining the causes of
hypertension from physiological studies alone have motivated studies to search for gene-
tic factors in the etiology of hypertension. Identification of genes influencing blood 
pressure variation may confer more insight into the physiological mechanisms 
underlying blood pressure variation and reveal pathways and targets for therapeutical
intervention. In recent years, several genes responsible for rare Mendelian forms of
hypertension have been identified.
In Chapter 1, a general introduction is given on the epidemiology, physiology and
genetics of hypertension. Chapter1.2 describes the methodological aspects of genetic
epidemiological research in the field of hypertension. An outline is given on the basic
principles of genetic epidemiological studies.
Chapter 2 and 3 present the results of several candidate genes studies performed in
the Rotterdam Study, a population-based cohort study. We studied an insertion/deletion
polymorphism in the angiotensin-converting enzyme gene in relation to blood pressure
and hypertension in chapter 2.1. In smokers we found a significantly higher systolic
blood pressure in DD-carriers of the ACE genotype compared to II-carriers. The risk of
hypertension was significantly increased in smokers who carried one or two copies of the
D-allele. In former and non-smokers no effect of the ACE gene on blood pressure was
observed. In chapter 2.2 we observed that the ACE I/D polymorphism and smoking were
the main determinants for plasma ACE activity. Persons who smoke and carry at least one
copy of the D-allele had significantly increased carotid intima media thickness (IMT) and
slightly more carotid plaques. This relationship again was not present in former and 
non-smokers. The studies described in chapter 2.1 and 2.2 underline the importance of
gene-environment interactions in the study of candidate genes for hypertension and
atherosclerosis. In chapter 2.3 we found an increased risk of heart failure in hyper-
tensive persons compared to normotensive persons that was dependent on the presence
of the D-allele of the ACE I/D polymorphism. The incidence rate of heart failure in hyper-
tensive persons increased with the number of D-alleles present. Hypertensive persons did
not have a significantly increased risk of heart failure compared to normotensive persons,
unless they carried one or two copies of the D-allele. This suggests that the ACE I/D 
polymorphism plays a modifying role in the development of heart failure in persons with
hypertension.
Chapters 3.1 and 3.2 present our findings regarding a promoter polymorphism in the
IGF-I gene in relation to early signs of atherosclerosis and left ventricular hypertrophy.
In chapter 3.1 we describe an association between this polymorphism in the IGF-I gene
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and IMT of the carotid arteries in the general population. Further analysis revealed that
the association between this polymorphism and atherosclerosis was most pronounced in
hypertensive persons. Hypertensive persons who did not carry a copy of the 192-bp 
allele (wildtype allele) had an increased carotid IMT and higher aortic pulse wave velo-
city (PWV) compared to heterozygous and homozygous carriers of the 192-bp allele. The
effect of this polymorphism was even stronger in persons with untreated hypertension.
In normotensive persons no association was found between this polymorphism and IMT
or PWV. The polymorphism we studied in the IGF-I gene most likely is a modifier of the
risk for atherosclerosis in persons with hypertension. Furthermore, non-carriers of the
192-base pair polymorphism in the IGF-I gene are more susceptible to the development
of left ventricular hypertrophy than individuals homozygous for this allele (chapter 3.2).
In chapter 4.1 we report the first results of the ERF study. This is a study conducted
among 2500 inhabitants of a genetically isolated population in the Southwest part of
the Netherlands, which aims to determine genetic risk factors in the development of
complex diseases. Inhabitants of this isolated community are thought the share a more
homogenous genetic background, which will facilitate the search for susceptibility genes
of complex diseases such as hypertension. We estimated the heritability and genetic cor-
relations of various blood pressure traits in the first 1000 participants of the ERF study.
They were all members of one extended pedigree. Heritability estimates ranged between
0.25 and 0.40, suggesting that up to 40 % of the blood pressure variance in this popu-
lation may be explained by genetic factors. Furthermore we observed high genetic cor-
relations between systolic, diastolic and mean arterial pressure, which indicates that
these traits may be influenced by the same genes. Pulse pressure was less strongly corre-
lated with the other blood pressure traits, suggesting a partly distinct genetic back-
ground for this trait. The results of this study provide a rationale to further explore the
genetic background of blood pressure in this population. Moreover, studying pulse 
pressure in future linkage or association analyses may lead to the identification of
susceptibility genes related to different aspects of blood pressure pathophysiology, such
as arterial stiffness. 
In a second study, we investigated 366 hypertensive patients ascertained in the same
isolated community (chapter 4.2). 229 patients could be linked to a common ancestor
within 10 generations. About 50 % of the hypertensive patients received anti-hyper-
tensive therapy and the median age-at-diagnosis was 50 years. In 80 % of the patients
at least one metabolically linked risk factor was present, obesity and overweight were the
most frequent ones. Hypertensive patients were more closely related than a normo-
tensive control group. They also had higher levels of inbreeding than this control group.
In addition to our findings in chapter 4.1, higher inbreeding levels among hypertensive
patients and the availability of an extended pedigree offer promising statistical tools to
identify new risk genes for hypertension in future genetic analyses in this population.
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Finally, chapter 5 provides a discussion of the results and outlines the future per-
spectives of the studies described in this thesis. Special emphasis is put on the value of
candidate gene studies and the advantages of genetically isolated populations in the
search of cardiovascular risk genes.
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Hypertensie is een veel voorkomende aandoening waar ongeveer 25 % van de volwassen
bevolking aan lijdt. Een hoge bloeddruk is een belangrijke risico factor voor het krijgen
van hart- en vaatziekten zoals een beroerte of een hartinfarct en daarom een groot pro-
bleem voor de volksgezondheid. Hart- en vaatziekten vormen de belangrijkste oorzaak
van ziekte en sterfte in de westerse wereld. Ondanks de ernstige gevolgen van een hoge
bloeddruk, zijn de oorzaken van een hoge bloeddruk niet duidelijk. Fysiologische studies
hebben geen eenduidige reden voor het ontstaan van hypertensie kunnen vinden. Dit
heeft er toe geleid dat er de laatste jaren ook veel onderzoek wordt gedaan naar gene-
tische factoren in de etiologie van hypertensie. Heel zeldzaam zijn de erfelijke vormen
van hypertensie die door een mutatie in slechts één gen worden veroorzaakt. In het alge-
meen wordt aangenomen dat hypertensie het gevolg is van mutaties in meerdere genen
in combinatie met de aanwezigheid van omgevings factoren zoals roken, een ongezond
dieet of te weinig fysieke activiteit. De identificatie van genen die de bloeddruk 
beïnvloeden zal meer inzicht geven in de (patho)fysiologie van bloeddruk regulatie en
hopelijk leiden tot de ontwikkeling van nieuwe therapeutische interventies. 
In hoofdstuk 1 wordt eerst een algemene introductie gegeven over de 
epidemiologie, fysiologie en genetica van hypertensie. Hoofdstuk 1.2 beschrijft de
methodologische aspecten van genetisch-epidemiologisch onderzoek. De basis-principes
van genetisch-epidemiologische studies als mede de reeds behaalde resultaten op het
gebied van hypertensie onderzoek komen aan de orde.
In de hoofdstukken 2 en 3 worden de resultaten van 5 kandidaat-gen studies in de
ERGO studie, een grootschalig populatie onderzoek, beschreven. We bestudeerden een
insertie/deletie variatie in het angiotensine converterende enzym (ACE) gen in relatie tot
bloeddruk en het risico op hypertensie in hoofdstuk 2.1. We vonden een significant 
verhoogde systolische bloeddruk in rokers die de DD variant van het ACE gen dragen in
vergelijking met rokers die de II variant dragen van het ACE gen. Rokers die een of twee
kopieën hebben van deze D variant in het ACE gen, hebben meer kans op het krijgen van
hypertensie dan rokers die twee kopieën van de I variant hebben. In niet-rokers had het
ACE gen geen effect op de bloeddruk. In hoofdstuk 2.2 beschrijven we dat het ACE gen
en roken de belangrijkste determinanten zijn van de plasma ACE activiteit. Personen die
roken en tenminste één kopie dragen van de D variant van het ACE gen hebben een 
dikkere vaatwand in de halsslagaders en meer aderverkalking in deze vaatwand. Deze 
relatie was afwezig bij niet rokers. De studies beschreven in hoofdstuk 2.1 en 2.2 
benadrukken het belang van gen-omgevings interacties wanneer kandidaat genen bestu-
deerd worden voor hypertensie en aderverkalking. In hoofdstuk 2.3 vonden we dat het
verhoogde risico op hartfalen in personen met hypertensie afhankelijk is van de D 
variant in het ACE gen. De incidentie van hartfalen bij hypertensieve personen nam toe
wanneer ze één of twee kopieën van de D variant hadden. In onze studie hadden 
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personen met hypertensie geen verhoogd risico op het krijgen van hartfalen in vergelij-
king met normotensieve personen, tenzij zij dragers waren van één of twee kopieën van
de D variant van het ACE gen. Dit suggereert dat de insertie/deletie variatie in het ACE
gen een modificerende rol speelt bij het ontstaan van hartfalen in hypertensieve perso-
nen.
Hoofdstuk 3.1 en 3.2 beschrijven de bevindingen van het insuline-afhankelijke groei-
factor-I (IGF-I) gen in relatie tot atherosclerose en linker ventrikel hypertrofie (LVH) van
het hart. In hoofdstuk 3.1 wordt een relatie gevonden tussen variaties in het IGF-I gen
en de dikte van de vaatwand (intima media dikte, IMT) in de halsslagaders in de 
algemene populatie. Verdere analyses lieten zien dat deze relatie het sterkst was in
hypertensieve personen. Hypertensieve personen die geen kopie van de meest voorko-
mende variatie in het IGF-I gen (het wildtype allel) hebben, hebben een dikkere IMT in de
halsslagader en stijvere vaten, hetgeen uitgedrukt wordt in een hogere pulse wave velo-
city (PWV). Het effect van deze variaties in het IGF-I gen was nog sterker in hyperten-
sieve personen die geen bloeddruk verlagende medicatie gebruikten. In normotensieve
personen vonden we geen relatie tussen het IGF-I gen en IMT of PWV. Het IGF-I gen beïn-
vloedt waarschijnlijk het risico op atherosclerose bij personen met hypertensie. Verder
observeerden we ook dat personen zonder het wildtype allel een groter risico hebben op
het ontwikkelen van linker ventrikel hypertrofie van het hart (hoofdstuk 3.2). 
In hoofdstuk 4 worden de eerste resultaten van de ERF studie gepresenteerd. Deze
studie is uitgevoerd onder 2500 inwoners van een genetisch geïsoleerde gemeenschap in
Zuidwest-Nederland. Het doel van deze studie is om genetische risico factoren te vinden
die een rol spelen bij het ontstaan van complexe ziekten. Bewoners van een geïsoleerde
gemeenschap delen waarschijnlijk een meer homogene genetische achtergrond hetgeen
een zoektocht naar risico genen voor complexe ziekten zoals hypertensie makkelijker
maakt. We hebben de erfelijkheid van verschillende bloeddruk maten berekend voor de
eerste 1000 deelnemers van de ERF studie. Deze deelnemers zijn allemaal aan elkaar ver-
want in een grote, zeer uitgebreide stamboom. De erfelijkheid van bloeddruk varieerde
tussen de 0.25 en 0.40, hetgeen wil zeggen dat tussen de 25 en 40 % van de bloeddruk
variatie in deze populatie veroorzaakt wordt door genetische factoren. De genetische
correlatie tussen systolische, diastolische en de gemiddelde arteriële bloeddruk was zeer
hoog. Dit suggereert dat deze bloeddruk maten waarschijnlijk beïnvloed worden door
dezelfde genen. De polsdruk was minder sterk gecorreleerd aan de andere bloeddruk
maten, hetgeen impliceert dat deze bloeddruk maat misschien een gedeeltelijk aparte
genetische achtergrond heeft. De resultaten van deze studie zijn een aansporing om de
genetische aspecten van bloeddruk in deze populatie verder te onderzoeken. Het bestu-
deren van de polsdruk kan in toekomstige genetische linkage of associatie-
analyses leiden tot de identificatie van genen die gerelateerd zijn aan verschillende
aspecten van de bloeddruk pathofysiologie, zoals bijvoorbeeld de vaatstijfheid.
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In een tweede studie onderzochten we 366 hypertensieve patiënten uit dezelfde
genetisch geïsoleerde gemeenschap (hoofdstuk 4.2). Een groot gedeelte van deze hyper-
tensieve patiënten (62 %) was binnen 10 generaties aan elkaar verwant via één gemeen-
schappelijke voorvader. Ongeveer 50 % van de patiënten werd behandeld met bloeddruk
verlagende medicijnen en de mediane leeftijd waarop de diagnose hyper-
tensie werd gesteld was 50 jaar. Tachtig procent van de patiënten had tenminste één
andere metabole risico factor, het meest frequent hadden ze overgewicht. Hypertensieve 
patiënten bleken nauwer aan elkaar verwant dan een groep normotensieve personen uit
dezelfde populatie. In de patiënten groep kwam bloedverwantschap ook vaker voor. Meer
bloedverwantschap onder hypertensieve patiënten en de beschikbaarheid van een grote
uitgebreide stamboom, bieden veelbelovende statistische mogelijkheden om nieuwe risi-
cogenen voor hypertensie te ontdekken in toekomstige genetische analyses in deze
populatie.
Tenslotte worden in hoofdstuk 5 de resultaten en de toekomst perspectieven van de
studies beschreven in dit proefschrift besproken. Speciale nadruk is in deze 
discussie gelegd op de waarde van kandidaat-gen studies en de voordelen van genetisch
geïsoleerde populaties in de zoektocht naar cardiovasculaire risicogenen.
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